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An investigation of the interaction between the immune system GTPase GIMAP6 and an 
autophagy gene 8 homologue GABARAPL2 
 
Summary 
The guanosine-nucleotide binding family of immunity-associated proteins (GIMAP) is expressed in 
eukaryotic phyla including a subset of molluscs, vertebrates, and some protists. It is predominantly 
expressed in the lymphoid organs of mammals and other vertebrates where it plays roles in the 
homeostasis of the immune system.  
My study focuses on human (h) GIMAP6, a cytosolic member of the GIMAP family that is widely 
expressed across the lymphoid lineages. Studies within our group have uncovered a highly specific 
interaction between GIMAP6 and hGABARAPL2 (gamma-aminobutyric acid receptor-associated 
protein-like 2), a mammalian homologue of the autophagy-related protein 8 (Atg8). Using bacterially 
expressed GABARAPL2 and GIMAP6 I have shown that the interaction between the two proteins is 
direct. My studies have attempted to gain an understanding of the molecular requirements for this 
interaction using site-directed mutagenesis and pull-down assays. Mutational analyses, including 
point mutations within, and truncations of, GIMAP6 and GABARAPL2 have revealed a number of 
things. Close to its N-terminus GIMAP6 carries a sequence corresponding to a canonical Atg8 
interacting motif (AIM), a motif frequently found in proteins that interact with the Atg8 family. My 
studies indicate, however, that these residues do not play a role in the interaction. Using GTP-
agarose I was able to demonstrate that GIMAP6 could bind GDP and GTP and by mutating key 
residues within its GTP binding domain I could disrupt the interaction of GIMAP6 with GABARAPL2. 
I have also shown that the C-terminal 10 amino acids of GIMAP6 are necessary for the interaction. 
Interestingly, variants of GIMAP6 that were unable to bind GTP-agarose were also unable to 
interact with GABARAPL2, hinting at a crucial role for nucleotide binding in the GIMAP6-
GABARAPL2 interaction. Within GABARAPL2, deletion of the N-terminal α-helix resulted in loss of 
the interaction. A chimeric protein in which the corresponding region in MAP1LC3B, a protein 
unable to interact with GIMAP6, was replaced by GABARAPL2’s N-terminal α-helix reproduced the 
interaction suggesting that this region is critical for the interaction. Studies in our group have shown 
that GIMAP6 relocalises to autophagosomes on induction of autophagy. I have shown that variants 
of GIMAP6 unable to interact with GABARAPL2 fail to display a similar relocalisation.  
Finally, recent research has demonstrated that members of the GIMAP family can homo- and 
hetero-dimerise. I have shown that GIMAP6 can interact with itself and intriguingly, also shows a 
specific interaction with GIMAP7. Contrary to what was observed for the GIMAP6-GABARAPL2 
interaction, truncating the N-terminus of GIMAP6 abrogated the interaction with GIMAP7.  
These findings evoke the possibility that the GIMAP GTPases function together in an interacting 
network.  
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Abstract
The GTPase of immunity-associated proteins (GIMAP) is expressed in eukaryotic phyla
including a subset of molluscs, vertebrates, and some protists. It is predominantly ex-
pressed in the lymphoid organs of mammals and other vertebrates where it plays roles in
the homeostasis of the immune system.
My study focuses on human (h) GIMAP6, a cytosolic member of the GIMAP family
that is widely expressed across the lymphoid lineages. Studies within our group have
uncovered a highly specific interaction between GIMAP6 and hGABARAPL2 (gamma-
aminobutyric acid receptor-associated protein-like 2), a mammalian homologue of the
autophagy-related protein 8 (Atg8). Using bacterially expressed GABARAPL2 and GIMA-
P6 I have shown that the interaction between the two proteins is direct. My studies have
attempted to gain an understanding of the molecular requirements for this interaction
using site-directed mutagenesis and pull-down assays. Mutational analyses, including
point mutations within, and truncations of, GIMAP6 and GABARAPL2 have revealed
a number of things. Close to its N-terminus GIMAP6 carries a sequence correspond-
ing to a canonical Atg8 interacting motif (AIM), a motif frequently found in proteins
that interact with the Atg8 family. My studies indicate, however, that these residues do
not play a role in the interaction. Using GTP-agarose, I was able to demonstrate that
GIMAP6 could bind GDP and GTP and by mutating key residues within its GTP bind-
ing domain, I could disrupt the interaction of GIMAP6 with GABARAPL2. I have also
shown that the C-terminal 10 amino acids of GIMAP6 are necessary for the interaction.
Interestingly, variants of GIMAP6 that were unable to bind GTP-agarose were also un-
able to interact with GABARAPL2, hinting at a crucial role for nucleotide binding in the
GIMAP6-GABARAPL2 interaction. Within GABARAPL2, deletion of the N-terminal
a-helix resulted in loss of the interaction. A chimeric protein in which the correspond-
ing region in MAP1LC3B, a protein unable to interact with GIMAP6, was replaced by
GABARAPL2’s N-terminal a-helix reproduced the interaction suggesting that this region
is critical for the interaction. Studies in our group have shown that GIMAP6 relocalises
to autophagosomes on induction of autophagy. I have shown that variants of GIMAP6
unable to interact with GABARAPL2 fail to display a similar relocalisation.
Finally, recent research has demonstrated that members of the GIMAP family can homo-
and hetero-dimerise. I have shown that GIMAP6 can interact with itself and intriguingly,
also shows a specific interaction with GIMAP7. Contrary to what was observed for the
GIMAP6-GABARAPL2 interaction, truncating the N-terminus of GIMAP6 abrogated the
interaction with GIMAP7. These findings evoke the possibility that the GIMAP GTPases
function together in an interacting network.
Nomenclature
ADS AIM docking site
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The subject of this thesis is a family of putative GTPases, encoded by the mammalian
GTPase of immunity-associated protein (GIMAP) genes, that are predominantly expressed
in the immune system. Homologues of this protein family are spread throughout verteb-
rates including birds, reptiles, fish, with more distant relatives also present in molluscs
and higher plants. The mammalian GIMAPs are believed to play a role in the devel-
opment of lymphocytes and have also been shown to play a role in the regulation of
cell death. This thesis focuses on the interaction between GIMAP6 and GABARAPL2
(gamma-aminobutyric acid receptor-associated protein-like 2). Therefore, in this intro-
duction, along with briefly introducing lymphocyte homeostasis and autophagy, I will
discuss GTPases and members of the GIMAP family.
1.1 Lymphocyte Homeostasis
The maintenance of homeostasis of the T- and B-lymphocyte populations is crucial for
the health of an individual. Lymphocytes are the principal cells of the adaptive immune
system; this system evolved in early vertebrates and is capable of immunological memory.
Immunological memory enables more efficient recognition of specific pathogens result-
ing in a stronger and quicker immune response upon re-exposure to the same antigen.
During infection, the numbers of lymphocytes increase to fight the invasion and sub-
sequently return to normal levels. The state of homeostasis is perturbed when there are
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high numbers of activated lymphocytes in the absence of any infection. To establish
lymphocyte homeostasis, lymphocyte development has a number of checkpoints, and the
mature lymphocyte population is regulated by appropriate pro- and anti-survival signals.
For T-cell development, the checkpoints include T-cell receptor (TCR) mediated-positive
and negative selection. Differential TCR interactions with the (peptide)-Major Histocom-
patibility Complex (MHC) Class I and Class II molecules lead to either pro-survival or
pro-apoptotic signals that then result in the activation of cell-survival regulators such as
the B-cell lymphoma (Bcl)-2 family proteins. Positive selection provides survival signals
to cells that recognise the MHC complex, while negative selection ensures that T-cells
displaying an inappropriately high affinity for the MHC complex undergo apoptosis, thus
preventing autoimmunity (Starr et al., 2003; Ohashi, 1996). Additionally, low affinity
antigen-receptor signals as well as growth factor signals, such as those mediated by IL-7
(reviewed in Mackall et al., 2011), play an important role in the maintenance of appropri-
ate numbers of mature T lymphocytes (Ekert and Vaux, 1997; Kondrack et al., 2003), as
does programmed cell death (apoptosis) (Rathmell and Thompson, 2002).
1.2 T-cell development and survival - a brief
overview
T-cells begin their development from a common lymphoid progenitor (CLP) in the bone
marrow. The progenitor migrates to the thymus and it is in this organ that T-cell devel-
opment occurs. During the course of T-cell development the CLP undergoes numerous
genetically controlled stages that culminate in mature T-cells that express either CD4
or CD8 on their cell surface (Figure 1.2.1). Upon entering the thymus the progenitors
express neither CD4 nor CD8 and are called double-negative (DN) thymocytes. They
move through the thymus and progress through stages DN1-DN4, as determined by the
surface expression of CD25 and CD44 (Figure 1.2.1). At DN3, the thymocytes reach a
2
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critical checkpoint termed b-selection. Rearrangement and expression of the TCRb allele
controls the expression of the pre-TCR, and only thymocytes that express the pre-TCR
can progress through to the DN4 stage, the immature single-positive stage (CD8+) and
the double-positive (DP) stage (CD4+CD8+). At the DP stage, further development of
the thymocytes depends on the rearrangement of the TCRa locus and expression of a
clonotypic abTCR (Mallick et al., 1993; Dudley et al., 1994). The abTCR chains have
randomly generated specificities and their interactions with the MHC control whether a
thymocyte fulfils the requirements to differentiate into single-positive (SP) mature T-cells
(Fehling and vonBoehmer, 1997). T-cell development is dependent on cytokine signals
notably, IL-7, that affect the expression levels of the pro- and anti-apoptotic members of
the Bcl-2 family. The members of this family play an important role in determining the
fate of thymocytes as only 5% of all cells leave the thymus to circulate as T-cells in the
periphery. The default outcome of cells that do not pass selection is apoptosis, as only
cells that receive a TCR-ligation signal of the correct affinity can up-regulate the expres-
sion of the anti-apoptotic protein Bcl-2. Cells with too high an affinity or no affinity for
the MHC complex undergo apoptosis (Kisielow and von Boehmer, 1995). Hence, at the
positive selection stage, only thymocytes that recognise the pMHC complex can survive
and, at the negative selection stage those that do are eliminated. How this essential dif-




Figure 1.2.1: Outline of T cell development.
Right side-Cell surface markers to identify specific developmental stages. DN: double-
negative for both CD4 and CD8. Stages of DN cell differentiation (DN1-DN4) are dis-
tinguished by CD44, c-kit and CD25 expression. DP: double-positive for both CD4 and
CD8. ISP: immature SP CD8, represents the transition between DN4 and DP stages.
Figure taken from Rothenberg and Taghon (2005).
Even T-cells that mature and leave the thymus to circulate in the blood and peripheral
lymphoid tissues (lymph nodes, spleen etc.) are not protected from apoptosis. Interac-
tion between the TCR and the MHC is necessary for the continued survival of these cells,
with IL-7 and the Bcl-2 family members once again playing crucial roles (Strasser, 2005).
T-cells that bear specific antigen receptors are activated when antigens are presented to
them during an infection. This triggers the proliferation and differentiation of these T-
cells into effector cells and memory cells. Post-infection, the activated T-cells undergo
apoptosis, possibly due to the decline in cytokine levels which dampens the expression
of anti-apoptotic proteins. Ninety-five percent of activated T-cells die at this stage. The
memory cells survive and are now primed to mount a quicker and more effective immune
4
1.3. GTPASES
response should the same pathogen attack the host again (Strasser and Pellegrini, 2004).
Recent research has revealed that, in addition to apoptosis, the process of autophagy also
has a crucial role in the survival and maintenance of the immune cell population (Pua
et al., 2009, 2007; Virgin and Levine, 2009; Levine et al., 2009). Autophagy regulates re-
cycling of proteins and organelles via the lysosome and crucially also plays a role in innate
immunity by restricting infections caused by intracellular bacteria, viruses, and parasites
(Schmid and Munz, 2007; Munz, 2009; Mostowy and Cossart, 2011; von Muhlinen et al.,
2012).
Members of the GIMAP family are implicated in autoimmune diseases (Hornum et al.,
2002; Shin et al., 2007; Lee et al., 2013; Lim et al., 2009), and mutations and deletions
in some family members, such as GIMAPs 1 and 5, in rodent models, can produce severe
lymphopenias (Schulteis et al., 2008; Barnes et al., 2010; Saunders et al., 2010; Elder and
Maclaren, 1983). Studies have shown that the expression of proteins within this family
can be regulated by TCR signals (Nitta et al., 2006). Members of the GIMAP family have
also been shown to be able to bind to pro- and anti- apoptotic proteins of the Bcl-2 fam-
ily (Nitta et al., 2006; Nitta and Takahama, 2007). Thus, this GTPase family may play
important roles in the survival and maintenance of immature and mature lymphocytes.
However, little is known about their mechanism of action. As a product of investigations
to identify novel protein interactions mediated by the GIMAP family, the Butcher labor-
atory has recently identified a highly specific interaction between human GIMAP6 and
GABARAPL2 , a mammalian homologue of the yeast autophagy protein Atg8 (Pascall
et al., 2013). This interaction is the focus of this thesis.
1.3 GTPases
Guanosine triphosphatases (GTPases), a super-family of proteins found in Bacteria, Ar-
chaea and Eukaryota, are capable of binding and hydrolysing GTP and have diverse roles.
5
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They are believed to have their origins in translational modifiers and have diversified into
distinct forms before the last common ancestor of all modern life forms (Leipe et al.,
2002). GTPases function in a variety of fundamental cellular processes, such as cell sig-
nalling and motility (heterotrimeric G-proteins, Ras superfamily), membrane trafficking
and cytoskeletal dynamics (Rab GTPases, dynamin and tubulins), translation and protein
translocation (Ef-Tu and the SRP/SR family) and cell autonomous resistance to infec-
tion (interferon inducible GTPases, Mx and p47 GTPases; Martens and Howard, 2006),
amongst others.
GTPases share a related structural core that is reflected in sequence similarity and points
towards a common evolutionary origin for these proteins (Bourne et al., 1990; Leipe et al.,
2002). They contain a ~200-residue guanine nucleotide-binding domain (G domain) that
is composed of six-stranded b-sheets surrounded by a-helices (Kjeldgaard et al., 1996).
The five polypeptide loops, designated G1 through G5 (Figure 1.3.1), are conserved mo-
tifs, with the primary structures of G1, G3 and G4 being the most highly conserved (Dever
et al., 1987; Vetter and Wittinghofer, 2001). Based on studies carried out in the Ras super-
family, the loop regions between helix 1 and strand 2 and, between strand 3 and helix 2,
are called switch I and switch II, respectively and these are particularly important for the
conformational switch mechanism underlying their general mechanism of action. The
switch regions primarily bind the g-phosphate group of GTP with little or no involve-
ment in binding GDP. Switch I contains the G2 motif, and the G3 motif is located at the
beginning of switch II (Sprang, 1997).
6
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Figure 1.3.1: Topology diagram of the GTPase G domain.
b-strands in green, a-helices in red, and N and C termini as indicated. Conserved motifs
are indicated. Figure adapted from Vetter and Wittinghofer (2001).
The G1 motif, also called the diphosphate-binding loop (P-loop), contains the consensus
sequence GXXXXGK(S/T) and binds the a- and b-phosphates of the nucleotide molecule
(Bourne et al., 1991). The G2 loop contains a conserved threonine residue (XTX) that
is required for Mg2+ co-ordination (Traut, 1994). The magnesium ion is necessary for
the hydrolysis of GTP (Figure 1.3.2). The sequence DXXG, G3, stabilises the interaction
between the g-phosphate of the GTP and Mg2+. The G1 and the G3 motifs are present
in several nucleotide-binding proteins; however the specificity of GTPases for guanosine
is due to the G4 loop. G4 contains the conserved sequence (N/T)KXD that specifically
recognises the guanine ring over adenine. G5, with the consensus sequence (T/G)(C/S)A,
strengthens the interaction with GDP/GTP, reviewed in (Sprang, 1997).
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Figure 1.3.2: Schematic representation of the G domain fold.
A schematic diagram of Ras. Switch regions and secondary structure elements are la-
belled. Mg2+ represented by the solid yellow sphere. Figure adapted from McMahon
(2004).
1.3.1 Mechanisms of GTPases
Remarkably, the various diverse functions of GTPases are carried out via an almost uni-
versally conserved mechanism (Figure 1.3.3; Bourne et al., 1990). The classical mode of
action of GTPases, exemplified by the Ras super family of GTPases, is as a molecular
switch. GTPases cycle between an ’off/inactive’ state when they are bound to GDP and
unable to bind downstream effectors, and an “on/active” state when they are bound to
GTP and are able to bind downstream effectors (Figure 1.3.3).
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Figure 1.3.3: The functional cycle of Ras-like proteins.
Ras-like proteins are regulated by GEFs and GAPs as depicted. When GTP-bound, GT-
Pases are able to interact with downstream effectors. Figure adapted from Vetter and
Wittinghofer (2001).
The molecular switch is well described as a loaded spring mechanism (Vetter and Witting-
hofer, 2001). In the on-state, the conserved threonine in switch I (G2 motif) and the gly-
cine residue in switch II (G3 motif) interact with the g-phosphate of the nucleotide. Sta-
bilised by the g-phosphate, the switch regions of all small G proteins adopt a remarkably
similar, rigid conformation, allowing recruitment and, in some cases, allosteric activation
of effector proteins, with one or both switch regions involved in the binding interface.
Upon nucleotide hydrolysis and release of inorganic phosphate, the switch-g-phosphate
interactions are disrupted resulting in the switch regions relaxing into a conformation that
represents the GDP-bound off state. The presence of divalent magnesium ions is crucial
for the interconversion between the functional states as it contributes to catalysis. The
ions provide a temporary storage for the electrons taken from the triphosphate and return
them back to the diphosphate after bond cleavage and P(i) release (Rudack et al., 2012).
Dissociation of GDP and binding of GTP produces a conformational change in the pro-
tein resulting in activation of transduction. The release of GDP is intrinsically very slow
and the switch between the GDP and GTP bound states is regulated by guanine nucle-
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otide exchange factors (GEFs) that catalyse the release of GDP allowing the binding of
GTP. The switch regions are unable to interact stably with GDP, with the switch II region
disordered in the GDP-bound form and the switch I region interacting only loosely with
GDP. The GEFs remodel the switch regions, with the switch II region interacting intim-
ately with the GEFs to induce conformation changes that displace the GDP (Figure 1.3.4).
To become ’switched on’, GTP must enter the nucleotide-binding site and dissociate the
GEF. GTP enters via its GMP moiety and a low-affinity GEF–GTP–small-GTP-binding-
protein complex forms and isomerises to bind the b- and g-phosphate groups, resulting
in the dissociation of the GEF (Wang et al., 1997; Kawashima et al., 1996; Cherfils and
Chardin, 1999).
Figure 1.3.4: Mechanistic principles of nucleotide exchange mediated by GEFs.
The Mg2+ ion is pushed out from the active site either by elements of the GEF or by
residues in switch II, which is in turn pulled towards the nucleotide-binding site. The
conformation of the P-loop is disturbed by GEF binding, leading to loss of interaction
with the phosphates. GNBP-guanine nucleotide binding protein. Figure taken from Vetter
and Wittinghofer (2001).
The return to the inactive GDP bound state is regulated by GTP hydrolysis. This is an
intrinsically slow reaction and is catalysed by GTPase activating proteins (GAPs), re-
viewed in (Cherfils and Zeghouf, 2013). The actual GTP hydrolysis reaction, like the
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GDP/GTP exchange reaction, is intrinsically very slow within small G proteins as they
are inefficient enzymes and GTPase activating protein (GAP) activity is required to cata-
lyse this process (Bos et al., 2007a). An example of GAP-stimulated GTP hydrolysis is
the Ras-RasGAP association (Scheffzek et al., 1997). RasGAP increases the GTPase rate
of Ras by the following processes: (i) a positively charged arginine residue (the arginine
finger) at the binding interface of Ras-GAP inserts into the active site and neutralises the
developing negative charge in the transition state of GTP hydrolysis; (ii) A main chain
hydrogen bond from the arginine finger of the RasGAP to Gln61 of Ras stabilises this
residue (Figure 1.3.5). Gln61, also called the catalytic glutamine, which is located just
downstream of the G3 motif, is thought to be important for GTP hydrolysis by positioning
a water molecule which in turn acts as nucleophile and attacks the g-phosphate (Schweins
et al., 1995). The arginine finger mechanism is also conserved in other G protein-GAP
systems. A pertinent example is the arginine finger within GIMAP7 that enables it to
catalyse the GTP hydrolysis reaction in both GIMAP2 and GIMAP7 (Schwefel et al.,
2013). Another example is that of the TBC-domain proteins which act as GAPs for Rab
GTPases and catalyse the GTPase reaction by inserting both an arginine finger and a cata-
lytic glutamine into the active site. In the case of Rabs, the putative catalytic glutamine
within it is involved only in GAP binding and not in GTP hydrolysis (Pan et al., 2006). An
exception in the mechanism of GTPase stimulation is the Rap1 GTPase. Here, the GAP
provides a catalytic asparagine residue, rather than the canonical arginine residue as the
glutamine is missing in the Rap1 active site (Scrima et al., 2008; Daumke et al., 2004). As




Figure 1.3.5: Conserved mechanism of GTPase-activation for Ras, Rho, Rac and Ga.
The switch I and switch II regions of the GTPase are shown in the cartoon representation.
Also shown are the GAP loops that provide the arginine fingers. The remainder of the
proteins is indicated schematically. Colours refer to protein backbone; Ras-RasGAP is
coloured light green, Rho-RhoGAP red, Rac-ExoS cyan and Ga magenta. All structures
were solved in the presence of GDP, magnesium and aluminium fluoride, which is a mimic
of the transition state during GTP hydrolysis (indicated as AlF3). The catalytic water is
indicated as W (in red). The arginine fingers and catalytic glutamines are indicated as Arg
and Gln, respectively. Figure taken from Vetter and Wittinghofer (2001).
1.3.2 Subfamilies of GTPases
The mammalian genome encodes hundreds of GTPases that can be split into two main
classes based on shared sequence and structural motifs: the TRAFAC (translational factors)
and SIMIB1 (signal recognition particle, MinD and BioD) classes (Leipe et al., 2002).
GTPases within the TRAFAC class are involved in a myriad of biological functions in-
cluding translation, signal transduction, motility, and intracellular trafficking. The SIMIB1
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class is different from the TRAFAC class in a few significant ways. First, the G1 motif,
contains an additional conserved glycine residue, resulting in GxxGxGK[S/T] being the
consensus sequence. Second, instead of the conserved threonine within the G2 motif,
SIMIBI GTPases contain a conserved aspartate residue. Third, the G4 specificity motif
is not as conserved as in the TRAFAC class, and consequently, many SIMIBI members
have lost GTP specificity and can exhibit ATPase activity. An example of an NTPase
(GTPase) within the SIMIB1 class is the signal recognition particle GTPase (SRP54/Ffh
in bacteria) and the signal recognition particle receptor (SR/FtsY in bacteria). These pro-
teins are universally conserved and mediate co-translational targeting of proteins destined
for membrane-insertion or secretion (Egea et al., 2005).
GTPases are either monomeric, like those belonging to the Ras super-family, homo- or
heterodimeric, like those belonging/related to the septin and dynamin families, or het-
erotrimeric. The membrane-bound heterotrimeric GTPases, a subfamily of the Ras-like
superfamily, are composed of three sub-units: Ga, Gb and Gg. These are partners of
intracellular G-protein coupled receptors (GPCRs). In the inactive state, GDP is bound
to the Ga sub-unit that is closely associated with the Gbg heterodimer. GPCRs behave
like GEFs: binding of the receptors by a ligand catalyses the exchange of GTP for GDP
and results in the activation of signal transduction. GTP/GDP exchange occurs at the
Ga sub-unit, and results in the dissociation of the heterotrimeric complex into Ga/GTP
and Gbg. Both these sub-units are capable of functioning as independent transducers of
upstream signals, activating or inactivating various downstream effectors. The intrinsic
GTPase activity of the Ga sub-unit results in the re-association of the heterotrimeric com-
plex (Ford et al., 1998; Li et al., 1998; McCudden et al., 2005).
Monomeric GTPases like Ras are homologous to the Ga sub-unit of the heterotrimeric
GTPases. However, GTPases are divided into several sub-families, and not all GTPases
function as canonical molecular switches (Colicelli, 2004). For instance, the dynamin
sub-family of GTPases, a family that is critical for proper endocytosis and vesicle form-
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ation, is dependent on self-oligomerisation to carry out its functions (McNiven et al.,
2000a,b; Figure 1.3.6).
Figure 1.3.6: The functional cycle of GTPases activated by dimerisation.
Functional GTPases activated by dimerisation (GAD) do not require a GEF or GAP and
can stimulate GTP hydrolysis by homo- or heterodimerisation.
Dynamins use the net motive force generated by the hydrolysis of GTP for the scission
of newly formed clathrin-coated vesicles and for the division of organelles (Urrutia et al.,
1997). Another group of GTPases that do not function like canonical molecular switches
is the septin group. They were first identified in Saccharomyces cerevisiae and were
shown to participate in cytokinesis (Hartwell, 1971). Septins also play roles in vesicular
trafficking (Beise and Trimble, 2011; Trimble, 1999), exocytosis (Beites et al., 1999), and
stem cell biology (Hall and Russell, 2012).
Here, I will briefly introduce a few key members of the GTPase family that are of partic-
ular interest. These will include the most studied family of GTPases: the Ras-like GT-
Pases; an interesting family of large GTPases, the dynamins; the dynamin-like interferon-
inducible GTPases, a family involved in the immunity; the septins, and the paraseptins
which include the GIMAP proteins.
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1.3.2.1 The Ras-like superfamily
The Ras-like family is the best studied family of GTPases. This superfamily is predomin-
antly eukaryotic, but also includes a few members that are found in prokaryotes. Ras-like
GTPases consist of Ras, Rho, Ran, Rab and Arf GTPases. Members of the Ras subfam-
ily generally regulate cell signalling through multiple pathways that include an MAPK
(mitogen-activated protein kinase) cascade (Campbell et al., 1998). Rab GTPases, like
Arf GTPases (Deretic, 2013), are implicated in the formation, regulation, fusion and
movement of vesicles (Burd and Collins, 2004; Hutagalung and Novick, 2011; Hardiman
et al., 2012). Interestingly, members of the Ras-like family have also been shown to have
fundamental roles in the process of autophagy. Members of the Rab GTPase family in par-
ticular are active at various stages of autophagy spanning from autophagosome formation
through to autophagosome maturation (reviewed in Ao et al., 2014). The Rho GTPases,
through their ability to modulate microtubule dynamics and the actin-myosin cytoskel-
eton, can regulate a diverse range of cellular functions including cell morphogenesis,
migration, division and adhesion (Ridley and Hall, 1992; Chircop, 2014), additionally, a
recent study has demonstrated a role for Rho signalling in the regulation of autophagso-
some formation (Mleczak et al., 2013). The Ran family is implicated in nucleoplasmic
transport (Melchior et al., 1993; Moore and Blobel, 1993; Matchett et al., 2014). Mem-
bers of the Ras superfamily act like a classic molecular switch (subsection 1.3.1) such
that when they are GTP-bound they are able to interact with downstream effectors and
regulate critical cellular functions. Despite this mechanistic similarity among the various
Ras subfamilies, this family has significant functional diversity.
Ras has been shown to have roles in T- and B-cell development and is also involved in
signalling pathways that result in cytokine induction (Genot and Cantrell, 2000; Genot
et al., 2000). As mentioned in section 1.2, developing T-cells are required to express a
pre-TCR to be able to differentiate and proliferate. Ras has been shown to play an active
role at this stage of development, as expression of constitutively active Ras mutants, or the
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Ras effector Raf-1, can allow cells to bypass this checkpoint (Iritani et al., 1999; Gärtner
et al., 1999; Alberola-Ila et al., 1995). Ras is also stimulated on T-cell activation via the
inhibition of protein kinase C (PKC) (Downward et al., 1990). Furthermore, disrupting
the activity of Ras has been shown to result in T-cell anergy as it adversely affects IL-2
transcription which is required for the survival of T-cells (Boussiotis et al., 1997). This
demonstrates that GTPases are important regulators of B- and T-cell biology.
1.3.2.2 Dynamins
Dynamins were first identified as mechanochemical enzymes that are able to mediate mi-
crotubule sliding (Shpetner and Vallee, 1989). Dynamins are larger compared to Ras-like
GTPases as they contain additional domains downstream of the G domain that are re-
sponsible for self-association, lipid binding, and recruitment of interaction partners. An-
other aspect that differentiates them from other GTPases is their low nucleotide binding
affinities and their tendency to oligomerise, either by themselves or on a lipid template,
leading to stimulation of the GTPase reaction. Dynamins play important roles in vesicle
scission from the membrane during clathrin-mediated endocytosis and are also involved
in a variety of membrane budding processes such as phagocytosis or caveola scission,
organelle fusion and fission events, and in regulating the actin cytoskeleton (Taylor et al.,
2012; Gu et al., 2010; Sever et al., 2013; Praefcke and McMahon, 2004; Ferguson and
De Camilli, 2012). An electron-microscopic study of a bacterial dynamin-like protein has
provided an insight into the conformational changes the protein undergoes upon mem-
brane binding and the mechanism by which it causes deformation of the lipid bilayer
(Low et al., 2009). Dynamins play roles in mitochondrial fission (Smirnova et al., 2001),
which has been shown to regulate oxidative signalling in T-cells (Röth et al., 2014). A
recent study has demonstrated that dynamin 2-dependent endocytosis is necessary for
lymphocyte egress from both the thymus and lymph nodes by maintaining Sphingosine-
1-phosphate (S1P) receptor 1 (S1PR1) signalling (Willinger et al., 2014).
16
1.3.2 Subfamilies of GTPases
1.3.2.3 Interferon-inducible GTPases
Interferons (IFN) induce numerous gene families that encode effectors and associated
regulators, an example of such an induced family of genes is the IFN-inducible GTPase
superfamily (MacMicking, 2004, 2012; Martens and Howard, 2006; Taylor et al., 1996).
The interferon-inducible GTPase superfamily comprises at least 47 members in humans
and mice (Kim et al., 2011). They can be divided into one of four subfamilies on the
basis of paralogy and molecular mass: the ~47 kDa immunity-related GTPases (IRG), the
~65–73 kDa guanylate-binding proteins (GBP), the ~72–82 kDa myxoma (MX) resist-
ance proteins, and the ~200–285 kDa very large inducible GTPases (VLIGs) (MacMick-
ing, 2004; Martens and Howard, 2006). Structural analyses of several IFN-inducible GT-
Pases have lead to their being grouped together with members of the dynamin-like family
of proteins (Ferguson and De Camilli, 2012; Praefcke and McMahon, 2004).
The IFN-inducible GTPases mediate cell-autonomous immunity, likely by localising to
pathogen containing vacuoles, and are expressed in most mammalian cell lineages ex-
amined to date (MacMicking, 2012, 2004). One of the pathways employed by this family
of proteins in the clearance of pathogens is the autophagic pathway. For example, mem-
bers of the GBP family help traffic autophagy effector-bound cytosolic proteins to auto-
phagic vacuoles for generating bacteriolytic peptides (Kim et al., 2011). Members of the
IRG family also have been shown to confer an autophagic defence against intracellular
pathogens (Gutierrez et al., 2004; Singh et al., 2010; Traver et al., 2011). The subcel-
lular localisation of the mouse IRGs is variable, with GTP dependent cycle of IRG-IRG
oligomerisation playing a key role in the re-location of IRGs. Unlike the mouse genome
which encodes 23 IRGs, the human genome encodes only three putative IRGs, and al-
though only the expression of only the mouse IRGs seems to be regulated by IFN-g, both
the mouse and human IRGM1 GTPases are believed to be required for IFN-g induced




The septin family of GTPases is predominantly more similar to bacterial GTPase famil-
ies, such as Era, EngA, and TrmE than to the TRAFAC family, indicating that this family
may have evolved from bacterial GTPases. Septins are only found in eukaryotes, whereas
the other subfamilies (paraseptins and other septin-related GTPases) are wider but more
sporadically distributed, extending also to prokaryotic lineages. All members typically
contain a divergent version of the guanine recognition motif (G4) at the end of the core
strand 5 and an additional helix at the C-terminus of the GTPase domain. Septins were
first identified as being involved in the formation of the septum of dividing cells during mi-
tosis and meiosis and have been shown to assemble in rings along the bud neck (Hartwell,
1971). They are able to function as scaffolds that organises the assembly of binding part-
ners. In vertebrates, septins are involved in cell division, cytoskeletal dynamics and secre-
tion (Weirich et al., 2008) and they are able to perform these functions by forming linear,
hetero-oligomeric filaments via two distinct interfaces (Sirajuddin et al., 2007). Recent
research has demonstrated a key role for septins in innate immunity. By infecting epi-
thelial cell lines with bacteria, Mostowy et al. (2009) demonstrated that septins regulated
the process of bacterial entry in epithelial cell lines infected with Listeria. Subsequent
studies have demonstrated the entrapment of intracytosolic bacteria, Shigella, within sep-
tin cages and shown an involvement of the septins in autophagic activity (Mostowy et al.,
2010). Depletion of members of the septin family adversely affected autophagy. These
septin cages with the trapped bacteria are recognised by autophagy cargo receptors, Se-
questosome 1 (SQSTM1; otherwise known as p62) and the calcium-binding and coiled-
coil domain-containing protein 2 (otherwise known as NDP52 and referred to similarly
in this thesis), resulting in the recruitment of microtubule-associated protein 1 light chain
3 (MAP1LC3B) to these cages which are then degraded by autophagy (Mostowy et al.,
2011).
The paraseptin family features a diverse group of proteins which includes, amongst oth-
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ers, a conserved branch called the AIG1 (avrRpt2-induced gene)-Toc34/Toc159 group
(translocon at the outer-envelope membrane of chloroplasts); sequence analysis has in-
dicated that the GIMAP proteins which are the focus of this study belong to the AIG1
branch of the paraseptins (Koenig et al., 2008). AIG1-like proteins are found both in
vertebrates and plants where they play roles in anti-pathogen resistance, whereas the Toc
group is found only in plants. A defining feature of the AIG1-like proteins is the pres-
ence of the G domain along with a functionally undefined, highly conserved sequence
termed the conserved box. This sequence, along with the G domain, is present in all
members of the GIMAP family. The Toc34/Toc159-like GTPases are mainly found in
plants where they function as integral components of the chloroplast protein import ma-
chinery (Sveshnikova et al., 2000; Fulgosi and Soll, 2002; Kessler et al., 1994; Kessler
and Schnell, 2002). Crystal structures have suggested that Toc34 exists as a dimer with
one monomer acting as a GAP for the other (Sun et al., 2002). In Toc33, another member
of this family, the dimerisation was required to control the nucleotide-binding state (Oreb
et al., 2011; Aronsson and Jarvis, 2011), akin to what is observed in GIMAP2 (Schwefel
et al., 2010). The AIG1 subgroup was first identified in Arabidopsis thaliana where it was
up-regulated when challenged with infection (Reuber and Ausubel, 1996). This subgroup
is also found in viruses and bacteria. Intriguingly, AIG1-like proteins are also found in the
protozoan parasite Entamoeba histolytica, where their expression in pathogenic strains is
higher when compared to non-pathogenic ones (Biller et al., 2010), hinting at a potential
role for AIG1 proteins in virulence of pathogens as well as in defence mechanisms of the
host organism.
1.4 The GIMAP family
GIMAPs or their relatives are expressed in vertebrates, molluscs and higher plants; how-
ever, they do not appear to be expressed in unicellular organisms like yeast, or Caenorhab-
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ditis elegans. GIMAPs are found in certain bacteria, picornaviruses and herpesviruses
(Schwefel et al., 2010; Schwefel and Daumke, 2011). The mammalian GIMAP family
of proteins is predominantly expressed in the lymphoid organs where they are believed to
play roles in lymphocyte development and survival. GIMAPs are putative GTPases that
vary between 35-80 kDa, comprising 7-8 genes that are tightly clustered within the gen-
omes of organisms in which they are found, suggesting that they have evolved via gene
duplication events. In humans, the GIMAPs are on chromosome 7, and in rats and mice
they are on chromosomes 4 and 6, respectively (Figure 1.4.1). The work in this thesis has
focussed on human GIMAPs. As mentioned in subsubsection 1.3.2.4, the amino (NH2)-
terminus of all members of the GIMAP family contains the conserved GTP binding AIG1
domain, while the carboxy (COOH)-terminal regions of these proteins display little se-
quence conservation (Figure 1.4.2). Furthermore, unlike many other GTPases, including
members of the Ras super-family, the dynamins, the septins, and indeed several other AIG
proteins, mammalian GIMAPs do not have the CaaX motif (C for Cysteine; a for any
aliphatic residue; x for any residue) within their C-terminal regions. This motif directs
the post-translational addition of a lipid moiety and has critical implications in the local-
isation and function of the modified protein (Del Villar et al., 1996). A defining feature
of the AIG1-like proteins is the presence of the G domain along with a highly conserved
sequence termed the conserved box [CYLLSxPGPHVLLLVxQLGRjTxY] where j rep-
resents an aromatic amino acid and Y represents an acidic amino acid (Schwefel et al.,
2013). This sequence, along with the G domain, is present in all members of the GIMAP
family. All members contain predicted coiled-coil domains at the carboxy end that may
be involved in protein-protein interactions. GIMAP1, 2, 3 and 5 also have transmem-
brane hydrophobic domains that are likely to influence their intracellular localisation and
function.
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Figure 1.4.1: The organisation of the GIMAP gene cluster in the genomes of human,
mouse and rat is shown.
The position of each GIMAP gene is indicated and the orientation shown with arrows.
GIMAP6, which is the research focus of this thesis, is highlighted in yellow. GIMAP3
is a pseudogene (ps) in rats and humans and is denoted accordingly. Genes flanking the
GIMAP cluster are shown.
GIMAP1 was the first member of the GIMAP family to be identified. It was identified
in a differential screening of a cDNA library made from spleen cells of mice immune to
malaria and, those that were not (Krucken et al., 1997). A screen employing the differen-
tial display technique to identify genes specifically switched on during positive selection




Figure 1.4.2: Schematic representation of GIMAP family members.
In all GIMAP members there is an AIG1 domain (including the ’conserved box’) towards
the NH2-terminus of the polypeptides. The COOH-terminus, however, is varied and con-
tains domains which are expected to influence the function and sub-cellular localisation of
each GIMAP protein. GIMAP6, which is the focus of this study, is circled in red. Amino
acid numbering for human GIMAP proteins.
1.4.1 GIMAPs as G proteins
A Ras-like G1 motif (section 1.3) is highly conserved among the GIMAPs; by contrast,
the G3 and G4 motifs are less-canonical. The G3 motif, responsible for the interaction
between the g-phosphate of the GTP and Mg2+, is Ras-like in GIMAPs 4 and 7. In the
other GIMAPs, however, the glycine residue of the DXXG motif is replaced by various
residues. While a G4 motif is conserved among the GIMAP members, the consensus
sequence is altered from (N/T)KXD to T(R/H)KXD. As the G4 motif specifically recog-
nises the guanine ring over adenine, the effect of these changes on the binding and hydro-
lysing ability of GTP by the GIMAPs is still unknown. To date, few studies have been
conducted on examining the GDP/GTP binding and hydrolysing abilities of the GIMAP
family. The first evidence for GIMAPs as putative G proteins came from the Calabretta
group (Daheron et al., 2001). They demonstrated that HA-tagged mouse GIMAP3 could
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bind GTP in vitro. Stamm et al. (2002) showed that mGIMAP1 could bind GTP specific-
ally, whereas human (h)GIMAP1 could not. Cambot et al. (2002) showed that hGIMAP4
could bind both GDP and GTP as well as hydrolyse GTP with hGIMAP4, and surpris-
ingly for a GTPase, displayed a greater affinity for GDP than GTP, approximately 12-fold
more. However, equilibrium-binding calculations indicated that, in the absence of GT-
Pase activity, hGIMAP4 should still bind GTP, indicating that this molecule could behave
like a molecular switch. Crystallographic analyses on GIMAP2 and GIMAP7 carried
out by the Daumke group (Schwefel et al., 2010) have shed more light on the GDP/GTP
binding properties of the GIMAP family. Their work has demonstrated that hGIMAP2
and hGIMAP7 dimerise in a GTP-dependent manner. They also showed that GIMAP2
exhibited strong GTP binding but no hydrolytic activity. GIMAP7, on the other hand,
bound the guanine nucleotides with a lower affinity, but was able to act as a GAP (argin-
ine finger mechanism; section 1.3) and could catalyse the hydrolysis of GTP by both, a
homo- and a heterodimerisation (with GIMAP2) mechanism, in a manner similar to what
is observed in the septin and dynamin families.
Putting the research on hGIMAPs and their ability to interact with GTP in context, GIMAP2,
4 and 7 have been demonstrated to bind GTP, with only GIMAP4 and GIMAP7 display-
ing hydrolytic activity. Interestingly, a mouse model with a single amino acid mutation
in GIMAP5 within its G1 domain resulted in a phenotype that mimicked the GIMAP5
knockout mouse model (Barnes et al., 2010; Schulteis et al., 2008). These findings
point towards interesting, but as yet incompletely characterised roles for the G domain in
GIMAP biology. GIMAPs are predominantly expressed in lymphoid organs and members
of this family are believed to play important roles in maintaining lymphocyte homeostasis.
While some GIMAPs are believed to have pro-apoptotic roles, for example GIMAP4
(Carter et al., 2007; Schnell et al., 2006), others like GIMAP1 and 5 are believed to play
a pro-survival role. For example, knocking out the GIMAP1 or the GIMAP5 genes in
mice leads to severe T-cell lymphopenia and a reduction in the mature B-cell popula-
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tion (Barnes et al., 2010; Nitta et al., 2006; Hellquist et al., 2007; Schulteis et al., 2008;
Saunders et al., 2010; Sandal et al., 2003). Findings thus far indicate that the G domain
may play an important role in the functioning of the GIMAPs. However, it could also be
that the GIMAPs have other, as yet, uncharacterised domain(s) and that these rather than
the G domain are necessary for their function(s). Hence, while all GIMAPs may play a
role in the functioning of the immune system they could do so via their G domains or
independently of it.
As mentioned above, GIMAPs can be divided into two subgroups: one in which the
members contain transmembrane domains, and a second group which lack them and are
presumed to be, at least in part, cytosolic. The current state of knowledge on the individual
GIMAPs will be introduced in the following sections.
1.4.2 GIMAPs with transmembrane domains
1.4.2.1 GIMAP1
Human GIMAP1, 306 amino acids long with a molecular weight of 34 kDa, was the first
member of the GIMAP family to be identified. It has the G domain at its NH2-terminus
and a predicted transmembrane domain at its COOH-terminus. During malaria infec-
tion gene expression of mGIMAP1 was reported to be increased and was at an elevated
level in immune mice both pre- and post-infection, suggesting that GIMAP1 had a role
to play in the immunity to malaria (Krucken et al., 1997). However, this increase in
GIMAP1 expression was not observed in subsequent studies carried out by the Butcher
group (Saunders et al., 2009), either at the mRNA level or at the protein level. In tis-
sue array hybridization experiments, human GIMAP1 was found mainly in spleen and
lymph node tissues and to a lesser extent in heart and lung tissues. GIMAP1, on the
mRNA level, is up-regulated in T lymphocyte development during the transition from the
CD4-CD8- DN to the CD4+CD8+ DP stage in mice and rats (Dion et al., 2005; Nitta et al.,
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2006), suggesting a role for GIMAP1 in thymocyte maturation. A quantitative proteomics
study showed that GIMAP1 was down-regulated during the differentiation of activated T
lymphocytes into T helper 2 cells (Filén et al., 2009).
A conditional GIMAP1 knockout mouse generated by the Butcher group (Saunders et al.,
2010) resulted in a phenotype in which extensive lymphopenia was observed, indicating
that it plays a vital role in the development and/or survival of T- and B-lymphocytes. The
Cre/LoxP method was used to generate the knockout, with the mice expressing the Cre
recombinase carrying the hCD2-iCre transgene. hCD2-iCre induces expression of the Cre
recombinase in the early stages of development of the T- and B-cells resulting in GIMAP1
being knocked out in these cells only. Studies carried out by the Butcher group indicate
that the intracellular localisation of mGIMAP1 is within the Golgi compartment (Wong
et al., 2010). A number of Bcl-2 family members can be found at the Golgi (Echeverry
et al., 2013) and it could be that the presence of GIMAP1 there is necessary to regulate
apoptotic signalling.
1.4.2.2 GIMAP2
GIMAP2 comprises 337 amino acids and has a molecular weight of 38 kDa. It is present
in humans but has no orthologue in the rat or mouse. An interesting feature of this protein
is that it has two hydrophobic domains at its COOH-terminus. It is predominantly ex-
pressed in the spleen, lymph nodes, peripheral blood leucocytes and the thymus (Krucken
et al., 2004). The structure of GIMAP2 was recently solved (Schwefel et al., 2010) show-
ing that dimerisation of this protein is dependent on GTP-binding, with GTP-binding
leading to the release of constituent amphipatic helix a7 from the G domain. Release
of the a7 helix could free it to interact with potential binding partners, for example, other
members of the GIMAPs, or indeed members of the Bcl-2 family. The release of this helix
on GTP association also leads to the oligomerisation of the protein (Schwefel et al., 2010).
Cellular localisation in the Jurkat T cell line of mCherry-tagged GIMAP2, carried out in
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the same study, indicated that GIMAP2 predominantly co-localises with lipid droplets
(LD) with the hydrophobic domains being required for this localisation. Over-expression
of GIMAP2 lead to an increase in the number of lipid droplets. The biological signific-
ance of this phenomenon remains unclear. It could be that the GIMAP2 oligomer acts
as a scaffold on the LD membrane and plays a role in orchestrating interactions between
different proteins.
1.4.2.3 GIMAP3
Mouse GIMAP3 consists of 301 amino acids with a molecular weight of 34 kDa, it is a
pseudogene in humans and is absent in rats. It is reported to play a role in the positive
selection of CD4 SP and CD8 SP T cells in the thymus (Nitta et al., 2006). Sequence
analysis indicates that GIMAP3 is closely related to GIMAP5, and interestingly, recent
work by the Takahama group suggests a role for GIMAP3 in the survival of T-cells in the
mouse. T-cell numbers were reduced when both GIMAP3 and GIMAP5 were knocked out
in mice, compared to knockout of GIMAP5 alone, and a defect in T-cell production was
seen in a competitive haematopoietic environment when only GIMAP3 was deleted (Yano
et al., 2014). GIMAP3 has a predicted C-terminal helical membrane anchor and has been
shown to possess GTP-binding activity (Daheron et al., 2001). Mouse GIMAP3 mRNA
is found almost exclusively in spleen and lymph nodes (Nitta et al., 2006). It has been
reported to be localised at the mitochondrial outer membrane and via as yet unidentified
mechanisms is suggested to be a key regulator of mtDNA segregation (Jokinen et al.,
2010; Battersby and Shoubridge, 2001).
1.4.2.4 GIMAP5
GIMAP5 is the most extensively studied member of the entire GIMAP family. It is a
308 amino acid protein with a molecular weight of 35 kDa that is strongly expressed at
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the DN stage and at the SP stage of the T-cell lineage. One of the studies that sparked
interest in the GIMAP family was the identification of a frameshift mutation in the open
reading frame of GIMAP5 in the BioBreeding (BB) rat model of type-1 diabetes. The
frameshift led to the last 224 amino acids being replaced with 19 nonsense amino acids
resulting in the alteration of the AIG1 domain as well as the loss of the coiled-coiled do-
main and the transmembrane domain. This mutation resulted in acute T-cell lymphopenia,
eventually leading to autoimmunity (MacMurray et al., 2002; Elder and Maclaren, 1983).
The CD8+ population of T-cells was severely affected, while a significant decrease was
seen in the CD4+ T-cell population. Further studies in the BB rat model demonstrated
increased apoptosis of the TCRhi SP thymocytes and peripheral T cells, but no defect in
the survival of peripheral B cells (Hernandez-Hoyos et al., 1999). The mutation in the
BB rat model results in an alteration in the survival and function of regulatory T cells
(CD8-4+25+) at the post-thymic level, which could play a central role in the pathogenesis
of the disease (Poussier et al., 2005). The importance of GIMAP5 in the immune system
was demonstrated in mouse models as well (Barnes et al., 2010; Schulteis et al., 2008).
Knocking out GIMAP5 in mice replicated the effects seen in the BB rat model. GIMAP5
deficiency also resulted in blocking natural killer (NK) and NKT cell differentiation and,
interestingly, liver failure due to severe apoptosis of the hepatocytes (Schulteis et al.,
2008). Another mouse model where the GIMAP5 gene was altered was where an ENU-
induced coding mutation (G38C) was introduced in the highly conserved G1 domain of
GIMAP5. Changing the single amino acid within the G1 domain replicated the pheno-
type seen in the knockout mouse model (Barnes et al., 2010), indicating its importance in
the functioning of GIMAP5. Taking these findings forward, a recent study demonstrated
that CD4+ T cells become Th1/Th17 polarised and cause the development of colitis. The
progressive changes in CD4+ T cells are associated with the loss of Forkheadbox group
O (Foxo)1, Foxo3, and Foxo4 expression. These findings suggest a novel link between
GIMAP5 and Foxo expression thereby providing evidence for a regulatory mechanism
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that controls Foxo protein expression and could help maintain immunological tolerance
(Aksoylar et al., 2012).
GIMAP5 demonstrates pro-survival properties (Barnes et al., 2010; Saunders et al., 2010;
Schulteis et al., 2008), and interestingly, has been shown to interact with both pro- and
anti-apoptotic members of the Bcl-2 family (Nitta et al., 2006). GIMAP5 was able to
protect Jurkat cells from apoptosis induced by toxins such as okadaic acid as well as ap-
optosis induced by g-radiation (Sandal et al., 2003). A recent study, also in Jurkat cells,
demonstrated that Notch signalling up-regulated expression of GIMAP5 and protected
cells from apoptosis (Chadwick et al., 2010). Notch signalling leads to the activation of
the NF-kB signalling pathway that has been shown to inhibit apoptosis. Pandarpurkar
et al. 2003 demonstrated that the absence of GIMAP5 in T-cells resulted in T-cell specific
cell death and inhibition of caspase 8, but not caspase 9, rescued cells from apoptosis. The
observation that caspase 9 inhibition could not rescue GIMAP5 deficient T-cells from
apoptosis indicates that GIMAP5 does not function in the canonical intrinsic apoptotic
pathway. Recent work, however, has indicated that GIMAP5 plays an important role not
just in the survival of T-cells. Deletion of GIMAP5 in mice resulted in an increase in
apoptosis of haematopoietic stem cells and progenitor cells leading to a deficient long-
term re-population capacity (Chen et al., 2011). GIMAP5 in this study was shown to
stabilise the interaction between Mcl-1 and Hsp-70, and this interaction was necessary
for the maintenance of mitochondrial integrity in progenitor cells. HSC-70 also inter-
acts with Bcl-2 and Bcl-xL (pro-survival proteins) and GIMAP5 deficiency affects this
association. The mechanism of the GIMAP5–HSC-70 interaction is still unknown as is
the structural basis of this interaction and provides an exciting avenue for research into
GIMAP5. Haematopoiesis was also affected in the mouse models where GIMAP5 was
mutated or knocked out (Barnes et al., 2010; Schulteis et al., 2008). In these studies, the
abnormalities, excessive haematopoesis amongst others, were limited to the liver. Given
that the GIMAP5 knockout mouse does not survive beyond day 14, it is not surprising
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that GIMAP5 has a role in the healthy functioning of other organ systems as well.
With regard to the intracellular localisation of GIMAP5, studies by our group have demon-
strated, via immunocytohistochemistry and sub-cellular fractionation, that endogenous
GIMAP5 is localised predominantly in the lysosome (Wong et al., 2010) and not the
mitochondria (Nitta et al., 2006; Pandarpurkar et al., 2003) or the Golgi apparatus as sug-
gested previously (Sandal et al., 2003). Previous studies used transient transfection of
tagged GIMAP5 to elucidate its localisation. However, the gross over-expression that res-
ults due to transient transfection is likely to have led to physiologically irrelevant findings
with regards to this protein’s localisation. Additionally, a mass spectrometric analysis
of the protein composition of the NK secretory lysosome membrane identified a single
GIMAP5 peptide (Casey et al., 2007). Given that GIMAP5 has a role to play in apop-
tosis, an obvious localisation for it is the mitochondria, as this is where members of the
Bcl-2 family are also found and regulate mitochondrial membrane integrity. However,
the lysosome is also implicated in apoptosis. Lysosomal membrane permeabilisation can
induce apoptosis. It is still unclear whether GIMAP5 has a role to play in maintaining the
integrity of the lysosome membrane.
As mentioned above, mutation of GIMAP5 results in autoimmunity. One reason why
autoimmune disorders may develop in systems where the GIMAP5 gene is mutated or
knocked out is that it may cause an unbalanced survival of T-cells. This was seen by
Hernandez-Hoyos et al. (1999) in the BB rat model. They observed that T-cell lymph-
openia was due to increased rate of apoptosis of cells that had passed positive selection.
Notwithstanding their reduced survival, the SP thymocytes and T-cells are still able to pro-
liferate, rescuing them from death. GIMAP5 deficiency could thus result in the ablation
of normal T-cells and a survival advantage for auto-reactive T-cells, eventually leading
to a state that is suited for the development of autoimmune disorders. Genetic studies in
humans have indicated that a polyadenylation signal polymorphism in GIMAP5 is associ-
ated with both systemic lupus erythematosus risk (Hellquist et al., 2007), and an increase
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in IA-2 antibodies in patients with type-I diabetes (Shin et al., 2007). An increase in the
IA-2 antibodies is a good predictor of onset of type-I diabetes. The detailed mechanisms
of the role of GIMAP5 role in lymphocyte signalling pathways are still to be resolved,
but work thus far indicates a crucial role for GIMAP5 in the maintenance of a healthy
immune system. GIMAP4 and GIMAP5 seem to have opposing roles in terms of survival
and it would be interesting to analyse whether they can interact with each. It would also
be interesting to analyse an animal model with both GIMAP4 and GIMAP5 knocked out.
1.4.3 GIMAPs without transmembrane domains
1.4.3.1 GIMAP4
A gene expression study identified GIMAP4 as being switched on specifically during pos-
itive selection of thymocytes, with its expression being linked to CD3-mediated events
(Poirier et al., 1999). It contains 328 amino acids and has a molecular weight of 38 kDa.
GIMAP4 has an interesting expression profile: it is undetectable in the early stages of
DP development and is only detected in the latter stages (DP TCRhi) as the thymocytes
mature to become SP cells (Saunders et al., 2010). GIMAP4 is thus expressed after both
b-selection (post DN3) and positive selection. A similar pattern of GIMAP4 expression
is seen in the B-cell lineage as well. In the bone marrow, it is detected in the trans-
ition between pro-B1 and pre-B1 populations after which it is detected only in the mature
B-cell. GIMAP4 is expressed in resting T and B cells, but disappears on lymphocyte
activation. Intriguingly, while the protein is undetectable, the mRNA levels remain un-
changed pointing to post-transcriptional regulation of GIMAP4 (Cambot et al., 2002).
How this regulation takes place has yet to be elucidated. Despite the evidence detailed
above regarding the importance of GIMAP4 in lymphocyte development, studies have
shown that knocking out the gene has no effect on lymphocyte development (Nitta et al.,
2006; Schnell et al., 2006), suggesting functional redundancy with another member of the
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GIMAP family. Alternatively, it could mean that GIMAP4 is not required in lymphocyte
development.
Although several conserved residues considered to be key for the activity of GTPases,
such as Ras, are substituted in GIMAP4, hGIMAP4 binds GDP/GTP and is believed to
have an intrinsic GTPase activity (Cambot et al., 2002). hGIMAP4, a cytosolic protein, is
also thought to be the only member of the GIMAP family to have an IQ domain that may
bind calmodulin (CaM) (Schnell et al., 2006), although the evidence for this is weak and
has not been replicated. While GIMAP4 may not be crucial for lymphocyte development,
it does play a role in apoptosis (Schnell et al., 2006). Mice deficient in GIMAP4 had peri-
pheral T-cells that displayed delayed apoptosis in vitro under serum starvation conditions
and other conditions of stress. Following on from this finding the authors determined
that while GIMAP4 was not required to initiate apoptosis it was required for the forma-
tion and clearance of apoptotic bodies (Schnell et al., 2006). In addition, over-expressing
GIMAP4 in foetal thymus organ culture (FTOC) accelerated apoptosis of DP thymocytes
(Nitta et al., 2006). Further evidence of GIMAP4 being important for apoptosis came
from the identification of a hypomorphic variant of GIMAP4 in the Brown Norway (BN)
rat by the Butcher group. An AT insertion in this rat allele truncates the protein towards
the C-terminus and results in a delayed apoptosis phenotype (Carter et al., 2007), similar
to that of the mouse knockout. GIMAP4 has been shown to interact with the pro-apoptotic
protein Bax (Nitta et al., 2006) by co-immunoprecipitation, thus providing a mechanism
for its ability to modulate apoptosis. GIMAP4 expression levels respond to TCR signals
at the DP thymocyte stage and increase (Nitta et al., 2006), and it could be that GIMAP4
plays an important role in negative selection. In fact, GIMAP4 expression levels were sig-
nificantly higher in apoptotic/negatively selected thymocytes than in non-apoptotic cells
(Poirier et al., 1999). Interestingly, GIMAP4 has conserved sites of phosphorylation and
there is evidence that these may play a role in its ability to regulate apoptosis. GIMAP4
is a target of PKC phosphorylation and phosphorylation was at a higher level in dead
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cells than in live cells (Schnell et al., 2006). GIMAP4 is believed to act downstream of
caspase-3 activation and, interestingly, PKC activation is dependent on caspase-3 (Zhang
et al., 2005). Further investigations to determine how GIMAP4 carries out its functions
are necessary to pinpoint its exact role in lymphocyte development and survival. Discov-
ering interacting partners for GIMAP4 would aid in characterising its function.
1.4.3.2 GIMAP6
GIMAP6 is a cytosolic protein on which little work has been published that has 292 amino
acids and a molecular weight of 33 kDa. It is widely expressed across the lymphoid
lineages and in mice has a higher expression level in B-cells when compared with the
other GIMAPs. In thymocytes, GIMAP6 mRNA is highly expressed at the DP stage (Dion
et al., 2005). GIMAP6 mRNA levels in the diabetes-resistant rat, in which GIMAP5 is
absent, were reduced in the spleen and mesenteric lymph nodes but not in the thymus
when compared to rats that did not have GIMAP5 knocked out in this system (Rutledge
et al., 2009). GIMAP expression (mRNA) was reduced in non-small cell lung cancer,
with GIMAP6 expression being significantly reduced in the tumour cells (Shiao et al.,
2008). The function of GIMAP6 is still uncharacterised, however, our group has recently
demonstrated a highly specific interaction with a mammalian homologue of the yeast
autophagy gene Atg8, GABARAPL2 (Pascall et al., 2013). This interaction is studied in
this thesis.
1.4.3.3 GIMAP7
Human GIMAP7 consists of 300 amino acids with a molecular weight of 34.5 kDa. As
in GIMAP4, approximately the last 100 amino acids are predicted to form a coiled-coil
region. In mice, its mRNA is detectable in thymus, spleen, lymph node and lung tissue,
and it is expressed in B and T cells (Nitta et al., 2006). In rats, it is most strongly expressed
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in peripheral T cells. In mice and rats, its expression in thymocytes is low and unchanged
over all developmental stages (Dion et al., 2005; Nitta et al., 2006). GIMAP7, along with
GIMAP2, is amongst the 15 most downregulated genes in human anaplastic large cell
lymphomas (Eckerle et al., 2009). GIMAP7 is highly expressed in peripheral T-cells and
displays a similar pattern of expression to GIMAP4 (Dion et al., 2005). It is expressed in
the spleen, lymph nodes, and thymus but is not highly expressed in B-cells.
A recent structural analysis of GIMAP7 revealed that it can act as a GAP with the catalytic
arginine finger in the GIMAP7 homodimer and GIMAP7-GIMAP2 heterodimer serving
a dual function by promoting self-association and stimulating GTP hydrolysis (Schwefel
et al., 2013). Like GIMAP2, GIMAP7 was also observed to localise to lipid droplets in
Jurkat T cells. What implications this interaction has for T-cell biology needs elucidating,
and identifying further interacting partners may help reveal its function and mechanism
of action.
1.4.3.4 GIMAP8
GIMAP8 has three putative GTP binding domains making it unlike any other member
of the GIMAP family or indeed any other GTP binding protein. It is unknown whether
any or all of the G domains within this protein are active and GIMAP8 is as yet func-
tionally uncharacterised. GIMAP8 was identified as a single protein rather than three
different proteins by the Butcher group (Dion et al., 2005). It was first discovered in mice
and contains 688 amino acids with a molecular weight of 77 kDa. It was reported to
have anti-apoptotic properties (Krücken et al., 2005) although this finding has not been
replicable by the Butcher group. GIMAP8 expression was reduced in the GIMAP5 defi-
cient rat, however this was not reflected in the mRNA levels, suggesting the occurrence
of post-transcriptional regulation (Dion et al., 2005). While GIMAP8 is predicted to be
cytosolic, work in the Butcher group (Hepburn L. PhD Thesis, University of Cambridge)
has indicated that a proportion of it could be loosely bound to a membrane. mGIMAP8
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is expressed in the lymph nodes, and to a lesser extent in the spleen, thymus and lung.
Interestingly, while GIMAP8 expression was reduced in non-small cell lung cancers, it
was highly expressed in the surrounding non-tumour tissues (Shiao et al., 2008). Why this
should be is unknown. Additionally, GIMAP8 knockout mice are viable (Pascall/Webb
unpublished).
1.5 Autophagy
As this thesis focusses on the interaction between the human GTPase GIMAP6, and,
GABARAPL2, a mammalian homologue of the yeast autophagy protein Atg8, I will
briefly introduce the autophagic pathway.
Autophagy is a conserved cellular process that mediates turnover of cellular constituents
in the lysosomes. Depending on the type of autophagic cargo being delivered to the lyso-
some, autophagy can be divided into three different pathways: macroautophagy (hereafter
referred to as autophagy and the type of autophagy referred to in this thesis), microauto-
phagy and chaperone-mediated autophagy. Macro-autophagy delivers cytoplasmic cargo
to the lysosome via a double membrane-bound vesicle, called the autophagosome, that
fuses with the lysosome to form an autolysosome. The process in which cytosolic com-
ponents are directly taken up by the lysosome itself through the invagination of the lyso-
somal membrane is termed micro-autophagy. Both macro-and micro-autophagy are able
to engulf large structures through both selective and non-selective mechanisms. How-
ever, in chaperone-mediated autophagy (CMA), targeted proteins are degraded by being
translocated across the lysosomal membrane in a complex with chaperone proteins (e.g.
Hsp-70) that are recognised by the lysosomal membrane receptor lysosomal-associated
membrane protein 2A (LAMP-2A).
Autophagy was initially characterised as a survival mechanism induced in response to
nutrient deprivation (starvation), leading to the production of metabolites required to syn-
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thesise essential molecules and ATP that is required for cell survival (Lum et al., 2005b,a;
Kuma et al., 2004). A major player in nutrient sensing is the protein kinase mammalian
target of rapamycin complex 1 (mTORC1), which is a key regulator of cell growth and
autophagy. During favourable growth conditions, mTORC1 is active and acts to in-
hibit autophagy, whereas in periods of stress (nutrient deprivation), mTORC1 is inactive
and autophagy is initiated, likely due to the release of mTOR-mediated inhibitory phos-
phorylation of Unc-51-like kinase (ULK)-1/2 in mammalian cells (Ganley et al., 2009).
Autophagy is tightly regulated as it participates in diverse processes including stress man-
agement, ageing, development and the immune response, amongst others (Mizushima and
Levine, 2010; Vellai et al., 2009; Levine and Deretic, 2007).
Autophagy can be non-selective or selective. Starvation-induced autophagy involves ran-
dom sequestration of cytoplasmic components within double-membrane vesicles termed
autophagosomes (Kopitz et al., 1990). Selective autophagy performs critical quality con-
trol functions that involve selective sequestration of substrates that include soluble pro-
teins, protein aggregates, damaged organelles (mitochondria, peroxisomes, lipid droplets,
amongst others), and invasive microbes (Yang and Klionsky, 2010).
1.5.1 Molecular machinery required for the formation of
autophagosomes
The identification of about 30 autophagy-related (Atg) genes, using yeast genetic screens,
has helped greatly in elucidating the core molecular mechanisms of autophagy (Thumm
et al., 1994; Harding et al., 1995; Tsukada and Ohsumi, 1993). Several Atg genes are con-
served from yeast to man, an exception being the mammalian-specific Atg101 (Hosokawa
et al., 2009), and encode proteins that are required for autophagy. Studies in yeast have
demonstrated that the Atg proteins are predominantly localised to cytosolic puncta termed
the phagophore assembly site (PAS) and the assembly of the Atg proteins at this site
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occurs in a hierarchical manner (Suzuki et al., 2001). However, in mammalian cells,
the co-localisation of Atg proteins is observed at multiple sites, instead of a single PAS
(Young et al., 2006; Yamada et al., 2005; Mizushima et al., 2001). This phagophore
expands to engulf intracellular cargo, and sequesters it in the double-membraned auto-
phagosome (Figure 1.5.1). This then fuses with the lysosome, promoting the degradation
of autophagosomal contents by lysosomal acid proteases (Glick et al., 2010). The PAS
forms constitutively, and under basal conditions a key component that marks this site
is Atg11. However, upon the induction of autophagy, Atg11 is replaced by the Atg17-
Atg31-Atg29 complex that assembles at the PAS along with Atg1 and Atg13 (Mao et al.,
2013; Cheong and Klionsky, 2008). Atg9 plays an important role in directing membrane
to the PAS for autophagosome formation by shuttling between the PAS and peripheral
sites. Subsequently, the Atg12–Atg5-Atg16 complex is recruited to the PAS where it
acts in a manner akin to that of an E3 ligase to facilitate the formation of lipidated Atg8
(subsection 4.1.3) (Feng et al., 2014).
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Figure 1.5.1: Process of autophagic degradation.
A schematic representation of the process of autophagy. The ULK and the PI3K com-
plexes are required for the phagophore formation. The Atg-Atg12-Atg16L complex and
MAP1LC3B-II sequester the cytosolic cargo and promote phagophore elongation and
autophagosome formation. The lysosome fuses with the autophagosome forming the
autolysosome and this is where degradation of the cargo occurs. Figure adapted from
Nakahira and Choi (2013).
Briefly, the machinery for autophagosome formation is made up of the following func-
tional subgroups: 1) the Atg1/ULK complex (Atg1, Atg11, Atg13, Atg17, Atg29 and
Atg31) that regulates the induction of autophagosome formation; 2) the Atg9 and its cyc-
ling system (Atg2, Atg9 and Atg18) that plays a role in delivering membrane to the ex-
panding phagophore after the assembly of the Atg1 complex at the PAS; 3) the autophagy-
specific class III phosphatidylinositol 3-kinase (PI3K)/vacuolar protein sorting (vps) 34
complex (Vps34, Vps15, Vps30/Atg6, and Atg14) that acts at the stage of vesicle nucle-
ation, where it is involved in the recruitment of phosphatidylinositol-3-phosphate binding
proteins to the PAS; 4) two ubiquitin-like (Ubl) conjugation systems: the Atg12 (Atg5,
Atg7, Atg10, Atg12 and Atg16) and Atg8 (Atg3, Atg4, Atg7 and Atg8) conjugation sys-
tems that play key roles in vesicle expansion and maturation (Suzuki et al., 2001; Xie
et al., 2008; Mizushima, 2007). As GIMAP6 interacts with a mammalian homologue of
the yeast Atg8, I shall focus on the ubiquitin-like conjugation systems in this thesis.
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In yeast, there are two Ubl protein conjugation systems that participate in autophagy.
These include two Ubl proteins, Atg8 and Atg12, that are used to generate the conjugation
products Atg8-PE and Atg12-Atg5, respectively. These conjugation systems participate
in phagophore biology, although their precise functions are not yet fully understood. The
Atg12-Atg5 conjugate, along with a third component, Atg16, is thought to act like an E3
ligase by facilitating the conjugation of Atg8 to PE. The amount of Atg8 can regulate the
size of autophagosomes (Young et al., 2006) and it also has functions in cargo binding
during selective autophagy (Velikkakath et al., 2012). Although the Ubl protein conjuga-
tion systems are highly conserved from yeast to mammals (Ohsumi, 2014), one primary
difference is the existence of multiple homologues of yeast Atg8. These are divided into
two subfamilies, the MAP1LC3 subfamily and the GABARAP subfamily. Refer Chapter
4 for further details on the MAP1LC3 and GABARAP subfamilies.
Atg12 is a unique ubiquitin-like molecule, that is 2.5 times larger than ubiquitin, and is
synthesised as an active form without the processing of its C-terminus. The C-terminal
glycine of Atg12 is first activated by the E1 enzyme Atg7, and is then transferred to an E2
enzyme, Atg10, before finally forming a conjugate with Atg5 (Mizushima et al., 1998).
This Atg12-Atg5 conjugate is essential for autophagy, although further work needs to be
done to reveal its precise role(s) in this process. Subsequent to the identification of the
Atg12 conjugation system, another conjugation system, the Atg8 conjugation system, was
discovered among the Atg proteins. Atg8 is a small hydrophilic protein whose expression
is up-regulated upon starvation (Kirisako et al., 1999). Starvation also causes a re-location
of Atg8 to the autophagosome (Kirisako et al., 2000), and therefore Atg8 is a useful
marker of the autophagic activity. Biochemical studies revealed a tightly membrane-
associated form of Atg8 (Kirisako et al., 1999), and additional work illustrated the role of
a unique ubiqutination-like modification system (Ichimura et al., 2000). Atg7 is unique
in that it is able to activate two ubiquitin-like molecules, Atg12 and Atg8, and transfers
them to different E2 enzymes. Given that they share a common E1 enzyme, it follows that
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these two conjugation systems function in a closely related manner. Indeed, Atg12-Atg5
functions as an E3-like enzyme to enhance the Atg8 lipidation reaction (Hanada et al.,
2007; Sakoh-Nakatogawa et al., 2013).
1.5.2 Autophagy and Immunity - A brief overview
Recent analyses have revealed complex connections between autophagy and immune sig-
nalling. Given that autophagy is believed to have evolved as a stress response to enable
survival in harsh conditions, it seems likely that it would diversify to counter stress im-
posed by invasive pathogens and inflammation, amongst other sources of stress. Indeed,
several studies have demonstrated key roles for autophagy in innate immunity (reviewed
in Deretic, 2012).
Autophagy has also been shown to play key roles in adaptive immunity by being involved
in the regulation of development and homeostasis of the immune system, and in the reg-
ulation of antigen presentation. Autophagy is involved in both cross-delivery of antigens
from intracellular pathogens thereby contributing to the development of an efficient im-
mune response, and in the delivery of endogenous antigens for MHC class II presentation
to CD4+ T cells (Cuervo and Macian, 2014; Paludan et al., 2005; Deretic, 2013; Schmid
and Munz, 2007). Knockout studies of autophagy genes in specific lymphocyte popula-
tions in mice have revealed roles for autophagy in the maintenance of normal numbers of
B1a B cells (Miller et al., 2008), CD4+ T cells, CD8+ T cells (Pua et al., 2007) and foetal
haematopoietic stem cells (Liu et al., 2010). Deletion of Beclin-1 in CD4+ T-cells inhibits
autophagy and causes an accumulation of apoptotic proteins, resulting in cell death (Ko-
vacs et al., 2011). Deletion of Atg5, a gene essential for autophagy, resulted in reduced
numbers of both thymocytes and mature T-cells (Pua et al., 2007, 2009). Interestingly,
the lymphopenic T cell phenotypes of GIMAP5-deficient rats and mice is also seen when
Atg5 and Atg7 have been ablated conditionally in the T cell lineage. In both cases, while
intrathymic T cell development is relatively normal, the peripheral T cell population is
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severely depleted and there is a marked absence of resting, naïve T cells. Genetic disrup-
tion of Atg5 in thymic epithelial cells also leads to altered selection of certain MHC class
II restricted T-cell specificities and autoimmunity (Nedjic et al., 2008). Conversely, induc-
tion of autophagy in T-cells has also been shown to induce apoptosis (Biard-Piechaczyk
et al., 2006). These two divergent phenomena have yet to be completely reconciled.
40
2 Materials and Methods
All results shown in this thesis are representative of at least 2 independent experiments.
2.1 Molecular biology techniques
2.1.1 Polymerase chain reaction
To keep cross-contamination to a minimum, all polymerase chain reactions (PCR) were
performed using aerosol-resistant and nuclease-free pipette tips, and stocks of autoclaved
ddH2O kept specifically for PCR. Amplification of the DNA sequences was performed
in a PTC-100 Peltier thermal cycler (MJ Research Inc, USA). Amplification of cDNA se-
quences for the purpose of cloning was performed using Accuzyme™ DNA polymerase
(Bioline). Each reaction was performed in a volume of 50 mL and was performed using
2.5 U enzyme, 50pmol primers (purchased from Invitrogen Life Technologies), 400 mM
dNTPs, 5 mL of the supplied 10x PCR buffer, 30 ng of plasmid DNA template and 5%
(v/v) DMSO to facilitate melting of GC-rich regions. A negative control containing no
template DNA was included in every experiment. Following initial denaturation of tem-
plate DNA for 3 min at 95 ºC, the reactions were subjected to 35 cycles with the following
protocol: 1. Denaturation for 30 s at 95 ºC; 2. Annealing for 30 s at a temperature 60 ºC;
3. Extension for 4 min at 72 ºC. The final cycle had an extension at 72 ºC for 10 min. On
completion of the programmed cycles, the reaction was maintained at 4 ºC by the thermal
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cycler. Samples were subsequently stored at -20 ºC. Products generated were analysed by
agarose gel electrophoresis.
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Table 2.1.1: Reagents: Buffers and Solutions.
Reagent Description
1x Phosphate Buffered Saline
(PBS)
8 g NaCl, 0.2 g KCl, 1.44
Na2HPO4, 0.24 g KH2PO4. pH
7.4. Appropriate volume of dH2O
added to make up to 1 L.
10x TBE (TBE)
108 g Tris base, 55 g boric acid,
40 mL 0.5 M EDTA (pH 8.0). Ap-
propriate volume of dH2O added to
make up to 1 L.
Luria-Bertani broth (LB) Recipe made up to 1 L by adding
appropriate volume of dH2O.
Tryptone 10 g, NaCl 10 g, Yeast
extract 5 g.
LB-agar Recipe made up to 1 L by adding
appropriate volume of dH2O.
Tryptone 10 g, NaCl 10 g, Yeast
extract 5 g, 15 g Agar.
100 × Tris-EDTA buffer (TE) 39.4 g Tris-HCL 9.03 g EDTA. Ap-
propriate volume of dH2O added to
make up to 250 mL (pH adjusted to
8 using NaOH).
Agarose loading buffer 0.25% (w/v) bromophenol blue,
30% (v/v) glycerol
1 × Complete Sample Buffer (CSB) 80 mM Tris pH6.8, 2% SDS, 10%
glycerol, 5% b-mercaptoethanol or
200 mM dithiothreitol
2 × Complete Sample Buffer (CSB)
160 mM Tris pH6.8, 4% SDS, 20%
glycerol, 10% b-mercaptoethanol
or 400 mM dithiothreitol, 0.008%
(w/v) bromophenol blue
10 × Tris-Glycine-Sodium dodecyl
sulphate running buffer (TGS)
0.25 M Tris, 1.92M glycine, 1.0%
SDS, use at 1 × dilution
Transfer buffer 39 mM glycine, 48 mM Tris,
0.0375% SDS, 20% methanol
Blocking buffer (Western) 5% (w/v) Marvel milk powder in 1
× PBS containing 0.1% (v/v) Tween
20
Wash buffer (Western) 0.1% (v/v) Tween 20 in 1 × PBS
E. coli lysis buffer 5 mM EDTA (pH 8.0), 1% (v/v)
Triton X-100, 5 mM MgCl2
Triton X-100 lysis buffer 10 mM HEPES, 150 mM NaCl, 1%
(v/v) Triton X-100, pH 7.5
GTP lysis buffer 50 mM Tris, 150 mM NaCl, 10 mM
MgCl2, and 0.1% Triton X-100, pH
7.4
NP40 lysis buffer 150 mM NaCl, 1% NP40, 50 mM
Tris, pH 8.0
SEC buffer 20 mM Tris-HCl pH 7.5, 150 mM
NaCl, 2 mM dithiothreitol
SOC medium 0.5% Yeast Extract, 2% Tryptone,
10 mM NaCl, 2.5 mM KCl, 10 mM
MgCl2, 10 mM MgSO4, 20 mM
Glucose
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2.1.1.1 Site-directed mutagenesis
Site-directed mutagenesis was performed employing a PCR-based strategy with the Ac-
cuzyme™ DNA polymerase (Bioline) with the primers listed in Table 2.1.2. N- and
C-terminally truncated fragments were generated using oligonucleotides located at the
desired ends of the fragments. Where necessary, internal site-specific mutations were in-
troduced by generating two overlapping PCR products incorporating the desired mutation
within the overlapping region. These were then joined in a second PCR reaction spanning
the whole desired fragment (primers JP539 and JP541; Table 2.1.2). The inserts of all
PCR-derived plasmids were sequenced completely by Cogenics to ensure that only the
desired mutations, and nothing else, had been introduced.
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Table 2.1.2: List of primers.
F: forward primer, R: reverse primer. Forward primers incorporated the EcoR1 restriction site
(underlined in red), while reverse primers incorporated the XhoI restriction site (underlined in
black).
Primer name Primer sequence (5´ - 3´)
JP539 (f) GCGGAATTCTGATGGAGGAAGAAGAAGAATATG
JP541 (r) GCGCTCGAGAAGGTCAGCCTTCCCCAGC
GIMAP6 Y6A (f) GCGGAATTCTGATGGAGGAAGAAGAAGCTGAACAAATTCC
GIMAP6 I9A (f) GCGGAATTCTGATGGAGGAAGAAGAATATGAACAAGCTCCCCAG
GIMAP6 G50D (f) GAAAACAGACAGTGGGAAG
GIMAP6 G50D (r) CTTCCCACTGTCTGTTTTC
GIMAP6 S54N (f) GGGAAGAATGCAACAGG
GIMAP6 S54N (r) CCTGTTGCATTCTTCCC
GIMAP6 T76A (f) CAGCACCAGACCCGTGGCCAAGACCTCCCAGAG
GIMAP6 T76A (r) CTCTGGGAGGTCTTGGCCACGGGTCTGGTGCTG
GIMAP6 D95A (f) GAGCTTGAGGTGATTGCCACACCCAAC
GIMAP6 D95A(r) GTTGGGTGTGGCAATCACCTCAAGCTC
GIMAP6 N98A (f) GTGATTGACACACCCGCCATTCTGTCCC
GIMAP6 N98A (r) GGGACAGAATGGCGGGTGTGTCAATCAC
GIMAP6 R134A (f) GTGACACAACTGGGCGCCTTCACGGATGAGGAT
GIMAP6 R134A (r) ATCCTCATCCGTGAAGGCGCCCAGTTGTGTCAC
GIMAP6 D167A (f) TTCACCCGGAAGGAAGCCCTGGCTGGCG
GIMAP6 D167A (r) CGCCAGCCAGGGCTTCCTTCCGGGTGAA
GIMAP6 N201A (f) GCGCCATTGCGGCTTCAACGCCAGGGCACAG
GIMAP6 N201A (r) CTGTGCCCTGGCGTTGAAGCCGCAATGGCGC
GIMAP6 37-292 (f) GCGGAATTCTGACCCCAAGGAGACTGAGGCTC
GIMAP6 1-243 (r) GCGCTCGAGAAAGTTTTGCTGGGTATATTGG
GIMAP6 1-272 (r) CGGCTCGAGGGACAGTCCTTCCAGCCA
GIMAP6 1-282 (r) CGGCTCGAGGTGGGCTTCCTCAGATTC
GIMAP6 1-287 (r) GCGCTCGAGTCACAGCAGGCATCTGTGGGC
GIMAP6 L292A (r) GCGCTCGAGTCAAGCGTCAGCCTTCCCCAG
GIMAP6 K289A (r) GCGGATGCTCGAGAAGGTCAGCCGCCCCCAGCA
GIMAP6 HR283284AA (r) GCGCTCGAGAAGGTCAGCCTTCCCCAGCAGGCATGCGGCGGCTTC
GIMAP6 R284A (r) GCGCTCGAGAAGGTCAGCCTTCCCCAGCAGGCATGCGTGGGCTT
GIMAP6 H283A (r) CGCCTCGAGAAGGTCAGCCTTCCCCAGCAGGCATCTGGCGGCTTCCTC
GABARAPL2 (f) GCTGGAATTCTGATGAAGTGGATG
GABARAPL2 (r) GCGCTCGAGTCAGAAGCCAAAAGTGTT
GABARAPL2 Y49A (f) GACAAACGGAAGGCCTTGGTTCCATCTGAT
GABARAPL2 Y49A (r) ATCAGATGGAACCAAGGCCTTCCGTTTGTC
GABARAPL2 L50A (f) GACAAACGGAAGTACGCGGTTCCATCTGAT
GABARAPL2 L50A (r) ATCAGATGGAACCGCGTACTTCCGTTTGTC
GABARAPL2 G116A (r) GCGCTCGAGTCAGAAGGCAAAAGTGTTCTC
GABARAPL2 11-117 (f) GCGGAATTCTGCTGGAACACAGATGCG
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2.1.2 Agarose gel electrophoresis
DNA samples generated from PCR or digestion by restriction endonucleases were mixed
with 1x DNA loading buffer for application onto a 1% (w/v) agarose gel containing 10 mg
ethidium bromide in 0.5x TBE buffer. To separate the DNA fragments, gels were subjec-
ted to a constant voltage of 90 V for 45 min using a Bio-Rad POWERPAC 300 (Bio-Rad
Laboratories Inc, USA) or until the dye front had migrated two-thirds of the way down the
gel. DNA bands were then viewed using UV transillumination and photographed using a
Gel Doc Imager.
2.1.3 Purification of PCR product
DNA amplified by PCR was purified using the QIAquick® PCR purification Kit (Qiagen,
Germany) according to the manufacturer’s instructions. This kit can purify up to 10 mg
DNA of 100bp-10kb.
2.1.4 Measurement of nucleic acid concentration
DNA concentrations were measured with a NanoDrop ND-1000 spectrophotometer (Nan-
oDrop Technologies, USA) using the ‘Nucleic Acid’ application module and DNA- 50
(double-stranded DNA) settings. Using a sample volume of 2 mL, the NanoDrop allows
quantitative analysis of samples between 2-3700 ng/mL for double-stranded DNA.
2.1.5 Ligation
Ligations were performed using a 1:1/1:3/1:5 molar ratio of vector to insert, with 100 ng
total DNA, 1 x T4 DNA ligase buffer and 1 unit of T4 DNA ligase (Invitrogen) in a total
volume of 20 mL at 16 ºC overnight.
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2.1.6 Preparation of LB (Luria-Bertani) agar plates
LB agar, prepared in-house, was melted in a microwave oven, then cooled to around 50 ºC
before addition of antibiotics, typically ampicillin (0.1 mg/mL) or chloramphenicol (34
µg/mL). The LB agar was then poured into sterile plates aseptically and allowed to cool
to room temperature. The plates were left to set and then were stored at 4 ºC until use.
2.1.7 Transformations
2.1.7.1 Using chemically competent bacteria
Heat shock transformation was performed. Briefly, the ligation mixture (20 mL) was added
to 100 mL of E.coli DH5 alpha cells and chilled on ice for 30 min and mixed gently by
tapping. The cells were then heat-shocked for 45 sec at 42 ºC before chilling on ice
immediately. SOC medium (1ml, Invitrogen) was added to the cells which were then
incubated with shaking (200 rpm) for 45 min. The transformed cells were then plated on
pre-warmed LB agar plates containing appropriate antibiotic. The plates were incubated
overnight at 37 ºC and then stored at 4 ºC.
2.1.7.2 Using electro-competent bacteria
For electroporation, PCR products or ligated DNA was added to electrocompetent bac-
teria, which was added to an electroporation cuvette with a 0.1 cm gap, on ice. The
bacteria/DNA mix was electroporated at 1.80 kV and then placed directly into 500 mL
SOC medium at 37 ºC for 1 h. An aliquot of bacterial suspension was spread onto an
LB-agar plate containing appropriate antibiotics.
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2.1.8 Isolation of plasmid DNA
For extraction of DNA, colonies were lifted off the agar plates using a sterile pipette tip
and were grown up in 5ml LB containing the appropriate antibiotic, with shaking (200
rpm, 37 ºC, o/n). Plasmid DNA was isolated using the QIAprep® Spin Miniprep and
Maxiprep Kits according to the manufacturer’s instructions. DNA was eluted in 50 mL
of ddH2O and DNA concentration measured. A diagnostic restriction digest with the
appropriate restriction enzymes was carried out to screen for positive clones. An ali-
quot (between 100 and 500 ng) of the DNA was digested with 10 units of restriction
enzyme in an appropriate buffer at 37 ºC for 1-4 h. The products were run on an agarose
gel (subsection 2.1.2) and the DNA from the colonies giving correctly sized DNA frag-
ments was sequenced (by Cogenics). Sequences were aligned with the BLAST2 sequence
alignment tool, and bacterial clones containing the desired constructs were maintained as
glycerol stocks at -80 ºC for long term storage.
2.2 Protein techniques
2.2.1 Preparation of cell lysates
Cells in suspension (Jurkat T cells) were collected by centrifugation at 400 x g, 4 ºC for
10 min while adherent cells (HEK293T cells) were harvested from plates with a sterile
cell scraper. The cells were lysed by the addition of the appropriate lysis buffer (TX100
lysis buffer for pull-downs with streptavidin-agarose, SEC experiments and other routine
experiments; GTP lysis buffer for pull-downs with GTP-agarose) containing a final con-
centration of 5 mL/mL of a protease inhibitor cocktail (Sigma P8340) and were incubated
on ice for 20 min. The cell debris was removed by centrifugation at 20 000 x g, 4 ºC for
10 min. Supernatants were transferred to fresh microfuge tubes, and to an aliquot of the
lysate, an equal volume of Laemmli sample buffer (Bio-Rad) containing 50 mM DTT was
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added.
2.2.2 In vitro interaction between GST-GIMAP6 and
GABARAPL2
This was carried out according to the protocol in Pascall et al., 2013. Briefly, full-length
GIMAP6 cDNA fragment was transferred to plasmid pGEX4T-1 and transformed into the
E. coli Rosetta strain (Novagen). A parallel transformation of plasmid pGEX4T-1 was
also performed. 20 mL overnight Rosetta cultures in LB medium containing either the
GST or the GST-GIMAP6 expression construct were used to inoculate 1 L pre-warmed
LB medium containing 200 mg/mL ampicillin and 50 mg/mL chloramphenicol. Cells were
grown at 37 ºC for 2-3 h to an OD600 of approximately 0.6. The cultures were then cooled
to 16 ºC and protein expression induced by the addition of 0.1 mM IPTG. Cultures were
then grown for a further 16 h at 16 ºC. All subsequent steps were carried out at 4 ºC.
Bacteria were collected by centrifugation at 5000 g for 5 min, pellets washed in 20 mL
PBS pH 7.3 and centrifuged as described above. The pellets were then re-suspended
in 20 mL lysis buffer {PBS containing 5 mM EGTA, 1% (v/v) Triton X-100, 5 mM
MgCl2, pH 7.4 with 1:100 Bacterial Protease Inhibitor Cocktail (Sigma)} per pellet and
cells were lysed by sonication. The resulting lysate was centrifuged at 10 000 g for 15
min and the supernatant applied to a 125 µL packed volume glutathione Sepharose 4B
column previously pre-equilibrated in binding buffer (140 mM NaCl, 2.7 mM KCl, 1 mM
DTT, 10 mM Na2HPO4, 10 mM KH2PO4 pH 7.3). The flow-through was collected and
rebound to the column twice. The column was washed with 3 x 5 column volumes of
binding buffer. Purified GABARAPL2 (20 µg) in 500 mL of binding buffer was added to
the column and incubated for 1 h at 4 ºC. The column was washed as described above,
and the bound protein (GST and GST-GIMAP6) was eluted by the addition of 2 x 100 µL
of elution buffer (50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0). Eluates were
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analysed by SDS-PAGE, and were then either stained with Coomassie Brilliant Blue R to
assess recovery of GST/GST-GIMAP6 or by Western blotting to assay for the presence of
GABARAPL2.
2.2.3 GTPgS loading assay
This assay was carried out in collaboration with Dr Heidi Welch (Babraham Institute).
Glutathione beads with immobilised GST-tagged protein (GST, GIMAP6, or Rac) were
washed in the assay buffer (20 mM Hepes, pH 7.5 at 4 ºC, 100 mM NaCl, 1 mM MgCl2,
1 mM EGTA, 10 mg/mL fatty-acid free BSA, 1 mM DTT). To the washed beads assay
buffer containing 100 µM GTPgS (tetralithium salt, from ICN, kept at -20 ºC) and 20
µCi [35S]GTPgS (1250 Ci/mmol, from NEN) was added. The low Mg2+ concentration in
the assay buffer helps to GTP-load the protein, as the GTPase nucleotide binding pocket
requires Mg2+. Aliquots of 50 mL containing EDTA at a final concentration of 2 mM or
not and 2mCi [35S]GTPgS were incubated for 30 min at 30 ºC. The reaction was stopped
by adding ice-cold wash buffer (1xPBS, 1 mM EGTA, 10 mM MgCl2, 1% Triton X-100,
0.1 mM GTP). The high Mg2+ concentration in the wash buffer inhibits further nucleotide
exchange. The beads were washed with 8 x 400 mL ice-cold wash buffer and the beads
recovered each time by centrifugation at 10 000 g for 15 s. After the final wash, the wash
buffer was thoroughly aspirated and 400 mL Ultima Gold scintillation fluid (Packard) was
added and vortexed well. The tubes with the beads were transferred into scintillation
vials (Packard) and 5ml scintillation fluid was added. This mixture was vortexed well and
[35S]GTPgS loading was measured by b-scintillation counting.
2.2.4 Size exclusion chromatography
Lysates were harvested from HEK293T cells and Jurkat T cells as described in subsection 2.2.1.
The lysate with a volume of 0.2 mL was applied on a Superdex 200 10/30 SEC column at
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a flow rate of 1ml/min. The column was equilibrated with 2 column volumes (CV) of SEC
buffer (20 mM Tris pH 7.5, 150 mM NaCl, 2 mM DTT). These experiments were carried
out in collaboration with Michael Wilson (Babraham Institute). Fractions of interest were
collected and analysed via western blotting.
2.2.5 SDS-PAGE
Cell lysates were analysed by sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) following the protocol described by Kolbe et al. (1984). 10-12% (w/v)
gels (30% acrylamide solution, 37.5:1 acrylamide:bis acrylamide) were prepared using
the Mini-PROTEAN® 3 system (Bio-Rad Laboratories Inc, USA) and the resolving gels
were overlaid with 200 mL of isopropanol to generate a flat gel interface. The isopropanol
was washed off prior to the application of the 10% (w/v) polyacrylamide stacking gel. All
samples added to the gels had been mixed 1:1 with 2x Laemmli sample buffer (Biorad;
35 mM DTT final) and denatured by heating at 95 ºC for 5 min. Precision Plus Protein
Markers (BioRad) were run alongside the lysate samples to mark the molecular weights.
The gels were subjected to a constant voltage of 90 V for 1.5 h. On completion of elec-
trophoresis the proteins separated on the gel were transferred to polyvinylidene fluoride
(PVDF) membranes (Immobilon-P) for analysis by immunoblots. Alternatively, proteins
on the gel were detected by silver staining (Sigma) or Coomassie Blue staining (Gel Code
Blue reagent, Pierce). For both silver and Coomassie Brilliant Blue staining, manufac-
turer’s instructions were followed. For western blotting, the transfer was carried out using
a semi-dry apparatus. The gels were subjected to a constant current of 4 mA for 80 min.
2.2.6 Immunoblotting
Following transfer, PVDF membranes were blocked (either o/n at 4 ºC, or 45 min at RT)
in 5% milk powder in PBS-0.1% Tween-20 (hereafter referred to as blocking buffer). The
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membrane was then probed with primary antibody in blocking buffer at RT for between
1 and 3h or overnight at 4 ºC. The membrane was then washed repeatedly in PBS-0.1%
Tween-20. Following this, the membrane was probed with a secondary antibody conjug-
ated to horseradish peroxidase for 1 h at RT. The membrane was again repeatedly washed
in PBS-0.1% Tween-20 before being incubated with Pierce Super Signal or Millipore Im-
mobilon enhanced chemiluminescence reagents for 5 min. The membrane was blotted
dry again, was wrapped in Saran Wrap and was exposed to X-ray film (Amersham) which
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2.3 Cell based methods
2.3.1 Cell line establishment and maintenance
2.3.1.1 Biot-GIMAP4/7-His myc-BirA Jurkat cell line
Jurkat T cells stably expressing either GIMAP4 or GIMAP7 were established following
the protocol described in Pascall et al., 2013. Briefly, the myc-BirA-Jurkat cell line (Pas-
call et al., 2013) was maintained in RPMI (Invitrogen) supplemented with 10% FCS, 100
units/mL penicillin and 100 mg/mL streptomycin (Invitrogen) and containing 500 µg/mL
G418. Approximately 107 cells were transfected by electroporation with 20 µg of either
PvuI-linearised plasmid biot-GIMAP4/7-His-pCAG-iPuro or the corresponding vector.
Cells were allowed to recover overnight in complete medium containing 500 µg/mL G418.
The following day, the cells were spun down and resuspended in 20 mL of complete me-
dium containing 500 µg/mL G418 and plated at 100 µL/well into 96-well plates. The
following day an equal volume of complete medium containing 500 µg/mL G418 and
6 µg/mL puromycin was added to each well. Every 3-4 days thereafter, half of the me-
dium was replaced with fresh complete medium containing 500 µg/mL G418 and 3 µg/mL
puromycin. Cells carrying the parental pCAG-iPuro vector were isolated in parallel, as
controls. Biot-GIMAP4-His and Biot-GIMAP7-His expressing clones were identified
by western blotting of cell lysates with a horseradish peroxidase-conjugated streptavidin
probe. A single vector clone and a single clone carrying Biot-GIMAP4/7-His (termed the
Biot-GIMAP4/7-His myc-BirA-Jurkat cell line) were maintained for subsequent analysis.
Cells were maintained by the removal of an aliquot of cells and transferring to a new flask
containing fresh medium (in vitro passage).
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2.3.1.2 HEK293 cell lines expressing myc-tagged wt GIMAP and
myc-tagged GIMAP variants
Cell lines were established following the protocol described in Pascall et al., 2013. HEK293
cells were plated in a 6-well plate and 24 h later were transfected using lipofectamine
(Invitrogen) with a myc-tagged human GIMAP6-expressing plasmid or a myc-tagged
plasmid expressing either GIMAP61-282, GIMAP6G50D or GIMAP6S54N. The cells were
trypsinised 24 h later and re-plated in a 10cm tissue culture plate. 48 hours after transfec-
tion, stably transfected cells were selected by growth in DMEM/10% fetal calf serum/100
units/mL penicillin/100 µg/mL streptomycin/800 µg/mL G418. Single colonies were
screened for GIMAP6 expression by western blotting and immunofluorescence.
The cells were passaged when confluent by aspirating the medium and washing with
sterile PBS. The cells were then detached by the addition of trypsin-EDTA (Invitrogen).
The cells were resuspended in culture medium and were either used or, for maintenance,
10% of the cells were placed into a fresh flask/10 cm dish with fresh culture medium. To
freeze the cells down, they were removed from the flask/dish as detailed for passaging.
The cells were centrifuged and were resuspended in FCS containing 10% DMSO (Sigma),
transferred to cryovials and frozen at -80 ºC in a freezing container (5100 Cryo 1 ºC
Freezing Container, "Mr. Frosty", Nalgene). After at least 24 h the vials were transferred
to liquid nitrogen.
2.3.2 Transient transfection of HEK293T cells
Cells were maintained in DMEM/10% (v/v) fetal calf serum/penicillin/streptomycin. Trans-
fections were performed using either polyethyleneimine (Boussif et al., 1995) or lipo-
fectamine (Invitrogen) according to the manufacturer’s instructions and cells were ana-
lysed 48h post transfection. HEK293T cells that were approximately 40% confluent were
transfected with 20 mg of plasmid DNA. Cell medium was replaced 14-16 h post transfec-
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tion. Transfections were performed with plasmids biotGIMAP6 and biotGABARAPL2
which had been derived previously by PCR-based transfer of human GIMAP6 and GABAR-
APL2 from full-length cDNA clones BC074744 and BM544477, respectively, into the
EcoRI-XhoI site of pcDNA3Biot1His6iresBirA (Pascall et al., 2013). Plasmids encod-
ing N-terminally myc-tagged GIMAP proteins were derived by cloning the correspond-
ing cDNA sequences into the EcoRI-XhoI site of pCANmyc3 (as pCANmyc1 (Saunders
et al., 2009, 2010; Rubinfeld et al., 1996) but with a different reading frame downstream
of the myc tag). Site-directed mutagenesis via PCR was performed on the above men-
tioned constructs to generate the variant GIMAP6 and GABARAPL2 proteins.
2.3.3 Induction of autophagy
The protocol described in Pascall et al., 2013 was followed. Amino acid starvation was
employed. Briefly, cells to be starved were washed twice with starvation medium (140
mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 5.5 mM glucose, 20 mM HEPES pH 7.4, 1%
(w/v) BSA) and then maintained in the same medium for the duration of the starvation.
2.3.4 Immunoprecipitations
Approximately 3 x 106 actively growing HEK293T cells were transfected with plasmids
as indicated using polyethyleneimine. Approximately 24 hours later, cells were trans-
ferred to fresh medium. The following day, dishes were washed in PBS and lysed into
the appropriate lysis buffer supplemented with mammalian protease inhibitor cocktail
(Sigma-Aldrich) at 4 ºC for 10 min (subsection 2.2.1). The supernatant was clarified by
centrifugation at 20,000 g for 10 min at 4 ºC. An aliquot of the supernatant (50 µL) was
removed to an equal volume of 2 x CSB and boiled to represent a lysate sample. To the
remaining supernatant was added either a 100 µL packed volume of streptavidin-agarose
(for transfections including pcDNA3Biot1His6iresBirA-based expression plasmids) or
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100 µL GTP-agarose beads. The suspensions were rotated at 4 ºC for 2h (streptavidin-
agarose; Sigma-Aldrich), or for 2h-overnight (GTP-agarose; Sigma-Aldrich) and then
centrifuged at 20 000 g for 30 s. The pellets were washed with 8 x 1ml lysis buffer and
the beads recovered each time by centrifugation at 20 000 g for 30 s. The final washed
pellets were resuspended in 50 µL 2 x CSB (and heated to 95 ºC for 5 min to elute the
bound proteins. SDS-PAGE gel electrophoresis and western blotting of the samples were
then performed as described previously (section 2.2), using antibodies as indicated.
2.3.5 Immunocytochemistry
Immunocytochemistry studies were performed following the protocol described in Pascall
et al., 2013. Cells grown on glass coverslips were washed with PBS and then fixed by one
of two methods:-
1. Cells were fixed in 4% (w/v) paraformaldehyde for 20 min at room temperature. Sub-
sequently, coverslips were rinsed 2-3 times with DMEM and left shaking gently for 15
min to remove all traces of paraformaldehyde before subsequent processing. 2. Cells
were fixed in ice-cold methanol (for staining with rabbit anti-MAP1LC3B antibody) for
1-2 min and then in 1% (w/v) bovine serum albumin (BSA) in PBS (BSA block) with
shaking at room temperature for at least 1 h.
After the fixation and washing steps, cells were permeabilised by incubation with 0.1%
(v/v) Triton X-100 in BSA block for a further 15 min at room temperature. The permeab-
ilisation step was omitted for methanol fixed cells. The cells were then rinsed with 3 × 2ml
PBS (total wash time 20 min) before incubation for 1 h with BSA to block non-specific
sites. The cells were then incubated with primary antibodies diluted in 100 mL of BSA
block for 30 min in the dark at room temperature. Cells were then rinsed with 4 × 2ml
PBS before a 30 min incubation with secondary antibodies which were diluted in 100 mL
BSA block. The cells were again rinsed with 4 × 2ml PBS to remove any excess anti-
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bodies. VectaShield containing DAPI (Vector Laboratories Inc.) was then mounted onto
the cells and a coverslip was carefully placed onto the glass slide covering the cells. Con-
focal images were captured using an Olympus FV1000 imaging system. Co-localisation
of proteins was determined using Imaris software.
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3.1 Context
3.1.1 Interaction between GIMAP6 and GABARAPL2
While it has been shown that the GIMAP GTPases play important roles in the devel-
opment and survival of lymphocytes (Barnes et al., 2010; Ciucci and Bosselut, 2014;
MacMurray et al., 2002; Saunders et al., 2010; Schnell et al., 2006; Schulteis et al., 2008;
Nitta et al., 2006; Yano et al., 2014; Hernandez-Hoyos et al., 1999), little is known of
the molecular mechanisms by which they carry out their function(s). To gain an insight
into the molecular mechanisms underlying the function of this family of small GTPases,
our laboratory undertook a biochemical approach to identify in vivo binding partners for
the GIMAPs. Employing a biotin-tag affinity approach combined with formaldehyde
cross-linking to stabilise possible molecular interactions, GABARAPL2, a mammalian
homologue of the yeast autophagy protein 8 (Atg8), was identified as a major and highly
specific interacting partner of human (h) GIMAP6 (Pascall et al., 2013). GABARAPL2
is a ubiquitin-like protein that has been reported to be required for the autophagic pro-
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cess: specifically it is believed to play a role in the maturation of the autophagosome
(Weidberg et al., 2010). Our group has also shown that the normally cytosolic GIMAP6
re-localises to autophagosomes on induction of starvation-induced autophagy (Pascall
et al., 2013). This chapter will focus on the structural basis of the molecular interaction
between GIMAP6 and GABARAPL2 and investigate whether this interaction is required
for the relocalisation of GIMAP6 to autophagosomes.
3.1.2 The Atg8 interacting motif (AIM) and the GTPase/AIG1
domain within GIMAP6
Autophagy was originally regarded as a non-selective, bulk degradation process that was
primarily required for balancing sources of energy at critical times in development and
in response to nutrient stress. Over the past decade, however, evidence has accumulated
suggesting that autophagy can be highly selective and it has been shown to be responsible
for the selective degradation of specific proteins and protein aggregates, organelles, and
micro-organisms, amongst other cellular constituents (Lamark et al., 2009; Kirkin et al.,
2009b,a). Selective autophagy is facilitated by the presence of selective autophagy recept-
ors including SQSTM1, NDP52, Nix, and Optineurin that can bind specific cargo and in-
teract with a member/s of the Atg8 family. For example, SQSTM1, the first selective auto-
phagy receptor to be identified (Bjorkoy et al., 2005), interacts with MAP1LC3B and is a
cargo receptor for the autophagic degradation of ubiquitylated protein aggregates (Pankiv
et al., 2007). Abrogating autophagy by deleting the Atg7 gene in mice, a gene required for
autophagosome biogenesis, resulted in the failure of degradation of SQSTM1 and led to
the accumulation of protein aggregates (Komatsu et al., 2007). Detailed deletion mapping
combined with point mutation analyses has led to the identification of Atg8 interaction
motifs (AIM) within the selective autophagy receptors. The consensus sequence of an
AIM consists of acidic residues (D/E) N-terminal to a core [W/F/Y]xx[L/I/V] sequence
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(Ichimura et al., 2008; Noda et al., 2008). Interestingly, hGIMAP6, but not mouse or
rat GIMAP6, has a sequence of amino acids spanning positions 3-9 of the protein that
corresponds to the canonical AIM. The putative AIM within GIMAP6 is composed of
the following sequence of residues - EEEYEQI. I carried out point mutation analyses to
investigate whether the putative AIM motif within GIMAP6 plays a role in its interaction
with GABARAPL2.
The GIMAP family of proteins contain the well-conserved GTP-binding AIG1 domain
and hence are considered to be GTPases. So far, however, the actual GTP binding ability
and enzymatic activity of only hGIMAP2, hGIMAP7 and hGIMAP4 have been character-
ised. Prior to commencing my study, the GTP binding ability of GIMAP6 was unknown.
It had also not been determined whether this domain played a role in the interaction with
GABARAPL2. Assays to determine the GTP binding ability of GIMAP6 and point muta-
tion analyses to analyse the requirement of the GTPase domain within GIMAP6 for its
interaction with GABARAPL2 have been carried out.
3.2 Chapter Aims
1. Carry out studies to assess the GTP binding ability of hGIMAP6
2. Identify domains within GIMAP6 that are required for the interaction with GABARAPL2
3. Investigate whether the interaction between GIMAP6 and GABARAPL2 is required
for the relocation of GIMAP6 to autophagosomes
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3.3 Results
Prior to commencing my studies on GIMAP6 and its interaction with GABARAPL2, I
attempted to discover novel interacting partners of hGIMAP4 and hGIMAP7 employing
tag-mediated pull-downs as well as cross-linking. This search for novel interacting part-
ners of GIMAP4 and GIMAP7 was performed by employing streptavidin affinity puri-
fication from Jurkat T cells. The Jurkat T cell line is derived from the peripheral blood
of a patient with T-cell acute lymphoblastic leukaemia (T-ALL; Schneider et al., 1977)
and was chosen as it is widely used to study T-cell signalling and, importantly, exhibits
endogenous expression of hGIMAPs. Labelling proteins with biotin is widely used in
order to take advantage of the strong and highly specific nature of the biotin-streptavidin
interaction. The biotinylation reaction can be carried out by the BirA enzyme, a 35 kDa
DNA-binding biotin protein ligase found in E.coli that catalyses the covalent addition of
biotin to the lysine side-chain present within the 15 amino acid biotinylation tag that is
fused to the target protein (Schatz, 1993; Drakas et al., 2005). A Jurkat T cell line stably
transfected with the pmycBirA-ires-neo plasmid (referred to as the myc-BirA-Jurkat cell
line henceforth) had been previously engineered in the laboratory. The myc-BirA-Jurkat
cell line was engineered to stably over-express either GIMAP4 or GIMAP7 carrying a
biotinylation target sequence. Cross-linking was performed using formaldehyde, disuc-
cinimidyl suberate (DSS) (a homobifunctional lysine specific cross-linking reagent with a
longer spacer arm than formaldehyde) and 1,6-bis-maleimidohexane (BMH) (a homobi-
functional cross-linker that irreversibly conjugates sulfhydryl groups). Formaldehyde has
a number of advantages in its use as a cross-linker: it is highly permeative, enabling cross-
linking within the intact cell; its small size ensures that only closely associated proteins
are cross-linked, and it is fast-acting, enabling rapid stabilisation of transient interactions.
Unfortunately, for both GIMAP4 and GIMAP7 this strategy was unsuccessful due to the
formation of high molecular weight protein aggregates, possibly due to excessive specific
cross-linking. Additionally, no specific proteins appeared to co-purify with biotinylated
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GIMAP4 or GIMAP7 after streptavidin affinity purification (results not shown).
3.3.1 Cross-linking using DSS confirms the presence of the
GIMAP6-GABARAPL2 protein complex
GABARAPL2 was previously identified as an interacting partner of hGIMAP6 by using
formaldehyde as a cross-linker to stabilise potential interactions, followed by mass spec-
trometry (Pascall et al., 2013). Further confirmation of the existence of this complex was
performed by using DSS as a cross-linker. DSS is a water-insoluble, non-cleavable and
membrane permeable cross-linker with an amine-reactive N-hydroxysuccinimide (NHS)
ester at each end of an 8-carbon spacer arm. Jurkat T cell lines stably over-expressing
a plasmid containing myc-tagged BirA and a plasmid carrying hGIMAP6 with an N-
terminal biotinylation target sequence (Biot-GIMAP6-His myc-BirA), or the correspond-
ing vector cell line (Biot-vector-His myc-BirA), that had been previously established
in the laboratory were used and streptavidin affinity purification of a cross-linked bi-
otinylated GIMAP6 protein complex was carried out. The cross-linking reaction was
performed in cell lysates that were treated with a final concentration of 2 mM DSS for
a duration of 1 h at RT. This was followed by streptavidin-affinity purification which
was carried out by incubating lysates with the streptavidin-agarose beads for 2h at 4 ºC.
Lysates were separated via SDS-PAGE and transferred to a PVDF membrane, following
which immunoblots were probed with either a streptavidin-HRP conjugate or a rat mono-
clonal antibody (mAb) to GABARAPL2, MAC446, followed by an HRP-conjugated goat
F(ab’)2 fragment anti-rat IgG to detect GABARAPL2. A discrete DSS cross-linked spe-
cies corresponding to a relative mass (Mr) of ca. 55 kDa was detected when the membrane
was probed with either the streptavidin-HRP conjugate or MAC446 (Figure 3.3.1). Biot-
inylated GIMAP6 exhibits a mobility on SDS-PAGE corresponding to an Mr of ca. 40
kDa while GABARAPL2 displays a mobility corresponding to Mr ca. 15 kDa. In the
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cross-linked sample, however, both the streptavidin-HRP conjugate as well as MAC446
detected the presence of a cross-linked species corresponding to an Mr of ca. 55 kDa.
As MAC446 was also able to detect a species of the same Mr , the presence of a complex
containing GIMAP6 and GABARAPL2 was confirmed. Furthermore, GABARAPL2 was
detected at a much lower intensity by MAC446 at its expected molecular mass in the
cross-linked sample consistent with its presence in the ca. 55 kDa complex.
Figure 3.3.1: GIMAP6 is cross-linked to GABARAPL2 when DSS is used as a cross-
linker.
Jurkat T cells engineered to over-express myc-tagged BirA and GIMAP6 carrying a biot-
inylation target sequence were incubated with or without 2 mM DSS for 1 h at RT. Cell
lysates were analysed by immunoblotting with either (A) the streptavidin-HRP conjug-
ate to detect biotinylated proteins or (B) the rat monoclonal antibody to GABARAPL2,
MAC446 followed by an HRP-conjugated goat F(ab’)2 fragment anti-rat IgG to detect
GABARAPL2. The mobilities of the biotinylated GIMAP6 and the cross-linked species
are shown. The cross-linked species is within the red circle in both A and B. In figure
A, proteins with an electrophoretic mobility of approx. 75 kDa are believed to endogen-
ous proteins biotinylated proteins by BirA. In Figure B, the reason behind the presence
of the proteins in lanes 1 and 3 displaying mobilities between 37 kDa and 75 kDa is not
understood. These may be non-specific in nature.
The streptavidin-HRP conjugate was able to detect biotinylated GIMAP6 at its expected
molecular mass, albeit at a lower relative intensity, in the cross-linked sample. The size
of the individual components of the GIMAP6-GABARAPL2 complex (ca. 40 kDa and
ca. 15 kDa, respectively), and the size of the cross-linked complex (ca. 55 kDa) strongly
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suggested that the interaction between GIMAP6 and GABARAPL2 was direct. This hy-
pothesis was tested and the findings are shown later on in the thesis. The ca. 55 kDa
complex was absent in samples that were not cross-linked and was also absent in lysate
samples prepared from the Biot-vector-His myc-BirA Jurkat T cell line.
3.3.2 The GIMAP6-GABARAPL2 interaction can be detected
without cross-linking
To investigate whether the GIMAP6-GABARAPL2 interaction could be detected without
cross-linking, I assessed the ability of hGIMAP6, when over-expressed either in tran-
siently transfected HEK293T cells or in the Biot-GIMAP6-His myc-BirA Jurkat T cell
line, to interact with endogenous GABARAPL2. HEK293T cells were transfected with
a plasmid in which wild-type (wt) GIMAP6 was cloned into the pcDNA3 vector carry-
ing a CMV promoter, an N-terminal biotinylation tag and the internal ribosome entry
site (IRES) sequence followed by BirA (Biot1-GIMAP6-His6-IRES-BirA). The IRES
enables the bicistronic expression of wt GIMAP6 and BirA. This plasmid (20 mg) was
transfected in HEK293T cells and lysates were prepared 48h post transfection. Lys-
ates were also prepared from the Biot-GIMAP6-His myc-BirA Jurkat T cell line, or
the corresponding vector-only cell line and biotinylated and associated proteins were re-
covered by streptavidin-agarose affinity purification. Lysates were separated via SDS-
PAGE and transferred to a PVDF membrane and immunoblots were probed with either
the streptavidin-HRP conjugate or MAC446. Immunoblots showed the recovery of biot-
inylated GIMAP6 and the co-precipitation of endogenous GABARAPL2. Co-precipitation
of GABARAPL2 is not seen in cells (both HEK293T and Jurkat T cells) carrying the vec-
tor without GIMAP6 (Figure 3.3.2). Unfortunately this interaction could not be detected
between endogenous GIMAP6 and endogenous GABARAPL2 (Pascall et al., 2013), pos-
sibly due to either the transient nature of the interaction or the inability of the available
65
3 Molecular requirements of GIMAP6 for the interaction with GABARAPL2
antibodies to immunoprecipitate or to recognise the complex.
Figure 3.3.2: The GIMAP6-GABARAPL2 interaction can be detected without cross-
linking.
A: Immunoblots carried out on lysates obtained from HEK293T cells that were tran-
siently transfected with wt GIMAP6 in plasmid pcDNA3Biot1His6iresBirA (+), or the
corresponding vector (-). SP: streptavidin pull-down. B: Immunoblots carried out on
lysates obtained from Jurkat T cells that were either stably transfected to over-express
myc-BirA and GIMAP6 carrying a biotinylation target sequence (+) or engineered to
stably express myc-BirA and the corresponding vector (-). Biotinylated and associated
proteins were recovered by streptavidin-agarose affinity purification (48h post transfec-
tion in the case of HEK293T cells). Immunoblots of the recovered proteins were probed
with the streptavidin-HRP conjugate to detect GIMAP6 proteins or the rat monoclonal an-
tibody MAC446 to GABARAPL2 followed by an HRP-conjugated goat F(ab’)2 fragment
anti-rat IgG.
3.3.3 The role of the AIM in the interaction of GIMAP6 with
GABARAPL2
As introduced in subsection 3.1.2, the N-terminus of hGIMAP6 contains within it a ca-
nonical putative AIM sequence spanning amino acids 3-9 (EEEYEQI). Constructs were
designed to: (i) substitute Y6 and, separately, I9, to A. The Y and I residues of the AIM are
believed to bind the hydrophobic pockets 1 and 2, respectively, within the core ubiquitin-
like domain of GABARAPL2 (Noda et al., 2010, 2008; Ichimura et al., 2000). These
mutant GIMAP6 sequences were generated via PCR mutagenesis and were cloned into
the Biot1-His6-IRES-BirA plasmid. HEK293T cells were transfected with these con-
structs and lysates were prepared 48h post transfection. Streptavidin affinity purification
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was performed and the recovered biotinylated and associated proteins were detected as
described in the legend to Figure 3.3.3. As shown in the figure, the putative AIM is not
required for the interaction of GIMAP6 with GABARAPL2 as the latter is seen to co-
precipitate with the variant GIMAP proteins. The GIMAP6 amino acid sequence was
further inspected to attempt to identify additional regions within the protein that may
correspond to an AIM. No such sequence could be identified.
Figure 3.3.3: The putative AIM within the N-terminal region of GIMAP6 is not required
for the GIMAP6-GABARAPL2 interaction.
HEK293T cells were transfected with wt GIMAP6 or the indicated mutated derivatives in
plasmid pcDNA3Biot1His6iresBirA. Biotinylated and associated proteins were recovered
by streptavidin-agarose affinity purification 48h post transfection. Immunoblots of the re-
covered proteins were probed with the streptavidin-HRP conjugate to detect the GIMAP6
proteins (upper panel) or the rat monoclonal antibody MAC446 followed by an HRP-
conjugated goat F(ab’)2 fragment anti-rat IgG to detect GABARAPL2 (lower panel).
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3.3.4 Role of the GTPase AIG1 domain within GIMAP6 in its
interaction with GABARAPL2
As mentioned in subsection 3.1.2, the GIMAP family contains the highly conserved GTP
binding AIG1 domain. Prior to investigating whether this region played a role in in-
teracting with GABARAPL2, it was pertinent to ask whether GIMAP6 is indeed able
to bind GTP. The nucleotide binding and hydrolytic activity of GTPases is commonly
characterised by generating purified protein and employing radioactive [35S]GTPgS and
[a32P]GTP or [g32P]GTP. Measuring the amount of GTP bound to the protein is possible
when the assay is carried out with GTPgS, the slowly hydrolysable analogue of GTP.
The catalytic activity can be analysed by using the isotopically-labelled native GTP and
measuring the amount of either GDP or radioactive phosphate released. The GIMAP6
gene was inserted into the bacterial expression vector pGEX-4T-1 and Escherichia coli
(E.coli) Rosetta DE(3) bacteria (Novagen) were transformed with this construct, enabling
IPTG-inducible expression of a fusion protein with the glutathione-S-transferase (GST)
tag N-terminal to GIMAP6. Expression of GST-GIMAP6 was induced by the addition
of 100 mM IPTG when cultures that had reached the exponential phase of growth had
been cooled to 16 ºC. Subsequent to the addition of IPTG, an overnight incubation of the
cultures was carried out at 16 ºC. A low temperature was chosen for induction of protein
expression as this has been shown in other cases to enhance the yield of active soluble
protein (Coligan et al., 2001). Attempts made to purify GST-GIMAP6 by solubilising the
pellet in E.coli lysis buffer showed that the majority of the protein appeared to accumulate
as insoluble aggregates (inclusion bodies) (Figure 3.3.4).
68
3.3.4 Role of the GTPase AIG1 domain within GIMAP6 in its interaction with
GABARAPL2
Figure 3.3.4: GST-GIMAP6: bacterial expression and purification.
Various samples taken during the purification were resolved by SDS-PAGE; proteins were
subsequently visualised by Coomassie Blue staining. M: molecular weight marker; -/+
IPTG (final concentration 0.1 mM), whole-cell bacterial lysates before and after overnight
induction at 16 ºC; SN: supernatant of bacterial lysates after centrifugation (20000 g, 10
min, 4 ºC); E: GST-GIMAP6 eluted with glutathione; IB: sample extracted from bacterial
pellet suspended in 6M urea.
The small proportion of GST-GIMAP6 that appeared soluble was affinity purified us-
ing glutathione-Sepharose beads. Assays to characterise whether GIMAP6 could bind
GTP were carried out by loading [35S]GTPgS on to GST-GIMAP6 that was immobil-
ised on the glutathione-Sepharose beads. Purified GST-Rac that had been immobilised
on glutathione-Sepharose beads (a kind gift from Dr. Heidi Welch, Babraham Institute)
was used as a positive control. The experiment was carried out in the presence or ab-
sence of EDTA. EDTA chelates the Mg2+ ions which would allow the [35S]GTPgS to
be loaded. [35S]GTPgS-loading of GST-Rac, GST and GST-GIMAP6 was quantitated
by b-scintillation counting. While GST-Rac was able to load [35S]GTPgS, counts gen-
erated by GST-GIMAP6 were very similar to those generated by the no protein negative
control (Figure 3.3.5). Inconclusive results were also obtained when GST-GIMAP6 was
eluted off the beads, concentrated, and then loaded with [35S]GTPgS (not shown). The
technical hurdles in obtaining active soluble GIMAP6 have also been encountered by a
research group in Germany working on the GIMAP GTPases (personal communication,
O. Daumke). They have also observed that GIMAP6 has a strong propensity to aggreg-
ate, thereby posing a significant hurdle in the biochemical characterisation of purified
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GIMAP6.
Figure 3.3.5: [35S]GTPgS loading of GST-GIMAP6.
GST, GST-GIMAP6 or GST-Rac immobilised on glutathione beads were used for this
assay. The beads were incubated with 10 µM GTPgS and and 2mCi [35S]GTPgS for 30
min at 30 ºC in the presence (or not) of EDTA at a final concentration of 2 mM. The
reaction was stopped by adding ice-cold wash buffer (subsection 2.2.3). To the beads 400
mL Ultima Gold scintillation fluid was added and vortexed. The tubes with the beads were
transferred into scintillation vials and scintillation fluid was added. [35S]GTPgS loading
was measured by b-scintillation counting. Technical replicates done in duplicates. Error
bars represent standard error of mean.
3.3.4.1 GTP-agarose beads
An alternate approach to answering the question of whether a putative GTPase can in
fact bind GTP/GDP is the use of GTP-agarose beads (Carlessi et al., 2011; Jebelli et al.,
2012). While characterising nucleotide binding ability using purified protein is the canon-
ical approach, for proteins that are prone to aggregation, the use of GTP-agarose beads
can provide a viable approach to determine, in general terms, their nucleotide binding
abilities. It is advantageous in this respect that the beads can be used to interrogate crude
cell lysates in which the target protein (identifiable by means of a specific antibody or
generic epitope tag) may have a greater opportunity to retain its native, undenatured con-
formation. In this approach, the beads can be incubated with either lysates from cells that
endogenously express the protein in question or lysates from cells that have been engin-
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eered to over-express the protein or its variants. As Jurkat T cells express the GIMAP
family of proteins endogenously, they were used for this assay. Aliquots of Jurkat T cell
lysate were incubated overnight at 4 ºC with the GTP-agarose beads in the presence or
absence of free GDP or GTP. Western blots of bound proteins probed with rat anti-human
GIMAP6 monoclonal antibody MAC445 showed that GIMAP6 can bind the GTP-agarose
beads and that this interaction could be efficiently abrogated by the addition of increasing
concentrations of free GTP or GDP. GDP was less efficient than GTP at competing with
the interaction between GIMAP6 and the GTP-agarose beads, indicating that GIMAP6
has a higher affinity for GTP than for GDP (Figure 3.3.6). To demonstrate specificity
of the GIMAP6-GDP/GTP interaction, lysate from Jurkat T cells was incubated with the
GTP-agarose beads in the presence of free ATP. The free ATP did not have any measurable
effect on the interaction between GIMAP6 and the GTP-agarose beads.
Figure 3.3.6: GIMAP6 binds GTP
Lysates from wt Jurkat T cells were incubated overnight with GTP-agarose beads at 4
ºC in the presence of increasing concentrations of GTP, GDP or ATP. After incubation
beads were washed with GTP lysis buffer to wash away unbound proteins. Western blots
were carried out on the extracts from 105cells in the Total Lysate (TL) lane, and on the
extract from 6x105 cells in the other lanes, indicating a recovery of approx. 15% of
GIMAP6 following incubation with GTP-agarose beads when the samples are treated
with vehicle (PBS; 0 mM lane). Immunoblots were probed with MAC445, followed by an
HRP-conjugated goat F(ab’)2 fragment anti-rat IgG, to detect GIMAP6.
71
3 Molecular requirements of GIMAP6 for the interaction with GABARAPL2
Next, to analyse the dynamics of GIMAP6 binding to the GTP-agarose beads, aliquots of
the lysate from Jurkat T cells were incubated with the GTP-agarose beads for a duration
ranging from 2h to an overnight incubation at 4 ºC, with or without the inclusion of 1 mM
free GTP. Immunoblots indicated that a 2h incubation was sufficient for GIMAP6 to bind
the GTP-agarose beads, and that this interaction reached its maximum level after about
8h incubation at 4 ºC, after which time-point no significant increase in binding efficiency
was seen (Figure 3.3.7). The length of the incubation required may suggest a slow on-
rate. The results in this section support the view that GIMAP6 is a bona fide GTP binding
protein and that therefore it is valid to consider its functional activity in this context.
Figure 3.3.7: Dynamics of GIMAP6 binding to GTP.
Lysates from wt Jurkat T cells were incubated with GTP-agarose beads at 4 ºC for dura-
tions ranging from 2h to overnight in the presence or absence of 1 mM free GTP. After
incubation, beads were washed with GTP lysis buffer to wash away unbound proteins.
Western blots were carried out on lysates from 105cells in the Total Lysate (TL) lane,
and on the extract from 6x105 cells in the other lanes. Immunoblots were probed with
MAC445, followed by an HRP-conjugated goat F(ab’)2 fragment anti-rat IgG to detect
GIMAP6. The Jurkat T cell lysate needs to be incubated with the GTP-agarose beads for
at least 8 h to obtain an efficient recovery of GIMAP6.
3.3.4.2 The effect of mutations within the AIG1/GTP binding domain of
GIMAP6 on its interaction with GABARAPL2
Data from the above experiments suggest that GIMAP6 is a bona fide guanine nucleotide
binding protein, if not an active catalytic GTPase. This raised the question of whether the
AIG1 domain of GIMAP6 is functionally required for its interaction with GABARAPL2.
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Magnesium ions (Mg2+) play an important role in the nucleotide binding and catalytic
activity of GTPases (Bourne et al., 1991); they force the triphosphate into a stretched
conformation in which the b- and g-phosphates are coordinated in a manner that allows
for hydrolysis (Rudack et al., 2012). A preliminary experiment using HEK293T cell lys-
ates was therefore carried out in which Mg2+ ions were chelated. HEK293T cells were
transiently transfected with biotin-tagged GIMAP6 and the lysates (prepared as described
in subsection 3.3.2) were treated with 15 mM EDTA or EGTA and streptavidin-agarose
affinity purification was carried out as described in subsection 3.3.2. EDTA chelates
divalent cations and has a high affinity for Mg2+ while EGTA has a lower affinity for Mg2+
but a high affinity for, e.g., Ca2+ ions, thus serving as a control in these experiments. Che-
lation of Mg2+ would be expected to disrupt the GTP binding by GIMAP6. Immunoblots
show the recovery of biotinylated GIMAP6, and show that the co-purification of endo-
genous GABARAPL2 is significantly affected by EDTA treatment, but not upon EGTA
treatment. This observation is consistent with the idea that the GTPase domain within
GIMAP6 has a role in the interaction with GABARAPL2 (Figure 3.3.8).
73
3 Molecular requirements of GIMAP6 for the interaction with GABARAPL2
Figure 3.3.8: Chelation of Mg2+adversely affects the GIMAP6-GABARAPL2 interac-
tion.
Cell lysates were prepared from HEK293T cells that had been transiently transfected
with wt GIMAP6 in the pcDNA3 Biot1-His6-IRES-BirA plasmid for 48h. Lysates were
treated with vehicle (PBS), 15 mM EDTA, or 15 mM EGTA and biotinylated proteins
along with associated proteins were recovered by streptavidin-affinity chromatography.
Immunoblots of the recovered proteins were probed with the streptavidin-HRP conjugate
(to show the GIMAP6 proteins; upper panel) or rat monoclonal antibody MAC446 to
GABARAPL2 followed by an HRP-conjugated goat F(ab’)2 fragment anti-rat IgG (lower
panel) to demonstrate co-precipitation of GABARAPL2. Treating lysate with EDTA, but
not EGTA, affected the GIMAP6-GABARAPL2 interaction, pointing to a role for the
GTPase domain within GIMAP6 in the interaction.
Selected mutations were introduced by mutagenic PCR into the G motifs (G1-G5; refer
introduction) of the GTPase/AIG1 domain within GIMAP6 (Figure 3.3.9). These mutant
GIMAP6 sequences were cloned into the Biot1-His6-IRES-BirA plasmid and then HEK293T
cells were transfected as detailed above. Introduction of mutations within the predicted
G1 (G50D and S54N), G2 (T76A), G3 (D95A and N98A) and G5 (N201A) motifs pre-
vented the GIMAP6-GABARAPL2 interaction.
74
3.3.4 Role of the GTPase AIG1 domain within GIMAP6 in its interaction with
GABARAPL2
Figure 3.3.9: A representation of the motifs within the GTP binding domains of
hGIMAPs.
Fully conserved amino acid residues are shown in red, and residues that are at least 60%
conserved in green. The three consecutive G domains of GIMAP8 were aligned indi-
vidually. b-strands are shown as green arrows, a-helices as red barrels and loops as black
lines. The G motifs involved in nucleotide binding and the switch I and II regions are
indicated. The C-terminal hydrophobic segments of GIMAP1, 2 and 5 are boxed. Black
stars indicate residues that were substituted. Figure adapted from Schwefel et al., 2013.
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Mutations were introduced at these particular sites based on the conserved nature of these
residues within the Ras superfamily of GTPases (refer section 1.3). The G50D mutation
within the G1 motif of GIMAP6 is postulated to result in a gain of function variant of
GIMAP6 that is constitutively bound to GTP and can interact with downstream effectors.
The S54N variant in G1 is hypothesised to result in a dominant-negative variant that is
unable to bind GTP, but can bind GDP. The T76A mutation within the G2 motif is believed
to be constitutively bound to GTP, but unable to signal, while mutations within the G3 and
G5 motifs affect nucleotide binding (Feig, 1999; García-Mata et al., 2006; Cherfils and
Chardin, 1999).
The G4 motif normally determines selectivity for guanine nucleotides over adenine nuc-
leotides. Surprisingly, introducing a mutation within the putative G4 motif of GIMAP6
by mutating the conserved aspartic acid to alanine (D167A) did not affect the interaction
between GIMAP6 and GABARAPL2 (Figure 3.3.10). Structural analyses have revealed
that the GIMAP family displays some structural similarity to the dynamin family of pro-
teins (Schwefel et al., 2010) and, interestingly, mutating the conserved aspartic acid in
dynamin I (DymA) did not significantly affect nucleotide selectivity or nucleotide bind-
ing (McMahon, 2004). One possible reason for the finding seen with the GIMAP6D167A
variant could be that the role played by the aspartic acid residue in the selective recog-
nition of the guanine base in Ras may be taken on by a separate, as yet unidentified,
residue.
The arginine at position 134 was also mutated to alanine, as recent work on the structure
of GIMAP2 has shown that the corresponding arginine (117) plays a role in its homod-
imerisation and this associated with GTP binding (Schwefel et al., 2010). Mutating this
residue within GIMAP6 did not appear to affect the GIMAP6-GABARAPL2 interaction
(Figure 3.3.10).
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Figure 3.3.10: Mutations within the GTPase domain of GIMAP6 abrogate the interaction
with GABARAPL2.
HEK293T cells were transfected with wt GIMAP6 or the indicated mutated derivatives in
plasmid pcDNA3Biot1His6iresBirA. Biotinylated and associated proteins were recovered
by streptavidin-agarose affinity purification 48h post transfection. Immunoblots of the re-
covered proteins were probed with the streptavidin-HRP conjugate to detect the GIMAP6
proteins (upper panel) or rat monoclonal antibody MAC446 to detect GABARAPL2 fol-
lowed by an HRP-conjugated goat F(ab’)2 fragment anti-rat IgG (lower panel).
I then tested whether mutations within the GTPase domain of GIMAP6 affected the abil-
ity of the GIMAP6 variants to interact with the GTP-agarose beads and whether GIMAP6
variants that could interact with GABARAPL2 could still bind GTP-agarose. For this,
either HEK293 cells were engineered to stably over-express myc-tagged GIMAP6G50D or
GIMAP6S54N, or HEK293T cells were transiently transfected with the Biot1-His6-IRES-
BirA plasmid with either GIMAP6S54N, GIMAP637-292 (subsection 3.3.5), or GIMAP6R134A
inserted into the plasmid. Lysates were prepared from the stable HEK293 cell lines when
the cells reached a confluency of roughly 80-85%, while lysates from the transiently trans-
fected HEK293T cells were prepared 48h post transfection. The lysates were then incub-
ated with the GTP-agarose beads overnight at 4 ºC as detailed above. Proteins were eluted
from the beads and western blotting carried out with MAC445. Mutations within the G1
motif of the GTPase domain abrogated binding to the GTP-agarose beads, indicating that
these variants had lost their ability to bind GTP (Figure 3.3.11; Left panel). Mutants that
were known to be able to interact with GABARAPL2 (GIMAP637-292 (subsection 3.3.5)
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and GIMAP6R134A) are able also to bind GTP-agarose suggesting that an intact GTP bind-
ing ability may be essential for the GIMAP6-GABARAPL2 interaction (Figure 3.3.11;
Right Panel).
Figure 3.3.11: Analysis of some GIMAP6 mutants for binding to GTP-agarose.
Left panel; Cell lysates were prepared from HEK293 cells engineered to stably ex-
press myc-tagged GIMAP6G50D or GIMAP6S54N. Right panel; HEK293T cells were
transfected with biotin-tagged GIMAP6 or the indicated mutated derivatives in plas-
mid pcDNA3Biot1His6iresBirA. GIMAP6 or the variants were recovered (or not) by
GTP-agarose affinity chromatography 48h post transfection. Immunoblots of the re-
covered proteins were probed with MAC445 (anti-human GIMAP6) followed by an
HRP-conjugated goat F(ab’)2 fragment anti-rat IgG (lower panel). Mutations within the
G1 motif of the GTPase domain of GIMAP6 abrogate binding to GTP-agarose, while
the two GIMAP6 variants that can interact with GABARAPL2 are able to bind GTP-
agarose. Red asterisk denotes possible GIMAP6 breakdown product; green circle denotes
GIMAP637-292variant.
Could the active GTPase cycle of GIMAP6 be dependent on its ability to interact with
GABARAPL2? Jurkat T cells engineered to express the tetracycline repressor protein
(T-RExTM Jurkats) that were stably transfected with GABARAPL2 shRNA sequences
were employed to address this question. Expression of the shRNAs is induced upon treat-
ment with doxycycline. Cells were treated with either 1 mg/mL doxycycline for 4 days
or maintained without doxycycline. Consistent with the data in (Pascall et al., 2013), a
knockdown in the expression of GABARAPL2 is observed when the expression of the
shRNA against GABARAPL2 is induced (Figure 3.3.12). Interestingly, a downregula-
tion in the expression of GIMAP6 is also observed (Figure 5.2.2). Downregulation of
GABARAPL2 appears to have some effect on the efficiency of the pull-down, however,
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this could be due to the reduction in GIMAP6 levels that is observed when GABARAPL2
is knocked down. Data shown in this figure is inconclusive and not aided by the apparent
mutual stabilisation of GIMAP6/GABARAPL2 levels.
Figure 3.3.12: Effect of the knockdown of GABARAPL2 on the ability of GIMAP6 to
bind to GTP-agarose.
Jurkat T-RExTM cells carrying GABARAPL2 shRNA sequences were either treated for
4 days with 1µg/mL doxycycline or were similarly maintained in the absence of doxy-
cycline. Cell lysates were prepared and aliquots were assayed by western blotting for
GIMAP6 (using monoclonal antibody MAC445), GABARAPL2 (using monoclonal anti-
body MAC446), or b-ACTIN followed by the appropriate HRP-conjugated secondary an-
tibodies. The remainder of the lysates were incubated overnight with GTP-agarose beads
at 4 ºC. After incubation beads were washed with GTP lysis buffer to wash away unbound
proteins. Immunoblots were probed with MAC445, followed by an HRP-conjugated goat
F(ab’)2 fragment anti-rat IgG to detect GIMAP6.
3.3.5 The C-terminal domain of GIMAP6 is required for its
interaction with GABARAPL2
While there is a high level of conservation within the GTPase/AIG1 domain amongst the
mammalian GIMAP6 orthologues, the regions outside this domain show more divergence.
An interesting observation is that three rodent species (rat, mouse, chinese hamster), but
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not the mole rat, have divergent C-terminal domains (Figure 3.3.13).
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Figure 3.3.13: Sequence alignment of GIMAP6 protein sequences from various mam-
malian species.
Protein sequences were either taken directly from the NCBI protein database or were
deduced from expressed DNA sequence tags or genomic sequences. The conserved
AIG1/GTPase domain is boxed in black. The extended C-terminal region that is present
in most mammals but absent from mouse, rat and chinese hamster, is boxed in red. Figure
taken from Pascall et al. 2013. One-hundred percent type-conserved amino acid residues
are shown in red, while at least 60% type-conserved residues are in blue.
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The C-terminal domains within these organisms are truncated due to alternative splicing;
however, this difference in splicing does not affect encoding of the GTPase/AIG1 domain.
As part of a routine mapping exercise, GIMAP6 variants (human) with the N-terminal re-
gion (amino acids 1-36) and C-terminal region (amino acids 243-292) truncated were
assayed to check whether they could bind GABARAPL2. As mentioned earlier the N-
terminal region contains within it a putative AIM that does not appear to be involved in the
interaction (Figure 3.3.3). Deleting the N-terminal region had no effect on the interaction
with GABARAPL2 (Figure 3.3.14). Truncating the C-terminal region of GIMAP6, how-
ever, did abrogate the interact with GABARAPL2. The C-terminal domain of hGIMAP6
(amino acids 243-292) is predicted to contain two a-helical extensions (Figure 6.3.1) and
given that a-helices are often found at the interface of protein-protein interaction these
may be involved in the interaction with GABARAPL2. Constructs were prepared such
that hGIMAP6 was truncated in its C-terminal region in increments of 10 amino acids, up
to the 50 terminal residues. Truncating the protein in these ways completely abrogated the
interaction between GIMAP6 and GABARAPL2: i.e. deletion of the 10 terminal amino
acid residues was alone sufficient to abolish the interaction (Figure 3.3.14).
82
3.3.5 The C-terminal domain of GIMAP6 is required for its interaction with
GABARAPL2
Figure 3.3.14: The C-terminus of GIMAP6 is required for the GIMAP6-GABARAPL2
interaction.
Upper panel; schematic diagram of truncations introduced within GIMAP6. Lower panel;
HEK293T cells were transfected with 20 µg wt GIMAP6 or the indicated mutated deriv-
atives in plasmid pcDNA3Biot1His6iresBirA. Biotinylated and associated proteins were
recovered by streptavidin-agarose affinity purification 48h post transfection. Immunoblots
of the recovered proteins were probed with the streptavidin-HRP conjugate (to show the
GIMAP6 proteins; top panel of immunoblot) or rat monoclonal antibody MAC446 to
GABARAPL2 followed by an HRP-conjugated goat F(ab’)2 fragment anti-rat IgG (bot-
tom panel of immunoblot) to demonstrate co-purification of GABARAPL2. Truncation
of the C-terminus but not the N-terminus abolishes GIMAP6-GABARAPL2 interaction.
This 10 amino acid sequence contains a number of charged residues (for e.g., histidine,
arginine, lysine) that may play a role in the interaction with GABARAPL2 and, signi-
ficantly, does not have any obvious sequence homology to an AIM sequence. Mutations
were introduced within this C-terminal region of hGIMAP6 to pinpoint specific residues
that may play a role in the interaction. The terminal 5 amino acids were removed, selec-
ted charged residues were mutated to alanine and the terminal leucine, that is completely
conserved across all species in which GIMAP6 is expressed, was also mutated to alanine.
The variant with the terminal 5 amino acid residues removed (GIMAP61-287) was able to
interact with GABARAPL2, but at a noticeably reduced efficiency. This suggested that
residues both inside and outside this last 5-residue stretch are involved in the interaction.
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Mutations were introduced within this region; however, both the K289A and L292A vari-
ants of GIMAP6 were able to interact with GABARAPL2 as efficiently as wt hGIMAP6
(Figure 3.3.15).
Figure 3.3.15: The ability of GIMAP6 variants with mutations within the terminal 10
amino acids to interact with GABARAPL2.
Upper panel: amino acid sequence of the residues in the C-terminal region of GIMAP6.
Residues underlined were substituted with alanine. Red bars indicate the introduction of
stop codons. Lower panel: HEK293T cells were transfected with 20 µg wt GIMAP6 or the
indicated mutated derivatives in plasmid pcDNA3Biot1His6iresBirA. Biotinylated and
associated proteins were recovered by streptavidin-agarose affinity purification 48h post
transfection. Immunoblots of the recovered proteins were probed with the streptavidin-
HRP conjugate (to show the GIMAP6 proteins: top panel of immunoblot) or rat mono-
clonal antibody MAC446 to GABARAPL2 followed by an HRP-conjugated goat F(ab’)2
fragment anti-rat IgG (bottom panel of immunoblot) to demonstrate co-precipitation of
GABARAPL2.
The lysine residue was predicted to have a role in the interaction due to its charged
nature, but pull-down experiments showed that the K289A variant was able to interact
with GABARAPL2 in a manner similar to that of the interaction between wt GIMAP6
and GABARAPL2. Mutations were then introduced within resides spanning amino acid
positions 283-287 of hGIMAP6. While mutating the histidine at position 283 did not
appear to affect the interaction, interestingly, the R284A variant exhibited poor interac-
tion with GABARAPL2, as did the HR283,284AA variant (HR-AA). The results from
these interaction studies indicate that the arginine at position 284 is important for the
interaction, as are residues within the terminal pentapeptide, and also indicate that the
cumulative character of the terminal 10 amino acid residues within hGIMAP6 is critical
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for the interaction with GABARAPL2.
Figure 3.3.16: The GIMAP61-282 variant is unable to bind GTP-agarose.
Cell lysates were prepared from HEK293 cells that had been engineered to stably ex-
press either myc-tagged wt GIMAP6 or myc-tagged GIMAP61-282. Lysates were in-
cubated with GTP-agarose beads overnight at 4 ºC. Bound proteins were eluted off the
beads by boiling and proteins separated by SDS-PAGE. Separated proteins were analysed
by Western blotting using either MAC446 followed by an HRP-conjugated goat F(ab’)2
fragment anti-rat IgG (bottom panel of immunoblot) to demonstrate co-purification of
GABARAPL2 (right blot, lower half), or anti-myc monoclonal antibody 9E10 followed
by HRP-conjugated goat anti-mouse IgG to detect the myc-tagged GIMAP6 and the vari-
ant. As expected wt GIMAP6 can bind GTP-agarose and can co-purify GABARAPL2.
The variant cannot bind GTP-agarose.
The interaction between hGIMAP6 and GABARAPL2 could be a result of an interaction
between terminal helices present within both proteins: the structure of GABARAPL2
has been solved to show the presence of two a-helical extensions within its N-terminal
domain (Paz et al., 2000). Alternatively, the C-terminal region of hGIMAP6 may play
a role in maintaining the overall structural integrity of the molecule. wt hGIMAP6 has
been shown to interact with GDP and GTP (see (subsection 3.3.4)). I carried out experi-
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ments to investigate whether the C-terminally truncated variant, GIMAP61-282, was able
to bind GTP using lysates from stable cell lines expressing myc-tagged wt GIMAP6 and
myc-tagged GIMAP61-282 for GTP-agarose affinity purifications. While wt GIMAP6 was
able to bind GTP, the GIMAP61-282 variant was not, thus indicating that this region may
play a structural role in GTP binding by GIMAP6, and thereby in its interaction with
GABARAPL2. GABARAPL2 could be co-precipitated with GIMAP6 via GTP-agarose
affinity, but could not with the variant, as expected (Figure 3.3.16).
3.3.6 A GIMAP6 variant that is unable to interact with
GABARAPL2 does not re-locate to autophagosomes on
induction of autophagy
GIMAP6 has been shown to translocate to autophagosomes on the induction of auto-
phagy, where it co-localises with the classic autophagosomal marker MAP1LC3B, and
GABARAPL2 (Pascall et al., 2013). This phenomenon is also observed in Jurkat T cells
and in primary Human Umbilical Vein Endothelial Cells (HUVEC) in which GIMAP6 is
endogenously expressed. Could the variant GIMAP6 protein that was unable to interact
with GABARAPL2 also exhibit a similar translocation on induction of autophagy? Stable
HEK293 cell lines expressing myc-tagged wt GIMAP6 and myc-tagged GIMAP61-282
were used to carry out these experiments. Cells were treated with starvation medium
(amino acid starvation) for 90 min to induce autophagy. Cells were then fixed with para-
formaldehyde and permeabilised using methanol. Following this, cells were processed for
immunocytochemistry using MAC445 (anti-hGIMAP6) and rabbit anti-MAP1LC3B. In
contrast to wt GIMAP6, the variant GIMAP6 was not recruited to the autophagosomes un-
der starvation (autophagic) conditions (Figure 3.3.17). Expression of the variant GIMAP6
did not affect, in any obvious way, the re-localisation of MAP1LC3B (Figure 3.3.17) or
GABARAPL2 to autophagosomes on induction of autophagy (not shown).
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Figure 3.3.17: The C-terminal 10 amino acids of GIMAP6 are required for its recruitment
to autophagosomes.
A stable HEK293 cell line expressing a myc-tagged GIMAP6 lacking the C-terminal 10
amino acids (GIMAP61-282) and the myc-wt GIMAP6 HEK293 cell line were either left
untreated or were treated with starvation medium for 90 min to induce autophagy. Cells
were fixed with 4% paraformaldehyde, permeabilised with methanol and then processed
for immunocytochemistry using rat anti-human GIMAP6 monoclonal antibody MAC445
or rabbit anti-MAP1LC3B (Sigma) followed by an Alexafluor 488-conjugated anti-rat
IgG or an Alexafluor 568-conjugated anti-rabbit IgG, respectively. Images were captured
using an Olympus FV1000 imaging system. Scale bar represents 16µm.
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This observation was also true for the myc-tagged GIMAP6G50D (Figure 3.3.18) and
GIMAP6S54Nvariants (not shown).
There could be a few possibilities for such an observation; (i) it is the interaction between
GIMAP6 and GABARAPL2 that is responsible for the re-location of GIMAP6 to auto-
phagosomes when autophagy is induced; (ii) truncating the C-terminal region of GIMAP6
affects its structure and consequently its GTP/GDP binding ability in such a manner that
it prevents re-localisation to autophagosomes, or (iii) amino acids 283-292 of GIMAP6
interact with other proteins that mediate its recruitment to autophagosomes.
Figure 3.3.18: The GIMAP6G50D variant is unable to relocate to autophagosomes on in-
duction of autophagy.
A stable HEK293 cell line expressing myc-tagged GIMAP6G50D was treated with starva-
tion medium for 90 min to induce autophagy. Cells were fixed with 4% paraformaldehyde,
permeabilised with methanol and then processed for immunocytochemistry using rat anti-
human GIMAP6 monoclonal antibody MAC445 or rabbit anti-MAP1LC3B (Sigma) fol-
lowed by an Alexafluor 568-conjugated anti-rat IgG or an Alexafluor 488-conjugated





In this chapter, I have shown, for the first time, that hGIMAP6 is able to bind GTP, and
further showed that this region appears to be involved in the interaction of hGIMAP6 with
GABARAPL2 (Table 3.4.1). The C-terminus of hGIMAP6, and in particular the terminal
10 amino acids are also required for the interaction with GTP and GABARAPL2. Earlier
studies in our laboratory have shown that hGIMAP6 is able to relocate to autophagosomes
on the induction of autophagy (amino acid starvation) (Pascall et al., 2013), and this relo-
cation was abrogated when the ability of hGIMAP6 to bind GTP and GABARAPL2 was
blocked.
Variant Binds GTP Binds GABARAPL2







Table 3.4.1: Summary of results.
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4 Molecular requirements of
GABARAPL2 for the interaction
with GIMAP6
4.1 Context
GABARAPL2, also known as GATE-16 (Golgi-associated ATPase enhancer of 16 kDa),
is a homologue of the yeast Atg8 protein. It is a ubiquitin-like protein that is thought
to be involved in autophagosome biogenesis (Weidberg et al., 2010) and in the recruit-
ment of cargo into autophagosomes, possibly via its interaction with NBR1 (Kirkin et al.,
2009b,a), amongst other autophagy cargo receptors. While yeast possess one Atg8 gene,
mammalian cells express several Atg8-like proteins that, based on the similarities within
their amino acid sequences, can be divided into two sub-families: the MAP1LC3 sub-
group that contains the MAP1LC3A, MAP1LC3B, and MAP1LC3C proteins, and the
GABARAP sub-group that contains GABARAP, GABARAP-like protein (GABARAPL)
1, GABARAPL2/GATE-16, and GABARAPL3. GABARAPL3 has been demonstrated
to be expressed at only the transcriptional level and therefore is likely to be a pseudogene
(Xin et al., 2001).
The importance of yeast Atg8 was demonstrated by a genetic screen carried out to detect
mutants defective in autophagy (Tsukada and Ohsumi, 1993); the crucial nature of the
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Atg8 proteins in the process of autophagy was further demonstrated by studies reviewed
in (Shpilka et al., 2011). MAP1LC3B was the first mammalian Atg8 homologue to be
identified (Kuznetsov and Gelfand, 1987), and remains the best studied, with its role in
the process of autophagy now well established (Kabeya et al., 2000; Weidberg et al., 2010;
Pankiv et al., 2007; Tanida et al., 2008; Lang et al., 1998; Scott et al., 1996; Weiergraber
et al., 2013; Yang and Klionsky, 2009). GABARAPL2, on the other hand, has not been as
well studied. GABARAPL2 was originally shown to be involved in intra-Golgi transport
(Legesse-Miller et al., 1998). Further studies demonstrated that GABARAPL2 appeared
to play a critical role in Golgi reassembly by interacting with NSF (N-ethylmaleimide
sensitive factor), significantly enhancing its ATPase activity; the interaction with NSF
in turn stimulated GABARAPL2’s interaction with GOS-28, a Golgi v (vesicle)-SNARE
(Soluble NSF attachment receptor) in an ATP dependent manner (Muller et al., 2002;
Sagiv et al., 2000). The interaction between GABARAPL2 and GOS-28 was hypothesised
to protect the v-SNARE and regulate SNARE function. That GABARAPL2 may have a
role/s to play in the process of autophagy only became apparent with studies that reported
the localisation of GABARAPL2 to autophagosomal membranes on the induction of auto-
phagy, subsequent to its conjugation with phosphatidylethanolamine (PE) (Kabeya et al.,
2004; Kirisako et al., 2000). A later study that attempted to dissect the exact role played
by GABARAPL2 in autophagy reported that, unlike MAP1LC3B which was involved
in the elongation of autophagosome membranes, GABARAPL2 mediated the process of
autophagosome maturation (Weidberg et al., 2010).
4.1.1 The N-terminus of GABARAPL2
The crystal structure of GABARAPL2 demonstrated the presence of a ubiquitin-like fold
with an N-terminal extension consisting of two a-helices (Paz et al., 2000). Given the
significant similarities in amino acid sequence between members of the Atg8-like family,
the three-dimensional fold observed in GABARAPL2 is seen in the other Atg8-like pro-
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teins as well (Weiergräber et al., 2008; Rogov et al., 2013; Suzuki et al., 2014; Klionsky
and Schulman, 2014; Paz et al., 2000; von Muhlinen et al., 2012). There may, however,
be differences in conformational dynamics between the family members, particularly with
respect to the N-terminal helical extensions. The first a-helix within MAP1LC3B contains
residues with a positive charge, while the corresponding region within GABARAPL2 has
a more hydrophobic character. While the N-terminal regions of both proteins can pro-
mote membrane tethering and fusion when they are cross-linked to liposomes (Weidberg
et al., 2011), the differences between these regions may be why MAP1LC3B, but not
GABARAPL2, is able to mediate the selective incorporation of SQSTM1 into auto-
phagosomes (Shvets et al., 2011). The differences in the N-terminal region between
MAP1LC3B and GABARAPL2 could also be why the two proteins may be involved
in separate stages of autophagosome biogenesis (Weidberg et al., 2011, 2010). Does the
N-terminal region of GABARAPL2 have a role to play in the interaction with GIMAP6?
I have conducted experiments to attempt to answer this question.
4.1.2 The role of the AIM docking site within GABARAPL2 in
the interaction with GIMAP6
As mentioned in subsection 3.1.2, the AIM can play a critical role in the interaction of
binding partners with Atg8-like proteins. GIMAP6 has a peptide sequence consistent with
a canonical AIM within its N-terminus. Introducing point mutations within this motif did
not, however, affect interaction with GABARAPL2 (see Figure 3.3.3). The Atg8-related
proteins bind to the AIM motif of a substrate, which has been shown to adapt an extended
b-conformation, through their AIM docking site (ADS) (Rozenknop et al., 2011; Noda
et al., 2008). The N-terminal helical domain of Atg8-related proteins consists of helices,
a1 and a2; the presence of two helices within the N-terminal region that are attached to the
convex face of the b-grasp fold is conserved amongst the Atg8 homologues (Weiergraber
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et al., 2013; Paz et al., 2000).
Figure 4.1.1: Representation of the fold of GABARAPL2.
The GABARAPL2 crystal structure (PDB ID 1EO6 Paz et al., 2000), contains the b-grasp
motif (dark blue) which is a hallmark of the ubiquitin superfamily and is seen here decor-
ated with by two N-terminal helical regions (light blue). Figure adapted from Weiergraber
et al. (2013).
All Atg8-family proteins have an exposed b-strand (b2; corresponding to residues 48–52
of Atg8), which plays a role in the binding of the AIM through an intermolecular b-sheet.
They also possess two characteristic hydrophobic pockets (hp1 and hp2; Figure 4.1.2)
with hp1 comprising the side chains of Glu17, Ile21, Pro30, Ile32, Lys48, Leu50, and
Phe104, while hp2 is composed of the side chains of Tyr49, Val51, Pro52, Leu55, Phe60,
and Val63 (Noda et al., 2010, 2008; Behrends and Fulda, 2012). Residues within these
pockets make contact with residues in the AIM and are required for AIM-mediated inter-
actions. Does the ADS within GABARAPL2 play a role in the interaction with GIMAP6?
I have attempted to answer this question.
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Figure 4.1.2: Representative example of the structural determinants of AIM-Atg8 inter-
actions.
Surface representation of GABARAPL1 bound to the NBR1-LIR peptide. The hydro-
phobic pockets (hp1 and hp2) of GABARAPL1 are indicated in bright yellow. The amino
acids (yellow) of the AIM peptide of GABARAPL1 that bind in the pockets are shown.
Figure adapted from Birgisdottir et al. (2013).
4.1.3 Conjugation of phosphatidylethanolamine to
GABARAPL2
Members of the Atg family of proteins play critical roles in autophagosome biogenesis
(Xie et al., 2008). The Atg8-related family members are unique in that they can be con-
jugated to the lipid PE via a process that is analogous to protein ubiquitination. The
conjugation of PE to Atg8 and the Atg8-related proteins has been shown to be required
for their incorporation into the autophagosomal membrane (Ichimura et al., 2004, 2000).
Investigations into the potential post-translational modifications of the Atg8-related fam-
ily members were undertaken due to the detection of two species in immunoblot analysis
of MAP1LC3B, with the two species corresponding to masses of 25 kDa and 23 kDa be-
ing termed MAP1LC3B-I and MAP1LC3B-II, respectively. Further investigation demon-
strated the translation of MAP1LC3B as a full-length precursor (proMAP1LC3B; 30kDa).
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This is rapidly cleaved near its C-terminal end by the cysteine protease Atg4 to allow the
generation of MAP1LC3B-I and MAP1LC3B-II; MAP1LC3B-II is directly derived from
MAP1LC3B-I via the conjugation to PE and its formation can be abrogated by mutating
G120 to A (Fujita et al., 2008; Kabeya et al., 2000; Kirisako et al., 2000). To date four
mammalian homologues of Atg4 have been reported: autophagin 1 (Atg4B), autophagin
2 (Atg4A), autophagin 3 (Atg4C), and autophagin 4 (Atg4D) with Atg4B likely to be the
principal mammalian homologue (Mariño et al., 2003; Kirisako et al., 2000). Atg4B has
been shown to cleave all members of the Atg8-related family of proteins (Hemelaar et al.,
2003; Li et al., 2011), while Atg4A is specific for the GABARAP subfamily but not the
MAP1LC3 subfamily (Scherz-Shouval et al., 2003; Li et al., 2011).
Members of the Atg8-related proteins are subsequently delipidated by the activity of Atg4
homologues (Kirisako et al., 2000), with a recent study suggesting that this delipidating
activity of Atg4 is necessary for the recycling of lipidated members of the Atg8 family
of proteins that are generated in a constitutive and non-selective manner on inappropri-
ate membranes (Nakatogawa et al., 2012). The delipidating activity of the Atg4 homo-
logues, a step regulated by reactive oxygen species, is required for the maintenance of a
cytosolic pool of unlipidated Atg8-related proteins that can participate in autophagosome
biogenesis. The C-terminal cleavage activity of the Atg4 homologues is dependent on
the presence of Arg68 within MAP1LC3B; this residue forms a salt bridge with the Atg4
homologues (R65 within GABARAPL2) Liu et al. (2013), and the conserved glycine
residue (G116 of GABARAPL2; G120 within MAP1LC3B); the protein is cleaved after
this glycine residue (Kabeya et al., 2004, 2000). Mutating either residue to an alanine
has been shown to abrogate Atg4 cleavage activity and consequently the lipidation of the
MAP1LC3B (Liu et al., 2013; Kabeya et al., 2004). The cleaved Atg8-like proteins with
the exposed glycine serve as a substrate for the ubiquitin-like conjugation reaction carried
out by the E1-like enzyme Atg7, the E2-like enzyme Atg3, and the E3-like enzyme, the
Atg12-Atg5-Atg16 complex, resulting in the covalent conjugation of PE (Ichimura et al.,
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2004; Mizushima et al., 1998; Tanida et al., 1999, 2002, 2001; Ichimura et al., 2000;
Taherbhoy et al., 2011), thereby allowing the anchoring of the Atg8-like proteins to the
autophagosomal membrane.
While GABARAPL2, like MAP1LC3B, can also be cleaved by Atg4, the presence of
the lipidated form of GABARAPL2 is not always evident (subsection 3.3.2; Tanida et al.,
2004). Further, there is a divergence in the tissue distribution of MAP1LC3B and GABAR-
APL2 hinting at the possibility of GABARAPL2’s role in autophagy being tissue-dependent
(Elazar et al., 2003). It may also be that in addition to autophagy, GABARAPL2 has other
tissue-specific functions. In this study I have investigated whether G116 of GABARAPL2
is required for the interaction with GIMAP6. I have also conducted an experiment that
attempts to confirm whether the Gly residue within GABARAPL2 is exposed to behave
as a substrate for possible lipidation.
4.2 Chapter Aims
1. Identify domains within GABARAPL2 that are required for the interaction with
GIMAP6
2. Investigate whether the putative ADS within GABARAPL2 plays a role in the in-
teraction with GIMAP6
3. Carry out studies to investigate the role of the conserved Gly at position 116 within
GABARAPL2 in the interaction with GIMAP6
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4.3 Results
4.3.1 The role of the N-terminal region within GABARAPL2 in
the interaction with GIMAP6
While the three-dimensional fold of the different Atg8 homologues is believed to be sim-
ilar, the conformational dynamics may differ, with the N-terminal region of the Atg8
homologues, in particular, being capable of attaining alternative conformations (Weier-
graber et al., 2013; Paz et al., 2000). As mentioned above (subsection 4.1.1), the first
a-helix within GABARAPL2 has a more hydrophobic character than the corresponding
region within MAP1LC3B, which contains a number of positively charged residues. To
analyse the importance of the N-terminal helices of GABARAPL2 in the interaction with
GIMAP6, constructs were prepared such that both a-helices within the N-terminal re-
gion of GABARAPL2 were truncated. The mutant GABARAPL2 sequences were gen-
erated via PCR mutagenesis and were cloned into the Biot1-His6-IRES-BirA plasmid.
HEK293T cells were co-transfected with these constructs and with a plasmid encoding
N-terminally myc-tagged GIMAP6. Lysates were prepared 48h post transfection, strep-
tavidin affinity purification was performed and the recovered biotinylated and associated
proteins were detected by western blotting using the streptavidin-HRP conjugate and the
anti-myc mAb 9E10 (Figure 4.3.1).
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Figure 4.3.1: The N-terminal region of GABARAPL2 is required for the interaction with
GIMAP6.
HEK293T cells were transfected with a plasmid encoding myc-GIMAP6 together with
a second plasmid encoding GABARAPL2 or one of the two GABARAPL2 variants
(all biotinylated), as indicated. Cell lysates were prepared and biotinylated and as-
sociated proteins recovered by streptavidin-agarose affinity chromatography. Western
blots were probed with either the streptavidin-HRP conjugate to detect the biotinylated
GABARAPL2 proteins or the anti-myc monoclonal antibody 9E10 followed by an HRP-
conjugated goat anti-mouse IgG to detect myc-tagged GIMAP6.
Truncating GABARAPL2 in these ways completely abrogated its interaction with GIMAP6:
99
4 Molecular requirements of GABARAPL2 for the interaction with GIMAP6
indeed, deletion of the first a-helix (residues 1-10) was sufficient to abolish the interac-
tion. Based on this finding, I hypothesised that the first a-helix within the N-terminal
region of GABARAPL2 would be sufficient for the interaction with GIMAP6. I pre-
pared a chimera in which the first a-helix of GABARAPL2 replaced the corresponding a-
helix in MAP1LC3B. The constructs were N-terminally myc-tagged and transfected into
HEK293T cells along with a plasmid encoding biotin-tagged GIMAP6 (Figure 4.3.2).
Figure 4.3.2: Swapping the first a-helix within MAP1LC3B with the corresponding helix
found in GABARAPL2 results in a chimeric protein able to interact with GIMAP6.
Top panel: a schematic representation of the chimeric protein. Bottom panel: HEK293T
cells were co-transfected with a plasmid encoding either myc-tagged GABARAPL2, myc-
tagged MAP1LC3B, or the myc-tagged chimeric protein together with a plasmid encod-
ing the biotinylated form of GIMAP6, as indicated. Cell lysates were prepared and bi-
otinylated and associated proteins recovered by streptavidin-agarose affinity chromato-
graphy. Western blots were probed with either the streptavidin-HRP conjugate to detect
the GIMAP6 protein or the anti-myc monoclonal antibody 9E10 followed by an HRP-
conjugated goat anti-mouse IgG to detect the myc-tagged Atg8 homologues.
Lysates were prepared 48h post transfection and processed as described above. Interest-
ingly, and as hypothesised, the chimeric protein with the N-terminus of GABARAPL2
swapped into MAP1LC3B was sufficient to bind GIMAP6, suggesting that this region
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within GABARAPL2 is critical for the interaction.
4.3.2 The role of the ADS within GABARAPL2 in the
interaction with GIMAP6
The ADS within Atg8 homologues plays a critical role in the interaction with a sig-
nificant proportion of their binding partners (Behrends et al., 2010). As mentioned in
subsection 4.1.2, residues within the hydrophobic pockets, hp1 and hp2, within the Atg8
homologues make contact with the residues from the AIM (particularly the tyrosine or the
tryptophan at position 1 of the AIM, and the isoleucine or the leucine at position 4 of the
AIM) and are critical for interactions that are dependent on the AIM (see Figure 4.1.2: the
residues within hp1 and hp2 are conserved within GABARAPL1 and this figure is rep-
resentative of structural determinants of AIM-ADS interactions). Here, constructs were
designed to substitute the Tyr49 within hp2 and, separately, the Leu50 within hp1 of
GABARAPL2 to Ala to investigate whether these residues have a role to play in the in-
teraction of GABARAPL2 with GIMAP6. These residues were chosen for manipulation
as a study characterising the interaction between the AIM of NBR1 with GABARAPL1
highlighted them (Rozenknop et al., 2011). They are completely conserved within the
GABARAP sub-family, participate in the interaction with NBR1 (Rozenknop et al., 2011),
and have been substituted in other studies investigating aspects of AIM-ADS interac-
tions (Yamano et al., 2014; Shvets et al., 2011; Behrends et al., 2010). The mutant
GABARAPL2 sequences were generated via PCR mutagenesis and were cloned into
the Biot1-His6-IRES-BirA plasmid. HEK293T cells were co-transfected with this con-
struct and with a plasmid encoding N-terminally myc-tagged GIMAP6. Lysates were
prepared 48h post transfection, streptavidin affinity purification was performed and the
recovered biotinylated and associated proteins were detected by western blotting using
the streptavidin-HRP conjugate and the anti-myc mAb 9E10.
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Figure 4.3.3: The ADS within GABARAPL2 plays an important role in the interaction
with GIMAP6.
HEK293T cells were transfected with a plasmid encoding myc-GIMAP6 together with
plasmids encoding biotinylated forms of GABARAPL2 or the GABARAPL2 variants
as indicated. Cell lysates were prepared and biotinylated and associated proteins re-
covered by streptavidin-agarose affinity chromatography. Western blots were probed with
either the streptavidin-HRP conjugate to detect the GABARAPL2 proteins or the anti-myc
monoclonal antibody 9E10 followed by an HRP-conjugated goat anti-mouse IgG to detect
myc-tagged GIMAP6.
Interestingly, as seen in Figure 4.3.3, substituting these residues in GABARAPL2 com-
pletely abrogated the interaction with GIMAP6. This finding hints at the possibility of
the interaction between GABARAPL2 and GIMAP6 being mediated via an AIM. As
discussed in the previous chapter (subsection 3.3.3), the N-terminal region of GIMAP6
contains a sequence that would be predicted to be part of an AIM but my experimental
analysis argued against its relevance to the interaction under study. It may well be that
there is a non-canonical, as yet unidentified AIM elsewhere within GIMAP6 that is re-
quired for the interaction with GABARAPL2. Indeed, non-canonical AIMs have recently
been reported for proteins that interact with MAP1LC3C (von Muhlinen et al., 2012) and
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for Atg12 (Kaufmann et al., 2014).
4.3.3 Role of the conserved glycine in GABARAPL2 in the
interaction with GIMAP6
As introduced in subsection 4.1.3, the presence of the conserved glycine at the C-terminus
of the Atg8 homologues is crucial for cleavage by members of the Atg4 family and their
subsequent lipidation. Our research group has not been been able to detect the lipida-
tion of GABARAPL2 on a consistent basis via western blot assuming, as the literature
seems to suggest, that the PE-modified form of GABARAPL2 would display the same
mobility shift as MAP1LC3B. Here, I have attempted to confirm that GABARAPL2
is cleaved after the conserved Gly116 which would potentially point to the possibility
of it being lipidated at the glycine residue. This was done by engineering constructs
that expressed wild-type GABARAPL2 and a variant of GABARAPL2 in which the
Gly116 was substituted with an alanine. HEK293T cells were transfected with plasmids
in which either wt GABARAPL2 or GABARAPL2G116Awas cloned into the pcDNA3
vector carrying a CMV promoter, an N-terminal biotinylation tag, a C-terminal myc tag
(introduced via mutagenic PCR), and the internal ribosome entry site (IRES) sequence
followed by BirA (Biot1-GABARAPL2-Myc-IRES-BirA). This plasmid was transfec-
ted into HEK293T cells and lysates were prepared 48h later. The transiently transfected
HEK293T cells were also incubated in starvation medium for 90 min at 37 ºC. Lysates
were separated via SDS-PAGE and transferred to a PVDF membrane and immunoblots
were probed with either the streptavidin-HRP conjugate or the anti-myc mAb 9E10. The
hypothesis was that if GABARAPL2 was normally cleaved by members of the Atg4 fam-
ily, then no bands would be detected by the anti-myc mAb. Furthermore, if the Gly
residue played a role in this cleavage then the GABARAPL2G116A mutant would not be
cleaved at its C-terminal end and so would be detectable by the anti-myc ab. The results
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were consistent with these propositions: wt GABARAPL2 was undetectable by the anti-
myc mAb on western blotting, while GABARAPL2G116A was detected by the anti-myc
ab (Figure 4.3.4). The reason behind the detection of certain protein bands (red asterisk
Figure 4.3.4) is unclear. They are detectable by the anti myc mAb 9E10, but not by the
streptavidin-HRP conjugate, indicating that they may correspond to degradation products
that have lost their biotinylation tag but have maintained their C-terminal myc tag.
Figure 4.3.4: GABARAPL2 appears to be cleaved by Atg4.
HEK293T cells were transfected with a plasmid encoding GABARAPL2 or its G116A
variant. Both forms carried an N-terminal biotinylation tag and were myc-tagged at the
C-terminus. Cells were maintained in starvation medium at 37 ºC (or not) for 90 min
approx. 48h post transfection. Following this, cell lysates were prepared and biotinylated
and associated proteins recovered by streptavidin-agarose affinity chromatography. West-
ern blots were probed with either the streptavidin-HRP conjugate or the anti-myc mono-
clonal antibody 9E10 followed by an HRP-conjugated goat anti-mouse IgG to detect the
GABARAPL2 proteins. Red asterisk: possible degradation products.
The induction of autophagy had no obvious effect on the cleavage. Both wild-type and
mutant GABARAPL2 were detected with the streptavidin-HRP conjugate with the wt
GABARAPL2 migrating at a faster rate in the SDS-PAGE gel, providing further indica-
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tion of its cleavage by Atg4.
Given that the conserved glycine residue of GABARAPL2 appears to be necessary for
its potential lipidation and subsequent attachment to the autophagosomal membrane (the
G116 mutant of GABARAPL2 appears to be unable to relocate to autophagosomes upon
induction of autophagy: unpublished work from our group), I investigated whether G116
was required for the interaction between GIMAP6 and GABARAPL2. The mutant GABA-
RAPL2 sequence was generated via PCR mutagenesis and was cloned into the Biot1-
His6-IRES-BirA plasmid. HEK293T cells were transfected with this construct and, since
they do not express GIMAP6 endogenously, they were also transfected with a plasmid en-
coding N-terminally myc-tagged GIMAP6. Lysates were prepared 48h post transfection,
streptavidin affinity purification was performed and the recovered biotinylated and asso-
ciated proteins were detected by western blotting using the streptavidin-HRP conjugate
and the anti-myc ab.
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Figure 4.3.5: The conserved glycine116 within GABARAPL2 is not required for the in-
teraction with GIMAP6.
HEK293T cells were transfected with a plasmid encoding myc-GIMAP6 together with
plasmids encoding biotinylated forms of GABARAPL2, as indicated. Cell lysates were
prepared and biotinylated and associated proteins recovered by streptavidin-agarose af-
finity chromatography. Western blots were probed with either the streptavidin-HRP con-
jugate to detect the GABARAPL2 proteins or an anti-myc monoclonal antibody 9E10
followed by an HRP-conjugated goat anti-mouse IgG to detect myc-tagged GIMAP6.
As seen in Figure 4.3.5, the G116A variant was successfully pulled down with GIMAP6.
This indicates that G116 does not play a role in the interaction with GIMAP6. Hence, the
interaction between these proteins could possibly occur in the cytosol prior to lipidation
and the anchoring of GABARAPL2 to the autophagosomal membrane and so could be




In this chapter, I have demonstrated that the N-terminus of GABARAPL2 plays an im-
portant role in the interaction with hGIMAP6. Interestingly, I also observed that the
putative ADS within GABARAPL2 may have an important role to play in the interaction.
Intriguingly, hGIMAP6 appears to be able to bind GABARAPL2 irrespective of its ability
to be lipidated. Finally, while MAP1LC3B is unable to bind hGIMAP6, replacing the first
a-helix within MAP1LC3B with the corresponding a-helix within GABARAPL2 rescued




interaction is direct; GIMAP6 can
also interact with GIMAP7
5.1 Chapter Aims
5.1.1 Is the GIMAP6-GABARAPL2 interaction direct?
GIMAP6 was shown to interact with GABARAPL2 in studies that were carried out with
mammalian cell lysates. Due to the nature of these studies, it was not possible to comment
on the status of this interaction, i.e. it could be either a direct interaction or one that re-
quires additional proteins. Cross-linking studies hinted at the direct nature of the interac-
tion between GIMAP6 and GABARAPL2 subsection 3.3.1. Given the Mr shifts observed
but the relative inaccuracy of molecular weight estimations by SDS-PAGE meant that a
requirement for additional, small proteins in a complex could not be excluded. Therefore
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5.1.2 Is the putative GIMAP6-GABARAPL2 complex detectable
in vivo?
Given that GIMAP6 and GABARAPL2 could be detected as a complex upon cross-
linking (subsection 3.3.1), are they detectable as a complex in vivo? This question was ad-
dressed by employing size exclusion chromatography using lysates obtained from either
Jurkat T cells or from HEK293T cells that were transiently transfected with GIMAP6.
5.1.3 Can GIMAP6 interact with itself and can it interact with
other members of the GIMAP family?
Recent structural studies carried out on members of the GIMAP family have shown that
they can exhibit GTP-dependent oligomerisation, enabling scaffold formation e.g. on
lipid droplets (GIMAP2; Schwefel et al., 2010), and can behave as GAPs, not only by
displaying homodimerisation-stimulated GTP hydrolysis (GIMAP7), but also by stim-
ulating GTP hydrolysis in a heterodimeric setting, i.e., GIMAP7 acting as a GAP for
GIMAP2 (Schwefel et al., 2013). Can GIMAP6 interact with itself? Can it associate with
other members of the GIMAP family? A pull-down approach was used to address these
questions.
5.2 Results
5.2.1 The GIMAP6-GABARAPL2 interaction is direct
As mentioned above, the interaction between GIMAP6 and GABARAPL2 was detec-
ted in studies using mammalian cell lysates (Pascall et al., 2013). To address the issue
of whether this interaction required additional proteins or was a direct interaction, in
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vitro studies using purified proteins needed to be carried out. GST (control) and a GST-
GIMAP6 fusion protein were expressed in E.coli (see subsection 3.3.4) and the two pro-
teins column-purified on glutathione beads. The beads carrying the immobilised proteins
were then incubated for 1 h at 4 ºC with 20 µg of purified GABARAPL2 that had been
bacterially expressed (a kind gift from Michael Wilson, The Babraham Institute). The
column was washed, the bound proteins (GST and GST-GIMAP6) were eluted from the
beads with reduced glutathione and the eluates were separated by SDS-PAGE. The gel
was stained with Coomassie Brilliant Blue R to assess recovery of GST/GST-GIMAP6,
and then western blotting was carried out to assay for the presence of GABARAPL2.
Although GST was recovered at much higher levels than the GST-GIMAP6 fusion pro-
tein (technical issues concerning the purification of GIMAP6 have been described earlier
in this thesis; subsection 3.3.4), GABARAPL2 eluted with GST-GIMAP6 but was not
detected in the GST eluates. This indicated that the interaction between GIMAP6 and
GABARAPL2 was direct and did not require other proteins (Figure 5.2.1).
Figure 5.2.1: The interaction between GIMAP6 and GABARAPL2 is direct.
Glutathione Sepharose 4B-immobilised GST or GST-GIMAP6 was incubated with bac-
terially expressed purified GABARAPL2. Proteins were then eluted with glutathione and
the eluates (two eluted fractions from each column), resolved by SDS-PAGE. Proteins
were then visualised either by Coomassie Blue staining (top panel) or by Western blotting
with anti-GABARAPL2 monoclonal antibody MAC446 followed by an HRP-conjugated
goat F(ab’)2 fragment anti-rat IgG.
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5.2.2 Existence of a GIMAP6-GABARAPL2 complex in vivo?
Studies in our group have demonstrated that GIMAP6 can regulate intracellular GABARA-
PL2 levels, i.e. an increase in the expression levels of GIMAP6 results in an increase in
the level of GABARAPL2. This increase in protein levels was not observed for other
members of the Atg8 family thus demonstrating a specificity for GABARAPL2. Inter-
estingly, this regulation appears to be independent of any affect on GABARAPL2 mRNA
levels. Furthermore, a reduction in the endogenous levels of GIMAP6 resulted in re-
duced GABARAPL2 protein levels (Pascall et al., 2013). I asked whether this was a
unidirectional effect (i.e. GIMAP6 levels affecting those of GABARAPL2) or whether
the levels of the two proteins were mutually dependant. Experiments were carried out
with Jurkat T cells engineered to express the tetracycline repressor protein (T-RExTM)
that were stably transfected with GABARAPL2 shRNA sequences. Cells were treated
with either 1 mg/mL doxycycline for 4 days or maintained without doxycycline. A knock-
down in the expression of GABARAPL2 was observed when the expression of the shRNA
against GABARAPL2 was induced (Figure 5.2.2).
Figure 5.2.2: GABARAPL2 knockdown affects GIMAP6 protein levels.
Left panel: Jurkat T-RExTMcells carrying GABARAPL2 shRNA sequences were either
treated for 4 days with 1µg/mL doxycycline or were similarly maintained but in the ab-
sence of doxycycline. Cell lysates were prepared and assayed by western blotting for
GIMAP6 (using mAb MAC445), GABARAPL2 (using mAb MAC446), or b-ACTIN fol-
lowed by the appropriate HRP-conjugated secondary antibodies. Right panel: analysis of
GABARAPL2/actin and GIMAP6/actin ratios.
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Under these conditions, a downregulation in the levels of GIMAP6 was also observed,
while b-actin levels remained unaffected. A possible explanation for this could be that
GABARAPL2 is stabilised by the formation of a complex with GIMAP6, and vice versa.
To test this hypothesis I decided to conduct size exclusion chromatography (SEC) exper-
iments to investigate whether complexes of GIMAP6 and GABARAPL2 could be detec-
ted in vivo (in cellulo) (Figure 5.2.3). Size-exclusion chromatography is a widely used
method for the estimation of protein molecular weight. It has the advantage of being
non-denaturing and therefore permits the study of protein-protein interactions that occur
normally in vivo. The widespread use and availability of fast-protein liquid chromato-
graphy (FPLC) systems enables the rapid generation and analysis of data.
Figure 5.2.3: Schematic for Size Exclusion Chromatography.
A cartoon demonstrating the process of SEC. Larger molecules pass by the pores as they
are too large to enter the pores, while smaller molecules get trapped. Hence, larger solutes
elute before smaller ones.
Studies were carried out with lysates extracted from either the Biot-GIMAP6-His myc-
BirA Jurkat T cell line, or from HEK293T cells transiently transfected with the Biot1-
GIMAP6-His6-IRES-BirA plasmid. Following fractionation of the lysates on a Superdex-
200 column, fractions were separated via SDS-PAGE and western blots were carried out
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using the MAC445 and MAC446 antibodies against GIMAP6 and GABARAPL2, re-
spectively. Jurkat T cells that over-expressed GIMAP6 were used with the idea of optim-
ising the yield of stable complexes and increasing the likelihood of detecting a GIMAP6-
GABARAPL2 complex in vivo. Biotinylated GIMAP6 has a molecular mass of approx-
imately 40 kDa. Interestingly, however, its fractionation profile indicated that the major-
ity of GIMAP6 eluted at volumes where proteins with molecular masses of  70-100 kDa
would elute, with the peak in the profile indicating that GIMAP6 fractionated predomin-
antly at a molecular mass of approximately 70 kDa. This could have been the result of
homo/hetero GIMAP dimer formation, or could indicate the presence of a complex con-
taining GIMAP6 and (an)other protein(s) - but not GABARAPL2, as GABARAPL2 did
not appear to co-fractionate with GIMAP6 (Figure 5.2.4).
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Figure 5.2.4: Gel filtration analysis of biotinylated GIMAP6 and endogenous
GABARAPL2 expressed in Jurkat T cells.
A. Chromatogram representing analysis of gel filtration data via FPLC. Volumes at which
various protein markers elute are shown. The grey line denotes the representative fraction-
ation profile of lysates containing over-expressing biotinylated GIMAP6. A significant
proportion of the lysate is eluted in the void volume. Individual fractions were collected
and analysed via SDS-PAGE and western blotting. The x-axis denotes volumes at which
proteins markers elute. The y-axis reports milli Absorbance units. B. Lysate extrac-
ted from Jurkat T cells stably expressing biotinylated GIMAP6. Lysate containing 0.5%
NP-40 detergent was fractionated on a Superdex-200 gel filtration column. Individual
fractions were collected and immunoblotted with MAC445 (upper panel) and MAC446
(lower panel) followed by an HRP-conjugated goat (Fab’)2fragment anti-rat IgG. Red
asterisks denote possible GIMAP6 breakdown products. TL-total lysate.
The presence of GIMAP6 in the void volume fractions could indicate formation of oli-
gomers containing GIMAP6. GABARAPL2, with a molecular mass of approximately 15
kDa, is reported to be able to form dimers (Paz et al., 2000) and eluted in fractions where
a protein of approximately 15-30 kDa would be expected.
Could higher levels of GIMAP6 that may be obtained in a system where it is transi-
ently expressed make it possible to detect the presence of a GIMAP6-GABARAPL2
complex in vivo? To test this, I used lysates extracted from HEK293T cells that had
been transiently transfected with the Biot1-GIMAP6-His6-IRES-BirA plasmid to carry
out further gel filtration experiments. Prior to this, I analysed the fractionation profile of
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GABARAPL2 in HEK293T cells transiently transfected with the corresponding empty
vector (Figure 5.2.5).
Figure 5.2.5: Gel filtration analysis of GABARAPL2 expressed in vector transfected
HEK293T cells.
Lysate extracted from HEK293T cells 48h post transfection with control vector. Lys-
ate containing 0.5% NP-40 detergent was fractionated on a Superdex-200 gel filtration
column. Individual fractions were collected and immunoblotted with MAC446 followed
by an HRP-conjugated goat (Fab’)2fragment anti-rat IgG. Red arrows with molecular
masses above them denote the molecular masses of proteins that would be expected to
elute at those volumes. TL- total lysate. Vo- void volume.
GABARAPL2 eluted at volumes where a protein of its size would be expected to frac-
tionate, generating a fractionation profile similar to that seen using Jurkat T cells. Next,
lysates from HEK293T cells that transiently over-expressed biotinylated GIMAP6 were
analysed. Interestingly, while the fractionation profile of GIMAP6 was very similar to
that seen in Jurkat T cells stably over-expressing GIMAP6, GABARAPL2 co-fractionated
with GIMAP6, with no GABARAPL2 being detected in fractions where a protein of its
size would normally elute (Figure 5.2.6).
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Figure 5.2.6: Gel filtration analysis of biotinylated GIMAP6 and endogenous
GABARAPL2 and MAP1LC3B expressed in HEK293T cells.
A. Chromatogram representing analysis of gel filtration data via FPLC. The green line
denotes the representative fractionation profile of lysates containing over-expressing biot-
inylated GIMAP6. A significant proportion of the lysate is eluted in the void volume. In-
dividual fractions were collected and analysed via SDS-PAGE and western blotting. The
x-axis denotes volumes at which proteins markers elute. The y-axis reports milli Absorb-
ance units. B. Lysate extracted from HEK293T cells 48h post transfection with GIMAP6
in the pcDNA3Biot1His6iresBirA plasmid. Lysis buffer containing 0.5% NP-40 deter-
gent was fractionated on a Superdex-200 gel filtration column. Individual fractions were
collected and immunoblotted with either MAC445 or MAC446 followed by an HRP-
conjugated goat (Fab’)2fragment anti-rat IgG. Red arrows with molecular masses above
them denote the molecular masses of proteins that would be expected to elute at those
volumes. TL- total lysate. Red asterisks indicate probable GIMAP6 breakdown products.
Fractions in which GABARAPL2 co-fractionated with GIMAP6 are highlighted with the
red circle.
This result indicated that GIMAP6 and GABARAPL2 could exist as a complex in vivo.
The fractionation of GABARAPL2 coincided with the peak of the fractionation profile for
GIMAP6 and eluted at volumes that would be in agreement with the molecular mass of
a potential GIMAP-GABARAPL2 complex (approximately 55 kDa). In this experiment
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the apparent co-migration of GIMAP6 and GABARAPL2 was supported by the internal
control of the MAP1LC3B which migrated as a protein of its size would be expected to
migrate (data not shown), thereby going some way towards eliminating the possibility
of sample misidentification or gross denaturation. Unfortunately, the findings shown in
Figure 5.2.6 were not reproduced in two further attempts. Another caveat that remains
is that these experiments were done in HEK293T cells, and so whether this apparent co-
migration could be replicated in Jurkat T cells remains to be seen. The reasons behind the
lack of reproducibility are not understood. One possible source for this observation could
be that the interaction is labile and easily disrupted when cell lysates are made. Inducing
autophagy did not have any obvious effect on the fractionation profiles of GIMAP6 or
GABARAPL2 (not shown).
5.2.3 GIMAP6 can interact with itself
As mentioned above, GIMAP6 eluted predominantly in gel filtration analysis where pro-
teins with molecular masses of  70-100 kDa would elute, with the peak in the profile
indicating that GIMAP6 fractionated predominantly at a molecular mass of approxim-
ately 70 kDa. This was observed in both Jurkat T cells, in which GIMAPs are endogen-
ously expressed (experiments shown in this thesis were performed in Jurkat T cells stably
over-expressing biotinylated hGIMAP6), and HEK293T cells, which exhibit no endogen-
ous GIMAP expression. Given that hGIMAP6 runs at approximately 36 kDa and along
with the recent evidence of the association between GIMAP2 and GIMAP7 (Schwefel
et al., 2013), it was reasonable to hypothesise that possible reasons for the fractionation
profile of GIMAP6 could be due to homodimerisation, heterodimerisation with another
member of the GIMAP family (the molecular masses of members of this family, barring
GIMAP8, are approximately 35 kDa) or, indeed, association with other proteins. Invest-
igating whether GIMAP6 could interact with itself or with other members of the GIMAP
family was feasible given the reagents already available in the laboratory and I performed
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immunoprecipitation experiments to elucidate whether hGIMAP6 could interact with it-
self and/or other member/s of the hGIMAP family.
Figure 5.2.7: GIMAP6 can interact with itself.
HEK293T cells were transfected with a plasmid encoding myc-GIMAP6 together with
a plasmid encoding biotinylated form of GIMAP6 (+) as indicated. (-) Cells transfected
with empty vector and plasmid encoding myc-tagged hGIMAP6. Cell lysates were pre-
pared and biotinylated and associated proteins recovered by streptavidin-agarose affinity
chromatography. Western blots were probed with either the streptavidin-HRP conjug-
ate to detect biotinylated GIMAP6 or the anti-myc monoclonal antibody 9E10 followed
by an HRP-conjugated goat anti-mouse IgG to detect myc-tagged GIMAP6. -: Con-
trol biotinylation vector and myc-GIMAP6 co-transfected; +: Biotinylated GIMAP6 and
myc-GIMAP6 co-transfected.
HEK293T cells were transiently co-transfected with plasmids encoding biotinylated GIMAP6,
or the corresponding empty vector, and a plasmid encoding myc-tagged GIMAP6. Sub-
sequently, lysates were prepared 48h post transfection. Streptavidin affinity purifica-
tion was performed and the recovered biotinylated and associated proteins were detec-
ted by western blotting using the streptavidin-HRP conjugate and anti-myc mAb 9E10
(Figure 5.2.7). Myc-tagged GIMAP6 co-precipitated with biotinylated GIMAP6 indic-
ating that GIMAP6 could interact with itself. Next, I attempted to investigate whether
inserting mutations within GIMAP6 would affect its ability to interact with itself. I chose
to use the following variants of GIMAP6: GIMAP6S54N, a variant that affected the GTP
binding ability of GIMAP6; GIMAP6R134A, a variant hypothesised to affect the dimer-
isation of GIMAP6, GIMAP637-292, to investigate whether this variant that could bind
GABARAPL2 could interact with itself, and GIMAP61-282 ,a variant unable to bind GTP
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and GABARAPL2. HEK293T cells were co-transfected with biotinylated wt GIMAP6,
or variants thereof, and with myc-tagged wt GIMAP6. The results in Figure 5.2.8 show
that neither disrupting the termini of GIMAP6 nor mutating the arginine residue that ab-
rogates the homodimerisation of GIMAP2 (Schwefel et al., 2010) appeared to disrupt the
ability of biotinylated GIMAP6 (or relevant variants thereof) to pull-down myc-tagged
GIMAP6.
Interestingly, the conserved arginine does not interfere with the dimerisation of GIMAP7,
but does abrogate its GTPase activity (Schwefel et al., 2013). It remains to be seen what
role this conserved residue has in GIMAP6. Both GIMAP2 and GIMAP7 have been
shown to dimerise in a GTP-dependent manner and so I hypothesised that introducing
a mutation within the GTPase domain of GIMAP6, thereby potentially inactivating it,
might affect its ability to interact with itself. This was not observed. As seen in the
figure, variants of GIMAP6 that were unable to interact with GABARAPL2 were able to
pull-down wt myc-tagged GIMAP6 implying that the ability to dimerise or oligomerise is
independent from the ability of GIMAP6 to interact with GABARAPL2. Similar results
were obtained when mutant versions of both biotinylated and myc-tagged GIMAP6 were
transiently co-transfected in HEK293T cells (not shown). Taken together these results
imply that GIMAP6 has a tendency to oligomerise and does so in a manner that appears to
be independent of a functioning GTPase domain. A number of GTPase families, including
members of the dynamin superfamily, the septins (Sirajuddin et al., 2007), and the septin-
related Toc proteins (Sun et al., 2002; Koenig et al., 2008) display GTPase activity that
is triggered by the nucleotide-dependent dimerisation of their G domains (Gasper et al.,
2009). Further studies are necessary to investigate the structural basis of the apparent
oligomerisation of GIMAP6 and its role in its GTPase cycle and biological function.
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Figure 5.2.8: Selected mutations within GIMAP6 did not affect its ability to interact with
itself.
HEK293T cells were transfected with a plasmid encoding myc-GIMAP6 together with
plasmids encoding biotinylated forms of wt GIMAP6 or the biotinylated GIMAP6 vari-
ants as indicated. Cell lysates were prepared and biotinylated and associated proteins
recovered by streptavidin-agarose affinity chromatography. Western blots were probed
with either the streptavidin-HRP conjugate to detect biotinylated GIMAP6 or the anti-
myc monoclonal antibody 9E10 followed by an HRP-conjugated goat anti-mouse IgG to
detect myc-tagged GIMAP6.
5.2.4 GIMAP6 is able to interact with GIMAP7
In a number of GTPase families interactions between members of two functionally dis-
tinct subgroups have been shown to modulate catalytic activity. An example is the IRG.
Members of one IRG subgroup assemble with proteins of the second subgroup to prevent
GTP binding and activation (Hunn et al., 2008). Heterodimer formation and subsequent
GTPase activation is also observed in the signal recognition particle (SRP) and its re-
ceptor (SRPR) (reviewed in Grudnik et al. 2009). Interestingly, recent research on the
structure and on the nature of GTP binding and hydrolysis by members of the GIMAP
family has demonstrated an interaction between GIMAP2 and GIMAP7 (Schwefel et al.,
2013). Studies in the Ras superfamily of proteins have demonstrated that GTP hydrolysis
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is stimulated by association with GAPs which often supply a catalytic arginine residue in
trans to complement the active site (Bos et al., 2007b). Schwefel et al. (2013) have shown
that a highly conserved arginine, corresponding to R134 in GIMAP6, from the conserved
box motif in the GIMAP G-interface, has a dual function. While in the GIMAP2 ho-
modimer, it stabilises the dimerisation interface (Schwefel et al., 2010), the equivalent
arginine residue in GIMAP7 acts as a catalytic arginine finger in the GIMAP7 homod-
imer and GIMAP7-GIMAP2 heterodimer, by complementing the active site of the op-
posing monomer. Thus, the conserved box arginine serves a dual function by promoting
self-association and stimulating GTP hydrolysis.
I attempted to investigate whether GIMAP6 could interact with other members of the
GIMAP family using Jurkat T cells engineered to stably over-express biotinylated GIMAP6.
Streptavidin affinity purification was carried out and the recovered biotinylated proteins
and associated proteins were detected by western blotting using the streptavidin-HRP
conjugate and mAbs against other members of the GIMAP family that had been gen-
erated previously in the laboratory. Interestingly, GIMAP7, but not other GIMAPs co-
precipitated with biotinylated GIMAP6 (Figure 5.2.9)(A); the induction of autophagy did
not appear to have any effect on the interaction (not shown).
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Figure 5.2.9: GIMAP7 is a binding partner for GIMAP6.
Left panel: Lysates were isolated from Jurkat T cells stably expressing either empty
vector (-) or biotin-tagged GIMAP6 (+). Right panel: HEK293T cells were transfected
with a plasmid encoding myc-GIMAP7 together with a plasmid encoding biotinylated wt
GIMAP6 as indicated. In both cases, biotinylated and associated proteins were recovered
by streptavidin-agarose affinity chromatography. Western blots were probed with the
streptavidin-HRP conjugate to detect biotinylated GIMAP6. GIMAP7 expressed in the
Jurkat T cells was detected with the rat monoclonal antibody to GIMAP7, MAC447, fol-
lowed by an HRP-conjugated goat F(ab’)2 fragment anti-rat IgG. Myc-tagged GIMAP7
expressed in the HEK293T cells was detected by the anti-myc monoclonal antibody 9E10
followed by an HRP-conjugated goat anti-mouse IgG.
To follow up, HEK293T cells were transiently co-transfected with biotin-tagged GIMAP6
and myc-tagged GIMAP7 and pull-down experiments were performed. In confirmation
of the earlier finding, GIMAP7 co-purified with biotinylated GIMAP6 (Figure 5.2.9)(B).
Next, in order to determine the molecular requirements for the GIMAP6-GIMAP7 inter-
action, biotin-tagged GIMAP6 mutants were transiently co-transfected with myc-tagged
wt GIMAP7. Interestingly, disrupting the N-terminus (GIMAP637-292), but not the C-
terminus or the G domain of GIMAP6, abrogated the interaction with GIMAP7. Introdu-
cing mutations within the G domain of GIMAP6 or truncating the C-terminal 10 amino
acids of GIMAP6 can abrogate the interaction with GABARAPL2: however, these vari-
ants of GIMAP6 did not appear to have any deficit in their interaction with GIMAP7.
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These results indicate that different regions of the GIMAP6 protein are required for the
interaction with GIMAP7 and GABARAPL2, respectively (Figure 5.2.10).
Figure 5.2.10: The N-terminal region of GIMAP6 is required for the interaction with
GIMAP7.
HEK293T cells were transfected with a plasmid encoding myc-GIMAP7 together with
plasmids encoding biotinylated forms of wt GIMAP6 or the biotinylated GIMAP6 vari-
ants as indicated. Cell lysates were prepared and biotinylated and associated proteins
recovered by streptavidin-agarose affinity chromatography. Western blots were probed
with either the streptavidin-HRP conjugate to detect biotinylated GIMAP6 or the anti-
myc monoclonal antibody 9E10 followed by an HRP-conjugated goat anti-mouse IgG to
detect myc-tagged GIMAP7.
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6.1 Summary of Results
Studies on the GIMAP family have shown that members of this family play crucial roles in
the control of lymphocyte survival, with some members, namely GIMAP1 and GIMAP5,
being pro-survival (Hellquist et al., 2007; MacMurray et al., 2002; Schulteis et al., 2008;
Saunders et al., 2010; Barnes et al., 2010), and others, namely GIMAP4, being poten-
tially pro-death (Dion et al., 2005; Schnell et al., 2006). Little is known about the mo-
lecular mechanisms through which the GIMAPs affect lymphocyte survival. Recent stud-
ies have indicated that they may interact with members of the Bcl-2 protein family and
that GIMAP5 may exercise its anti-apoptotic properties by stabilising Mcl-1 (Chen et al.,
2011). A biochemical approach to identify interacting partners of the GIMAPs was under-
taken by our laboratory to extend knowledge of the molecular mechanisms that mediate
GIMAP function. This led to the identification of GABARAPL2, a mammalian homo-
logue of the yeast autophagy-related gene Atg8, as a major binding partner of GIMAP6
(Pascall et al., 2013). The primary aim of this thesis has been to analyse this interaction
in more detail. I have also identified GIMAP7 as a binding partner for GIMAP6. This
interaction which has also been observed, independently and using a different approach,
by another laboratory (Daumke group; personal communication), may have significant
mechanistic implications for the GIMAP family.
The interaction between GIMAP6 and GABARAPL2 was first detected via cross-linking,
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I have demonstrated that the interaction can also be detected without cross-linking and
have shown that the interaction between GIMAP6 and GABARAPL2 is direct. By em-
ploying site-directed mutagenesis and pull-down assays, I have been able to gain an under-
standing of the molecular requirements for this interaction. Mutational analyses, includ-
ing point mutations within, and truncations of, GIMAP6 and GABARAPL2 have revealed
a number of things. The N-terminal region of GIMAP6, which includes a putative AIM,
was not required for the interaction. This was interesting as AIMs are frequently found
in proteins that interact with Atg8 family members. However, point mutations within
the AIM docking site of GABARAPL2 did disrupt the interaction implying that there
could be an as yet unidentified, non-canonical AIM within GIMAP6. Interestingly, the
N-terminal region of GIMAP6 was required for its interaction with GIMAP7 as its trun-
cation abrogated the ability of GIMAP6 to bind GIMAP7. The GIMAP6-GABARAPL2,
but not the GIMAP6-GIMAP7 interaction, was disrupted by deleting the last 10 amino
acids of GIMAP6, a region predicted to form an a-helix. The GIMAP6-GABARAPL2
interaction was also abrogated when the putative GTPase domain of GIMAP6 was dis-
rupted by mutagenesis. However, interestingly, introducing a point mutation within the
GTP binding domain of GIMAP6 had no apparent effect on its interaction with GIMAP7.
To date, no studies have been published on the GTP binding ability of GIMAP6 and I
conducted experiments to throw some light on the nucleotide binding status of GIMAP6.
While purified GIMAP6 failed to bind isotope-labelled GTP to a detectable level, I have
shown for the first time that GIMAP6 expressed in mammalian cells can bind GTP-
agarose and that this interaction can be competed by the addition of free GTP and GDP,
but not ATP. Indeed, variants of GIMAP6 that could not bind GTP-agarose could also not
interact with GABARAPL2, indicating that nucleotide binding may play a crucial role in
the interaction.
The crystal structure of GABARAPL2 shows the presence of two a-helices within its N-
terminal region (Paz et al., 2000), and deletion experiments demonstrated that the first
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a-helix was not only required for the interaction with GIMAP6, but also proved to be suf-
ficient in reproducing the interaction when transplanted into a second Atg8 family mem-
ber (MAP1LC3B). This implies that the specific binding of GIMAP6 to GABARAPL2
may be due to an interaction between the putative a-helix within the C-terminal region of
GIMAP6 and the a-helix in the N-terminal region of GABARAPL2.
Like MAP1LC3B, GABARAPL2 is believed to dock on the autophagosomal membrane
through its conjugation to the lipid PE which occurs via a conserved glycine residue
present towards its C-terminus. Substituting this residue with alanine did not affect
the binding to GIMAP6 which may have implications on the intracellular localisation
of the interaction. GABARAPL2 is normally largely cytosolic and only relocalises to
autophagosomes when autophagy is induced. Mutating the glycine abrogates this relo-
cation (internal communication, Butcher group) and given that GIMAP6 is also, under
normal physiological conditions, believed to be cytosolic, a probable scenario is that the
GIMAP6-GABARAPL2 interaction occurs in the cytosol. GIMAP6, like GABARAPL2,
has been shown in our laboratory to relocate to autophagosomes on the induction of auto-
phagy where it co-localises with both MAP1LC3B and GABARAPL2 (Pascall et al.,
2013). In this thesis, I have demonstrated that a mutant GIMAP6 that is unable to interact
with GABARAPL2 loses its ability to relocate to autophagosomes and remains cytosolic.
Finally, as has been observed for GIMAP2 and GIMAP7 (Schwefel et al., 2010, 2013), I
have observed that GIMAP6 can interact with itself, a property that is shared with septins
(de Almeida Marques et al., 2012) and dynamins (Alpadi et al., 2013; Warnock et al.,
1996; de Almeida Marques et al., 2012) and is necessary for their ability to function. The
significance of this for the biology of GIMAP6 is as yet unclear.
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6.2 The N-terminal region of GIMAP6
Apart from mediating membrane fusion (Weidberg et al., 2011), a major role of mem-
bers of the Atg8 family is recruiting proteins to autophagosomes (Noda et al., 2010). As
has been mentioned earlier (subsection 3.1.2), proteins that interact with the Atg8 family
commonly do so via the presence of an AIM (W/YXXI/L; (Svenning et al., 2011; Noda
et al., 2010)). AIM-containing proteins are usually promiscuous and able to interact with
multiple members of the Atg8 family, with the promiscuity down to the presence of the
motif. An example of this is NBR1, which has been shown to interact with MAP1LC3B,
GABARAP and GABARAPL2 (Lamark et al., 2009; Kirkin et al., 2009a). Indeed, a
large-scale analysis found that out of 67 Atg8-interacting proteins identified, 31 inter-
acted with single members of the family, with GABARAPL2 interacting uniquely with
only one, WDR62 (Behrends et al., 2010). Intriguingly, while the N-terminal region of
GIMAP6 contains the AIM (6YEQI9), our laboratory has demonstrated that GIMAP6 is
specific for GABARAPL2, amongst Atg8 family members, which is rather unusual (Pas-
call et al., 2013). Mutational (Figure 3.3.3) and truncation studies (Figure 3.3.14) sug-
gested that the AIM motif within GIMAP6 did not have an obvious role in the GIMAP6-
GABARAPL2 interaction. The high specificity of the interaction may be consistent with
the apparent non-involvement of the putative AIM within GIMAP6. Recent work on the
Atg19-Atg8 interaction has suggested a similar phenomenon where the presence of an
AIM within Atg19 does not appear to play an important role in the interaction (Sawa-
Makarska et al., 2014).
Based on results obtained when the putative AIM within GIMAP6 was mutated and de-
leted, I hypothesised that the residues within the ADS of GABARAPL2 would not be
involved in the GIMAP6-GABARAPL2 interaction. Unexpectedly, mutations within
the ADS of GABARAPL2 resulted in a complete loss of interaction with GIMAP6-
(Figure 4.3.3), indicating that the GIMAP6-GABARAPL2 interaction may still involve
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AIM-ADS interactions, albeit with the AIM within GIMAP6 possibly being non-canonical
and as yet unidentified. Interestingly, recent work has demonstrated the existence of
non-canonical AIMs (von Muhlinen et al., 2012; Kaufmann et al., 2014; Newman et al.,
2012). von Muhlinen et al. identified that NDP52 is specific for MAP1LC3C and binds
to it by virtue of a variant AIM comprising the sequence ILVV. However, this interac-
tion takes place in a manner that bypasses docking of the hydrophobic residues of the
AIM (at positions 1 and 4) in the hydrophobic pockets of MAP1LC3C. A similar mo-
tif within the GIMAP6 amino acid sequence was not identified and, furthermore, it is
unlikely for GIMAP6 to have an AIM that functions in a manner analogous to the one
seen in NDP52 as mutations within the hydrophobic pocket abrogated the GIMAP6-
GABARAPL2 interaction. By analysing the structure of the Atg12-Atg5 complex solved
by Otomo et al. (2013), Kaufmann et al. 2014 demonstrated the existence of a non-
canonical, non-contiguous, three-dimensional AIM in Atg12 involving Trp139 and Val62,
with this motif proposed to be required for the Atg8-dependent recruitment of the Atg12-
–Atg5–Atg16 complex to the phagophore subsequent to the Atg12–Atg5–dependent con-
jugation of Atg8. They observed that these residues were positioned such that their Ca
atoms matched the critical distance of 9.8 Å, a distance that also separates the conserved
residues W/YXXI/L in canonical AIMs. Whether the AIM found in Atg12 makes con-
tact with the hydrophobic pockets of Atg8 is unknown, but if that were to be the case the
determination of the structure of GIMAP6 may aid in the identification of the proposed
AIM within its sequence.
While the N-terminal region of GIMAP6 did not have a role to play in the interaction
with GABARAPL2, interestingly, truncating it abrogated the interaction with GIMAP7
(Figure 5.2.10). Further work is necessary to identify the residues within the N-terminal
region of GIMAP6 that are required for its interaction with GIMAP7, and to identify re-
gions and residues within GIMAP7 that play a role in the GIMAP6-GIMAP7 interaction.
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6.3 The C-terminal region of GIMAP6 and the
N-terminal region of GABARAPL2
The region C-terminal to the GTPase/AIG1 domain of GIMAP6 (amino acids 243-292)
is predicted to contain two a-helical extensions by PSIPRED, a secondary structure pre-
diction programme (Buchan et al., 2013; Jones, 1999; Figure 6.3.1, C-terminal helices
highlighted in green). As mentioned previously (subsection 4.1.1), the N-terminal re-
gion of GABARAPL2 contains two a-helices (Paz et al., 2000). a-helices comprise
approximately 40% of all secondary structures (Cummings and Hamilton, 2010) and
are frequently found at the interface of protein-protein interactions (PPI). Truncating
the putative a-helices within the C-terminal region of GIMAP6 abolished the GIMAP6-
GABARAPL2 interaction (Figure 3.3.14). Point mutations were introduced within this
region and the results I obtained indicated an important role for R284 within GIMAP6 as
substituting this residue with an alanine almost completely abrogated the interaction with
GABARAPL2. This is consistent with the finding that arginines and aromatic residues
are over-represented as hot spots at helical interfaces (Bullock et al., 2011; Azzarito et al.,
2013). The results also indicated that the cumulative character of the terminal 10 amino
acids within GIMAP6 was critical for the interaction with GABARAPL2. This region
contains a mixture of both charged and hydrophobic residues - HRCLLGKADL (in col-
our, polar; in blue, positively charged; in red, negatively charged; other, hydrophobic).
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Figure 6.3.1: GIMAP6 secondary structure prediction.
Cylinders in green represent the helices within the C-terminal region of GIMAP6.
An interesting observation was that truncating the C-terminal region within GIMAP6 also
adversely affected GTP binding activity (Figure 3.3.16), possibly implying that this region
somehow plays a role in maintaining the structure of GIMAP6 such that it is able to have
a functioning GTP binding domain. Indeed, structural analysis of GIMAP2 indicated that
the a-helix within its C-terminal extension folded against its G domain (Schwefel et al.,
2010). Alternatively, as alluded to above, the C-terminal region of GIMAP6 may be dir-
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ectly involved in making contact with the N-terminal region of GABARAPL2. Disrupting
this interaction may ultimately, through as yet unknown mechanisms, disrupt the ability
of GIMAP6 to bind GTP.
Although the GTPase/AIG1 domain amongst the various mammalian GIMAP6 ortho-
logues is well conserved there is more divergence outside of that region. Interestingly,
three rodent species (mouse, rat and chinese hamster), but not the mole rat, have truncated
C-terminal domains compared with several other mammalian species, including humans.
Mouse GIMAP6 (mGIMAP6) did not, in my hands, interact with GABARAPL2, consist-
ent with importance of the C-terminal region for the interaction. Attempts were made to
replace the C-terminal region of mGIMAP6 with the corresponding region of hGIMAP6
and, separately, to fuse this region to the C-terminal end of GFP to analyse whether this re-
gion alone would reproduce the interaction with GABARAPL2. However, unfortunately,
I was unable to obtain functioning constructs. A variety of different cloning protocols
were employed to no avail.
As mentioned in subsection 4.1.1, the presence of two a-helices at the N-terminus of Atg8
homologues is well conserved (Weiergraber et al., 2013); however, the character of these
helices is not (this region within the MAP1LC3 subfamily is primarily composed of pos-
itively charged amino acids, while in the GABARAP subfamily the region is composed
of hydrophobic residues). This may have implications with respect to the stage of auto-
phagosome biogenesis at which MAP1LC3B and GABARAPL2 are involved (Weidberg
et al., 2010). While the MAP1LC3 subfamily is involved in elongation of the phagophore
membrane, the GABARAP subfamily is essential for the sealing of the autophagosomes
and, the difference in the helices may affect the nature of the interaction with the mem-
brane, leading to differing outcomes. The difference in the helices also affects the abil-
ity to bind SQSTM1, an autophagic cargo receptor implicated in autophagy-dependent
elimination of cytosolic ubiquitinated proteins, organelles such as mitochondria and per-
oxisomes, and bacteria (Komatsu and Ichimura, 2010). While both MAP1LC3B and
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GABARAPL2 can bind SQSTM1, only MAP1LC3B can deliver SQSTM1 to autolyso-
somes and this difference in the behaviour of the two proteins was pinpointed to the
differences in the N-termini of MAP1LC3B and GABARAPL2 (Shvets et al., 2011).
I swapped the first a-helix within the N-terminal region of MAP1LC3B with the corres-
ponding region of GABARAPL2 (comprising the amino acids MKWMFKEDHS; refer to
key above) and demonstrated that the chimeric protein was able to interact with GIMAP6
(Figure 4.3.2). Unlike SQSTM1 which is able to interact with both GABARAPL2 and
MAP1LC3B in the cytosol but only associates with membrane-bound MAP1LC3B and
not membrane-bound GABARAPL2 (Shvets et al., 2011); GIMAP6 appears to be unable
to interact with either form of MAP1LC3B. The N-terminal region of GABARAPL2 thus
plays a critical role in the interaction with GIMAP6, however, it is not yet possible to
comment on whether this helix alone is sufficient to mediate the interaction. As men-
tioned above, residues within the ADS of GABARAPL2 appear to be necessary for the
interaction with GIMAP6; this region is also present in MAP1LC3B and a potential fu-
ture experiment would be to analyse if the chimeric MAP1LC3B with point mutations
within its ADS was still able to interact with GIMAP6. Lystad et al., 2014, have recently
identified three residues, K24/Y25/D54, within the GABARAP subfamily that are re-
sponsible for the selective binding of ALFY (autophagy-linked FYVE protein, also called
WDFY3), a large phosphatidylinositol 3-phosphate-binding protein shown to be recruited
to ubiquitin-positive structures during stress that interacts with the ubiquitin-binding auto-
phagy receptors SQSTM1 and NBR1 and contributes to autophagic clearance of aggreg-
ated proteins (Filimonenko et al., 2010; Clausen et al., 2010). Whether these residues
within GABARAPL2 are responsible for the specificity of the interaction with GIMAP6
is a potential avenue for future research.
Interestingly, the 10 C-terminal amino acids of GIMAP6 did not appear to be required
for the interaction with GIMAP7 (Figure 5.2.10). The C-terminal truncate of GIMAP6
was unable to bind both GTP and GABARAPL2, however, the interaction with GIMAP7
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remained unaffected. This may indicate that the GIMAP6-GIMAP7 interaction could
be independent of the activity of the GTP binding/AIG1 domain of GIMAP6. Altern-
atively, GIMAP6 may adopt a conformation that allows its N-terminal region to make
contact with GIMAP7, while, simultaneously, the C-terminal region adopts a conform-
ation such that the putative GTP binding region of GIMAP6 remains active allowing it
to bind GABARAPL2. Cross-linking studies indicated that GIMAP6 and GABARAPL2
formed a complex, but this could be due to the particular spatial arrangement of a hypo-
thetical GIMAP6-GABARAPL2-GIMAP7 complex that precluded the identification of
GIMAP7 as an interacting partner via the cross-linking methodology.
GIMAP6, like GIMAP2 and GIMAP7, can interact with itself (Figure 5.2.7). GIMAP2
homodimerises to prevent the catalysis of GTP hydrolysis and heterodimerises with GIMA-
P7 to catalyse GTP hydrolysis (Schwefel et al., 2010, 2013). Whether the GIMAP6-
GIMAP6 interaction has a role in sequestering it from both GABARAPL2 and GIMAP7
is unknown and the physiological conditions under which these interactions occur need
investigating.
Whether mouse GIMAP6 interacts with mouse GIMAP7 (or the closely related mouse
GIMAP9) is currently unknown and would be interesting to investigate. Furthermore,
given that hGIMAP proteins exhibit intra-family interactions (this thesis and Schwe-
fel et al., 2013; Schwefel and Daumke, 2011), it will be interesting to test whether the
mGIMAPs display similar behaviour. These experiments would provide valuable insight
into the biology of the GIMAP family of proteins.
6.4 The GTPase domain of GIMAP6
Of the hGIMAP proteins, until recently the GTP binding and hydrolytic ability of only
hGIMAP4 had been characterised (Cambot et al., 2002). Recent work by the Daumke
group, a structural biology laboratory that studies the GIMAP family of proteins, has
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thrown light on the GTP binding and hydrolytic activities of hGIMAP2 (Schwefel et al.,
2010) and hGIMAP7 (Schwefel et al., 2013). Nothing about the GTP binding status or
hydrolytic activity of hGIMAP6 was known prior to my attempts to address these ques-
tions. Unfortunately, technical issues related to the purifying of GIMAP6, hindered my
attempts to characterise the GTP binding and hydrolytic abilities of GIMAP6. An at-
tempt was made to purify GST-tagged GIMAP6 that was bacterially expressed; however,
it proved very hard to obtain soluble GST-GIMAP6 that could be purified and employed in
assays with isotope-labelled GTP. Bacteria were induced at low temperature, and lysed, in
either the presence and absence of GDP, albeit without any positive effect on its solubility.
Assays with [35S]GTPgS were carried out both with GST-GIMAP6 that was immobilised
on glutathione beads and with GST-GIMAP6 that had been eluted off the beads. They
yielded results saying that the protein preparation did not bind GTP, either because that
is the intrinsic property of GIMAP6 in isolation or because the preparation was in some
way denatured. A literature review was carried out and an alternate method to answer the
question of whether GIMAP6 could bind GTP/GDP was employed.
The use of GTP-agarose beads has been used to analyse the GTP binding ability of various
GTPases (Pendin et al., 2011; Modiano et al., 2005; Jebelli et al., 2012; Carlessi et al.,
2011) and was used in this study to investigate the nucleotide binding ability of GIMAP6.
The advantage of this method is that it is possible to assay GTP binding in crude lysates
taken directly from living cells. Using this approach, I demonstrated that GIMAP6 was
unable to bind ATP but could bind GDP and GTP, with the affinity for GTP being higher
than that for GDP, a phenomenon observed in most GTPase families (Bourne et al., 1991).
This assay is unable to test the catalytic activity of GIMAP6 and therefore cannot be used
to determine whether a variant of GIMAP6 that could not bind to GTP-agarose was unable
to do so because it was unable to bind nucleotide at all or because it was inaccessible to
GAPs and therefore in a permanently GTP-bound state; the latter would result in awry
nucleotide cycling and prevent the variant in question from binding to GTP-agarose. It
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may require GIMAP6 to be expressed in (and purified from) an insect or mammalian
cell line to overcome solubility issues for assays with [35S]GTPgS or [g32P]GTP to be
feasible.
As detailed in subsection 3.3.4, point mutations within the GTP binding domain of GIMAP6
abrogated the interaction with GIMAP6, with variants unable to bind to GTP-agarose
also unable to interact with GABARAPL2. Mutations within the GTP binding domain
of GIMAP6 had been made on the basis of predictions made when similar mutations
had been studied in the Ras family of GTPases. This was the first opportunity to test
their validity in the GIMAPs. With the exception of D167A within the G4 motif -
(subsection 3.3.4), mutations within the other motifs within the GTP binding/AIG1 do-
main of GIMAP6 could abrogate interaction with GABARAPL2. It would be interesting
to check the ability of this variant of GIMAP6 to bind to GTP-agarose.
It is worth considering whether GIMAP6’s interaction partner GABARAPL2 shows any
characteristics of a classical GAP or GEF. If GABARAPL2 was an effector of GIMAP6,
then one could reasonably predict the GIMAP6G50D variant to be constitutively bound to
GABARAPL2, an interaction that has been observed with other GTPases and their effect-
ors (reviewed in Cherfils and Zeghouf, 2013 and Schubbert et al., 2007). Alternatively,
the putative constitutively active variant of GIMAP6 could be resistant to GAPs, a role
that may be played by GABARAPL2. GTP hydrolysis assays in the presence and absence
of GABARAPL2 are necessary to test this hypothesis. GABARAPL2 was first identified
as an ATPase enhancer (Muller et al., 2002; Sagiv et al., 2000 refer section 4.1), and it
may play an analogous role in the context of GIMAP6. Dominant-negative GTPases are
thought to be unable to bind GTP (Itzen et al., 2006; McMahon, 2004), and exhibit a
higher affinity for GEFs (reviewed in Cherfils and Zeghouf, 2013 and Heasman and Rid-
ley, 2008). The putative dominant-negative GIMAP6 variant, GIMAP6S54N was unable
to bind GABARAPL2, however, making it unlikely that GABARAPL2 acts as a GEF for
GIMAP6. It could be that nucleotide exchange is key for the ability of GIMAP6 to bind
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GABARAPL2 and to relocate to autophagosomes. A somewhat analogous phenomenon
was observed with the targeting of human GBP-1 to the Golgi. hGBP-1 can target spe-
cifically to the Golgi membrane in its GTP-bound form; non-hydrolysable GTP bound
mutants are unable to do so, however, suggesting that nucleotide exchange may be a sig-
nificant factor in hGBP-1 localisation (Modiano et al., 2005). Interestingly, GIMAP6S54N
was still able to interact with GIMAP7, indicating that GIMAP6 may not require an intact
GTP binding capacity for binding GIMAP7 (Figure 5.2.10). Further interaction studies
with other variants of GIMAP6 need to be carried out for a more detailed understanding
of this interaction.
The arginine at position 117 within GIMAP2 (this arginine is conserved across all GIMAP
family members) is required for dimerisation and GTP binding (Schwefel et al., 2010).
Mutating the corresponding residue in GIMAP6 (R134), however, did not have any appar-
ent effect either on its GTP binding (Figure 3.3.11), on its ability to bind GABARAPL2
(Figure 3.3.10) or with GIMAP7 (Figure 5.2.10). This is somewhat analogous to what has
been observed in GIMAP7, where mutating the arginine does not inhibit the dimerisation
or GTP binding ability of GIMAP7; however, this residue was shown to be necessary for
GIMAP7’s GAP activity, both for itself and for GIMAP2 (Schwefel et al., 2013). Does
GIMAP6 exhibit GAP activity for other members of the GIMAP family? This would
be an interesting question to work on. Interestingly, R117 within GIMAP2 makes con-
tact with the Q114 in the opposing GIMAP2 monomer and mutating the Q114 abrogated
GIMAP2 homodimerisation. A similar scenario may exist in GIMAP6, and substituting
the Q131 within GIMAP6 may affect its apparent oligomerisation. Neither truncating the
N-terminal region of GIMAP6, nor truncating the C-terminal region hampered the ability
of GIMAP6 to interact with itself. This may indicate that the GTP binding domain within
GIMAP6 may have a role to play in the self-interaction, however, the dominant-negative
mutant of GIMAP6 was also able to self-interact subsection 5.2.3 and Figure 3.3.10. Ana-
lysing further variants of GIMAP6 with mutations in its GTP binding domain may be
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helpful. Additionally, residues predicted to be involved in aggregation are represented
in (Figure 6.4.1) and introducing mutations within this region may affect the ability of
GIMAP6 to interact with itself.
Figure 6.4.1: Regions within GIMAP6 that may be involved for aggregation.
The peaks represent the regions within GIMAP6 that may be involved in it’s aggrega-
tion. The prediction is based on DisEMBL, a computational tool used to predict dis-
ordered/unstructured regions within a protein sequence Linding et al. (2003).
It may be that the structural conformation adopted by GIMAP6 with an active nucle-
otide (GTP) exchange capacity is key to its interaction with GABARAPL2. Solving
the structure of GIMAP6 will aid in better understanding the GIMAP6-GABARAPL2
and GIMAP6-GIMAP7 interactions. Technical issues with regards to the solubilisation
of GIMAP6 may be circumvented by co-purifying the GIMAP6-GABARAPL2 or the
GIMAP6-GIMAP7 complex or the use of antibody Fab fragments and then attempting
structural studies.
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6.5 Functional significance of the
GIMAP6-GABARAPL2 interaction
The GABARAP subfamily of which GABARAPL2 is a member has been proposed to
be involved in the latter stages of autophagosome biogenesis (Weidberg et al., 2010),
and the discovery of GIMAP6 as a seemingly quantitatively major binding partner of
GABARAPL2, along with the relocation of both proteins to autophagosomes in response
to cell starvation, suggests a potential role for GIMAP6 in the autophagic process. GT-
Pases and GTPase-associated proteins have been shown to play active roles in various as-
pects of membrane (reviewed in Burd and Collins, 2004; Lamb et al., 2013; Nachury et al.,
2007) and autophagosome biogenesis (Itoh et al., 2011; Popovic et al., 2012; Yamano
et al., 2014). GIMAP6, too, could have a role to play in autophagosome membrane elong-
ation, for instance in a manner similar to the interaction between Rab33-GAP, OATL1,
and Atg8 family members (Popovic et al., 2012), it is possible that GABARAPL2 could
serve as a scaffold from which GIMAP6 may perform as yet unidentified functions within
the autophagic pathway. Our laboratory has investigated whether modulating levels of
GIMAP6 could influence the autophagic process, however, no simple relationship to the
process of autophagy as defined by the conversion of MAP1LC3B-I to MAP1LC3B-II, or
a shift in the number of MAP1LC3B positive punctae (a classic autophagosomal marker)
was observed (Pascall et al., 2013). I asked whether the GIMAP6-GABARAPL2 interac-
tion was necessary for the relocation of GIMAP6 to autophagosomes to perhaps permit
either its selective degradation or to facilitate a specific function at the vesicles. I found
that variants of GIMAP6 that failed to interact with GABARAPL2 were not recruited to
autophagosomes. While it may be that GIMAP6 interacts with other proteins that medi-
ate its recruitment to autophagosomes, it seems likely that the GIMAP6-GABARAPL2
interaction has a key role in the recruitment. A possible strategy to add further clarity
to this particular question could be to conduct experiments with cell lines that preferably
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express GIMAP6 endogenously and either do not express GABARAPL2, or are engin-
eered to express GABARAPL2 at reduced levels. The imaging experiments were carried
out with engineered HEK293 cells due to the difficulties associated with imaging Jurkat
T cells which do express GIMAP6 endogenously.
Studies in our laboratory have indicated that the recruitment of GIMAP6 to autopha-
gosomes may be associated with its turn-over. These experiments were carried out using
Jurkat T cells and the endogenous protein levels were analysed. GIMAP6 has been shown
to be able to regulate cellular GABARAPL2 levels (Pascall et al., 2013). Mutating G116
within GABARAPL2, a residue that is critical for its lipidation and subsequent mem-
brane docking, did not affect its binding to GIMAP6, indicating that this interaction can
occur in the cytosol. I have demonstrated that the interaction is direct (Figure 5.2.1) and
have obtained very preliminary data indicating that these proteins may be able to exist
as a complex in vivo (Figure 5.2.6). Unfortunately, I was unable to obtain this result on
a consistent basis: different lysis buffers, and lysis buffer concentrations were trialled to
no avail and induction of autophagy also did not appear to have any effect (not shown).
The positive experiment performed Figure 5.2.6 was controlled internally as far as was
possible, and it may be that the complex is unstable and needs a very particular set of
circumstances to enable one to detect it.
Given that GIMAP6 can regulate GABARAPL2 protein levels, is GIMAP6 being se-
questered by GABARAPL2 in the cytosol (or vice versa), in a manner similar to when
Cdc42 is sequestered in the cytosol by its guanine nucleotide dissociation inhibitor (GDI)
(a molecule that maintains GTPases in the GDP bound state) (Dirac-Svejstrup et al., 1997;
Iden and Collard, 2008; Forget et al., 2002)? On a somewhat related note, a prelim-
inary examination of cell lines engineered to express biotinylated GIMAP6 with muta-
tions inserted within the G1 motif (G50D and S54N) indicated that neither cell line was
able to express the stably transfected protein to any detectable level. Could this be a
result of the inability of these variants to bind GABARAPL2 and thereby be protected
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from degradation? Stabilising GIMAP6 might facilitate its function if GABARAPL2
could dissociate adequately. Alternatively, the potential sequestration of GIMAP6 by
GABARAPL2 could prevent GIMAP6 from performing functions either related to auto-
phagy or not, and possibly in conjunction with GIMAP7. Does it require a particular
physiological event for the GIMAP6-GABARAPL2 interaction to be disrupted to then
allow the GIMAP6-GIMAP7, or GIMAP6-GIMAP6 interactions, amongst other as yet
undiscovered interactions? GABARAPL2, too, may have other functions in the cell be-
sides taking part in the autophagosome biogenesis and further studies on GABARAPL2,
particularly in relation to a knock-out animal model would be informative. As has been al-
luded to above, the mouse and the rat have truncated C-terminal domains (Figure 3.3.13)
and this may be why no interaction between the mouse GIMAP6 and GABARAPL2 is
observed. So, while these may not be the best animal models to study the significance
of the GIMAP6-GABARAPL2 interaction, it must be noted that all other mammalian
GIMAP6 sequences examined do not have similar truncations and may be able to interact
with GABARAPL2 (Figure 3.3.13). This suggests that the modification seen in muroid
rodents may be relatively confined taxonomically. This, along with the specificity of the
GIMAP6-GABARAPL2 interaction implies a potentially fundamental role and the inter-
action needs further investigating.
6.6 Functional significance of the GIMAP6-GIMAP7
interaction
GIMAP2 has been shown to associate with both itself and GIMAP7 and while GIMAP2
has no significant hydrolytic activity of its own (Schwefel et al., 2010), GIMAP7 can
act as a GAP for both itself and for GIMAP2 (Schwefel et al., 2013). On the basis of
these findings, I asked whether GIMAP6 was able to interact with other members of
the GIMAP family and discovered that it could interact with GIMAP7 (Figure 5.2.9).
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For members of the Ras superfamily, GTP hydrolysis is stimulated by association with
GTPase-activating proteins (GAPs) which often supply a catalytic arginine residue (Bos
et al. 2007b; subsection 1.3.1). Studies on other families of GTPases have demonstrated
that GTPase activity can be triggered by nucleotide-dependent dimerisation of the G do-
mains. Within the IRGs, for instance, interactions between members of two functionally
distinct subgroups have been shown to modulate catalytic activity (Hunn et al., 2008).
Unlike what has been observed with GIMAP2 and GIMAP7, members of one IRG sub-
group assemble with proteins of the second subgroup to prevent GTP loading and ac-
tivation, with homodimerisation being required for the catalytic mechanism (Pawlowski
et al., 2011). Heterodimer formation and subsequent GTPase activation is also observed
in the signal recognition particle (SRP) and its receptor (SRPR), septins, septin-related
Toc proteins, dynamins, and the Roco protein Leu-rich repeat kinase 2 (LRRK2) (Gasper
et al., 2009; Sun et al., 2002; Praefcke and McMahon, 2004; Sirajuddin et al., 2007;
Grudnik et al., 2009). In the case of the GIMAPs, work has shown that GTPase activity
is stimulated by dimerisation, with the conserved arginine from the conserved box motif
having a dual function: it plays a role in the homodimerisation of GIMAP2 and within
GIMAP7 is able to act as a catalytic arginine finger to stimulate GTP hydrolysis in both
GIMAP2 and GIMAP7 (Schwefel et al., 2010; Schwefel and Daumke, 2011; Schwefel
et al., 2013). Interestingly, however, in my experiments mutations of this arginine within
GIMAP6 did not reveal a role in either homodimerisation (Figure 5.2.8) or heterodimer-
isation (Figure 5.2.10) and its role in GIMAP6 biology needs further investigation. What
role does the GIMAP6-GIMAP7 interaction have? I postulate that GIMAP7 acts as a
GAP for GIMAP6. Given that it is able to act as a GAP for both itself and for GIMAP2, it
is plausible that GIMAP7 acts as a GAP activity for the GIMAP family and investigations
into whether other members of the GIMAP family can interact with GIMAP7 will be in-
teresting. Sub-cellullar localisation studies to investigate whether GIMAP6 co-localises





Members of the GIMAP family have opposing functions in lymphocyte survival. For in-
stance, GIMAP1 and GIMAP5 are believed to be pro-survival, while GIMAP4 is believed
to accelerate T cell death (Chen et al., 2011; Schulteis et al., 2008; Barnes et al., 2010;
Schnell et al., 2006; Saunders et al., 2010). One could envision a scenario where GIMAP
members act as sensors within the lymphocyte and are able to trigger apoptosis under
certain conditions. Members with differing functions might interact with one another and
somehow (possibly via GTP binding and hydrolysis) regulate the pro- and anti-apoptotic
function/s of their partners. The GIMAPs could then be seen as an interacting network
or system. While studies to date have by and large implicated the GIMAPs in adaptive
immunity, they may also have roles to play in innate immunity; plant homologues of the
GIMAPs have been shown to be induced when challenged by bacterial (Reuber and Aus-
ubel, 1996) and fungal infections (Liu et al., 2008) and a recent study has demonstrated
that GIMAPs were strongly up-regulated within corals when these were bacterially chal-
lenged (Weiss et al., 2013).
The dynamin-like IRG family of proteins is a pertinent example. IRGs respond to intra-
cellular pathogens and the various family members act in concert to deliver phagocytosed
pathogens for clearance via autophagy. Mouse IRGs can be divided into two subgroups
based on the presence of a canonical lysine or a non-canonical methionine within the G1
motif (GxxxG[K/M]S/T). The GMS proteins act as regulators of the nucleotide-bound
state of the GKS proteins, helping to control their GTP-dependent activation. In turn, this
controls the antimicrobial activities of their respective effectors which can include other
GKS-containing IRGs and proteins involved in autophagy (Taylor et al., 1996; Tiwari
et al., 2009; Kim et al., 2012; Hunn et al., 2008). Furthermore, the human IRGM protein
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is interesting as, in addition to playing a role in innate cell defense, it also plays a role in
cell survival through autophagy and, by localising to the mitochondria and affecting mito-
chondrial fission it is also involved in apoptosis. GIMAPs can also be subdivided into two
groups (albeit based on the ability to be membrane-bound or not): membrane-anchored
GIMAPs possessing a C-terminal hydrophobic segment (hGIMAP1, 2, and 5) and soluble
GIMAPs (4, 6, 7 and possibly 8) which do not have such a hydrophobic stretch. Data on
the GIMAPs so far suggest that membrane-anchored GIMAPs form nucleotide-regulated
oligomers on the surface of cellular organelles. These might function in a manner similar
to the septin oligomers (Weirich et al., 2008; Sirajuddin et al., 2007) and, amongst other
roles, they could organise the assembly of interaction partners in a manner that is ana-
logous to ’septin cages’ which compartmentalise pathogens within the cell and eliminate
them via autophagy (reviewed in Mostowy and Cossart, 2011).
The precise significance of the GIMAP6-GABARAPL2 and GIMAP6-GIMAP7 interac-
tions remains to be elucidated . Experiments that add further clarity to the GTP binding
and hydrolysis of the GIMAP members will be key. Studying GIMAP6- and GIMAP7-
deficient mice may also help in the understanding of GIMAP biology and studies that
examine whether the mammalian GIMAPs have a role to play in innate immunity would
seem to be justified.
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